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Abstract: 
 
Introduction: Bile acid diarrhoea (BAD) results from excess bile acids (BA) in the colon. Most BAs are 
reabsorbed at the terminal ileum. Increased colonic BA occur secondary to ileal disease or resection 
(common in Crohn’s disease [CD]) leading to BA malabsorption and secondary BAD (SBAD). Primary 
BAD (PBAD) occurs in the absence of overt ileal disease or malabsorption. The peptide FGF19 is 
produced from enterocytes in response to BA absorption and is a negative regulator of BA synthesis. 
Defects in FGF19 production may underlie the excess faecal BA loss observed in PBAD. 
Aim: This thesis reports studies testing the following hypotheses: (1) Ileal FGF19 expression is 
altered in both CD and PBAD; (2) Serum FGF19 is a diagnostic marker of BAD in CD; (3) Stimulating 
FGF19 with a BA analogue in patients with SBAD will have beneficial symptomatic effects.  
Methods: Groups of patients underwent fasting blood sampling or ileal biopsies during colonoscopy. 
Serum FGF19 was measured and biopsies were studied for expression of FGF19 transcripts and other 
genes before and after incubation with BA. RNA extraction, cDNA synthesis and RT-PCR were used 
for relative quantification of gene expression. A genotype study on a candidate SNP in the DIET1 
gene was performed on a cohort of PBAD patients.  
Results: Serum FGF19 levels were lower in CD patients with ileal resection, or diarrhoea or active 
disease. FGF19 transcripts were strongly induced by BAs in ileal explants but were lower in CD 
compared to controls. Baseline and BA-stimulated ileal FGF19 expression were related to measures 
of faecal BA loss. The DIET1 variant was associated with FGF19 levels. An open-label, pilot trial of the 
BA analogue, Obeticholic acid (OCA), in patients with SBAD produced variable changes in FGF19 
levels and symptomatic improvement. 
Conclusion: This work increases awareness of FGF19 and dysregulated BA homeostasis in the 
pathophysiology of certain chronic diarrhoeal diseases. FGF19 holds promise in guiding therapy for 
BAD 
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List of abbreviations: 
μM / µl micromolar / microlitre 
ASBT  Apical Sodium-linked Bile salt Transporter  
BA  Bile Acids  
BAD  Bile Acid Diarrhoea  
BAM  Bile Acid Malabsorption  
BMI  Body Mass Index  
BSFS  Bristol Stool Form Scale   
BSEP  Bile Salt Export Pump  
C4  7α-hydoxy-4-cholesten-3-one  
CA Cholic Acid 
CCK  Cholecystokinin  
CD Crohn’s Disease 
cDNA  complementary Deoxyribonucleic acid  
CDCA Chenodeoxycholic acid 
Ct Cycle Threshold 
CYP27A1  sterol 27-hydroxylase  
DCA Deoxycholic acid 
DMEM Dulbecco's Modified Eagle Medium 
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DEPC Diethylpyrocarbonate 
DTT Dithiothreitol 
EDTA  Ethylenediaminetetraacetic Acid  
ELISA  Enzyme-Linked Immunosorbent Assay  
FGF15/19  Fibroblast Growth Factor 15/19  
FGFR4  Fibroblast Growth Factor Receptor 4  
FXR  Farnesoid X Receptor  
g  grams  
GAPDH Glyceraldehyde 3-phosphate dehydrogenase 
GCDCA Glyco-chenodeoxycholic acid 
HBI Harvey Bradshaw Index 
HPLC  High Pressure Liquid Chromatography  
IBABP  Ileal Bile Acid Binding Protein  
IBAM  Idiopathic Bile Acid Malabsorption  
IBS  Irritable Bowel Syndrome  
IBS-D  Diarrhoea predominant Irritable Bowel Syndrome  
ICP  Intrahepatic Cholestasis of Pregnancy  
IL-1ß Interleukin 1 beta 
IL-6 Interlaukin 6 
IQR Inter-Quartile Range 
IR Ileal Resected 
IR-CD Ileal Resected Crohn’s Disease 
LCA Lithocholic aci 
LDH Lactate Dehydrogenase 
LPS Lipopolysaccharide 
MAF Minor Allele Frequency 
mRNA Messenger Ribo-Nucleic Acid 
NF-kB Nuclear Factor Kappa of B cells 
NR-CD Non Resected Crohn’s disease 
OCA Obeticholic Acid 
OSTa/OSTß Organic Solute Transporter alpha / Beta 
pg Picograms 
PBAD Primary bile acid diarrhoea 
RT-qPCR Real time Quantitative polymerase Chain reaction 
SeHCAT 23-seleno-25-homotaurocholic acid 
SHP Short Heterodimer partner 
SNV Single Nucleotide Variant 
TGR5/ GPBAR1 The G protein-coupled bile acid receptor 1 
TNFa Tumour Necrosis Factor Alpha 
UDCA Ursodeoxycholic acid 
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1 Introduction 
1.1 Bile acid (BA) homeostasis and the enterohepatic circulation of BA 
Bile acids are the end product of cholesterol metabolism and their secretion is the main determinant 
of hepatic bile flow. Bile is released into the duodenum after a meal in response to cholecystokinin 
(CCK) which induces contraction of the gallbladder and relaxation of the sphincter of Oddi. The 
amphipathic nature of bile acids (BA) enables them to emulsify the lipid component of a meal and 
form mixed micelles with fatty acids and monoglycerides within the small bowel.  This greatly 
enhances the passive diffusion and absorption of fatty acids and monoglycerides at the brush border 
membrane.  
The majority of BAs are conjugated and ionized before secretion from the liver, which ensures they 
stay in the intestinal lumen until they meet the BA transporter proteins of the terminal ileum. The 
specific BA transporter protein is the apical sodium-linked bile acid transporter (ASBT) which 
mediates a  Na-dependent reabsorption of BAs from the intestinal lumen, against a concentration 
gradient of BA into the enterocytes of the terminal ileum[1, 2]. Passive diffusion of unconjugated 
BAs throughout the distal small bowel also occurs [3]. The ileal reabsorption of conjugated BA is 
highly efficient, with less than 5 % of BA passing the ileum into the colon at each pass. The 
reabsorption of this specific component of biliary secretions in the distal small bowel leads to a pool 
of bile acids that cycles several times (5-12 cycles) between liver and ileum after each meal. The bile 
acid pool is approximately 2-3g. The liver secretes around 12g per day but only needs to synthesise 
an average of 400mg per day to keep up with the small amounts lost from the body . The 
homeostasis of this enterohepatic circulation of bile acids is complex. BA production in the liver 
matches the amount of BA lost in the faeces. 
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1.2 BA-FXR-FGF19 signalling 
In animal studies, diverting bile acids away from this enterohepatic circulation (such as a biliary 
fistula) will lead to increased hepatic BA biosynthesis[4]. Yet animal models involving bile duct 
ligation, which increase hepatic concentrations of BA are also found to have an increase in hepatic 
synthesis of BA[5].  In this situation duodenal administration of bile acids (chenodeoxycholic acid, 
CDCA) reduces hepatic BA synthesis but intra-venous administration does not[6]. An intestinal 
negative feedback signal from the gut to the liver was proposed. In 2005, such a signal was found to 
be an atypical Fibroblast growth factor, FGF15 in the mouse [7].  FGF15 inhibits de novo BA synthesis 
by inhibiting the transcription of cholesterol 7 alpha hydroxylase CYP7A1, the rate limiting enzyme in 
the production of primary BA, through the hepatic FGF receptor 4 (FGFR4) and the c-Jun NH2-
terminal kinase (JNK) pathway [8]. FGF15 is under the transcriptional control of the Farenesoid X 
Receptor (FXR), a nuclear receptor that is widely regarded as an intracellular BA receptor for BAs. BA 
are taken up by the ileal enterocyte where they bind and activate the transcription factor FXR.  CDCA 
is the most potent natural ligand for FXR [9]. FXR upregulates the transcription of many BA-
responsive genes but the most responsive in the mouse ileum is FGF15 [10]. This mechanism ensures 
that reduced ileal uptake of BA is met with counter regulatory increases in hepatic bile acid 
synthesis. 
BA can also signal via a G-protein coupled plasma membrane receptor, TGR5 leading to activation of 
adelynate cyclase and increasing the production of cAMP[11]. TGR5 is expressed on neuroendocrine 
cells secreting GLP1. Interest is now also mounting on systemic effects of BAs on energy 
consumption, glucose homeostasis and lipid metabolism via TGR5 receptors on non- enterohepatic 
tissues[12]. 
There are some intriguing differences between FGF15 and other distal peptide gut hormones. FGF15 
is produced in enterocytes rather than neuroendocrine cells, and it does not appear to be released 
from preformed vesicles. The expression of FGF15 in the mouse is largely restricted to the ileum [13] 
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unlike PYY and GLP1 whose expression is fairly widespread throughout and ileum and colon [14]. 
FGF15 is secreted from ileum (by unknown mechanisms), then travels to the liver via the portal 
circulation and binds to the cell surface receptor FGFR4.  
FXR is expressed in liver and intestine. BA can also down-regulate their own synthesis within the liver 
directly through FXR-mediated down-regulation of CYP7A1 transcription[15].Gut and liver specific 
FXR knockout mice have shown that liver FXR -/- still retain the capacity to inhibit hepatic 
biosynthesis in response to CDCA whereas ileal FXR -/- cannot [16]. BA FXR activation in the liver is 
likely to be important in responding to increasing intracellular concentrations of BA, particularly in 
situations of intra-hepatic cholestasis. Liver specific FXR activation transactivates BA transporters  
BSEP, MDR3 and OATP1B3, which promote BA efflux from the hepatocyte, limiting BA-induced intra-
cellular toxicity[17, 18]. Mutations in such genes are associated with conditions of intra-heptic 
cholestasis [19]. Ileal BA FXR activation is likely to be important in responding to changes in intra-
luminal BA concentrations leading to a protein signal FGF15/19 is sent to the liver.   
FGF19 is the human orthologue of FGF15, a 21kDa protein, which is able to send feedback signals to 
more proximal parts of the GI tract, similar to other distal gut hormones (PYY, enteroglucagon)[20, 
21]. Serum FGF19 levels [22] increase in the blood a few hours after meals, when ileal BA absorption 
is maximal.  BA synthesis is asynchronous with FGF19.  Both BA synthesis and FGF19 levels are 
affected by fasting.   FGF19 is not usually expressed in the liver, but in cholestasis, expression can be 
demonstrated, suggesting an additional role perhaps in helping to protect the liver from the toxic 
effects of BAs [23]. Some authors have also demonstrated in the mouse that FGF15 represents a 
post-prandial signal that antagonizes CCK induced gallbladder contraction and promotes gallbladder 
re-filling[24]. Another group conducting human studies  have shown that administration of oral 
CDCA increases FGF19 levels along with gallbladder volume up to 6 hours after administration[25]. 
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Patients suffering from intestinal faiture on long term parenteral nutrition can develop a liver 
disease characterised by steatosis and cholestasis. Such patients often have an anatomically short 
small intestine. The liver disease is therefore thought to relate to a disruption of the normal 
enterohepatic circulation of BA. These patients often lack an intact distal ileum and it is possible that 
such patients lose a protective influence from ileal -BA -FXR related FGF19 production [26]. 
With regards to BA homeostasis , it appears that more is known about how overexpansion of the BA 
pool size is prevented by inhibiting the addition of new BAs at the liver rather than increasing 
excretioninto the faeces atthe ileum. BA are present in all classes of vertebrates including primitive 
forms such as the lamprey[27]. Even the selective BA transporter, ASBT is present in the everted gut 
sac of the lamprey [28] , but it is not clear how far down the evolutionary tree the FGF15/19 
pathway is found. The FGF15/19 pathway may have evolved in higher vertebrates due to deleterious 
consequences of increasing concentrations of BA in the colon. Increased aqueous concentrations of 
BA in the colon promote water and chloride secretion, which stimulates colonic motility and watery 
diarrhoea. In human population studies there is evidence to suggest apossible association between 
increased secondary faecal bile acids with the incidence of colorectal cancer [29, 30].  
1.3 Secondary Bile Acid Diarrhoea (SBAD) in Crohn’s disease (CD) 
Diarrhoea is a major symptom in Crohn’s disease and causes significant concern in patients with 
inflammatory activity and also in surgically-treated patients.  It is a key component of the Crohn’s 
Disease Activity Index used in most studies of drug efficacy.  There are multiple mechanisms that 
lead to diarrhoea, including impaired absorption and secretion of electrolytes and water in the 
inflamed parts of the intestinal tract.  Bile acids which are normally absorbed in the ileum as part of 
an entero-hepatic circulation, may be implicated as they will produce a secretory diarrhea in the 
colon if ileal function is abnormal, as is usually the case in Crohn’s.  Many studies have demonstrated 
secondary bile acid malabsorption in most Crohn’s patients with diarrhoea, whether or not they 
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have undergone ileal resection.  Corticosteroids increase expression of bile acid transporters and 
improve diarrhoea. Therapy with bile acid sequestrants can be beneficial. 
Another potential mechanism for bile acid diarrhoea has become apparent recently.  It has been 
shown that the ileum produces a secreted hormone, fibroblast growth factor 19 (FGF19), which 
inhibits hepatic bile acid synthesis.  In our pilot data, we have measured the expression of FGF19 in 
human ileum and in blood, and have found very low levels in some patients who have undergone 
ileal resection for Crohn’s disease.  This is proposed to result in increased hepatic bile acid synthesis, 
which in the presence of sub-optimal ileal reabsorption of bile acids, will further worsen the 
secretory effects of bile acids in the colon, producing diarrhea. 
We hypothesize that FGF19 production is altered in patients with Crohn’s disease and so may serve 
as a marker for functioning ileal tissue and for disease activity.  Reduced FGF19 may contribute as a 
novel, unappreciated cause of the diarrheal symptoms 
1.4 Bile acid studies in  Crohn’s disease 
1.4.1 Post ileal resected-Crohn’s disease (IR-CD)  
The length of the small intestine is highly variable. Autopsy studies reveal a range from 2.5 – 6 
metres. The transition from intestinal secretion to active absorption of sodium and water is a 
gradual one from jejunum to ileum throughout the mid-small bowel. Active uptake of BA is more 
confined to the distal ileum [3, 31]. This is likely to relate to increasing expression of ASBT towards 
the terminal ileum[32] .  Ileal resections as small as 30cm are associated with significant faecal BA 
loss [33]. 
The increased faecal BA concentrations after ileal resection often lead to post operative diarrhoea. 
This situation was termed ‘cholerrheic diarrhoea’ by Alan Hofmann [34]  and also type I, or 
secondary bile acid malabsorption (BAM). The cholerrhesis refers to the loss of bile acids, from the 
entero-hepatic circulation between liver and small intestine, into the colon. Only a small proportion 
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of BA can be reabsorbed from the colon as secondary BA. BA kinetic studies reveal that endogenous 
BA synthesis can increase dramatically to match the faecal BA losses in this situation[35]. 
Diagnosis of BA malabsorption is usually made by the SeHCAT test in countries where this is 
available.  The SeHCAT test determines the 7-day retention of a l75Se tagged bile acid using simple 
nuclear medicine gamma scanning.  An important study using SeHCAT scans revealed that 90% of 
Crohn's patients suffering from chronic watery diarrhoea after ileal resection have evidence of 
BAM[36, 37]. Usually the lower the SeHCAT retention level, the more likely the patient will respond 
to BA sequestrants such as cholestyramine, colestipol or colesevelam, which bind BAs in the gut and 
prevent their secretory actions in the colon. A therapeutic trial with one of these agents is often 
used to indicate diarrhoea is due to BA malabsorption.   
With larger ileal resections, hepatic BA synthesis is not sufficient to keep up with faecal BA loss. One 
particular study elegantly showed faecal fat excretion was found to increase in direct proportion to 
the length of small bowel resected greater than 100cm [38]. This observation was thought to be due 
to reduced BA pool sizes, with consequent decreased small bowel luminal BA concentrations and fat 
maldigestion. Previously mentioned in vitro studies on human ileal tissue has demonstrated greatly 
increased BA uptake in the distal 100cm of ileum compared to more proximal ileal tissue [31]. 
1.4.2 Bile acid studies in non-resected Crohn’s disease (NR-CD) 
Similar observations are present in patients with NR-CD and regional ileitis. SeHCAT testing reveals 
that the majority of patients with active ileitis will have a decreased SeHCAT retention [39, 40]. Older 
studies using radio-isotope dilution studies have observed reduced BA pool sizes in such patients 
with ileal lesions that had been thought to be much less than 100cm[41]. In another study such 
observations have been attributed to concomitant colitis interfering with the colonic absorption of 
secondary BAs[42]. In others, it has been speculated that the ileal BA malabsorptive defects were 
more extensive than that revealed by the radiological studies. One particular animal model of 
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chemically induced terminal ileal inflammation revealed evidence of reduced BA absorption in ileal 
tissue some distance from the area of regional ileitis[43]. 
The idea that patients with NR- CD have a defect in ileal BA uptake in the absence of overt ileal 
inflammation has been further elaborated. Two groups have found decreased uptake of BAs in non- 
inflamed human ileal tissue from patients with colonic CD[44, 45].  Smith et al observed that up to 
50 % of non-resected patients thought to be in remission but suffering from chronic diarrhoea have 
evidence of reduced SeHCAT retention. Further recent work has identified that patients with NR-CD 
in remission have a reduced expression of ASBT mRNA and protein in terminal ileum. The same 
group also demonstrated that the expression of ASBT can be increased by the administration of the 
drug budesonide[46].  
Budesonide is an oral medication which is particularly useful for patients with ileal CD for a number 
of reasons. Firstly it is a glucocorticoid, and members of this family of drugs have long been a 
mainstay of treatment for active CD due to their anti-inflammatory properties. Secondly the drug 
has a very high first-pass metabolism limiting any systemic glucocorticoid effects and localizing its 
effects to the intestine. Thirdly current capsule formulations are available, which lead to drug 
release gradually within the small intestine rather than the stomach.  
One of the most commonly associated symptoms of active ileal CD leading to a prescription of 
budesonide is diarrhoea [47]. Some authors have suggested in addition to its anti-inflammatory 
properties, some of the beneficial symptomatic effects of budesonide may be attributable to an 
enhancement of BA absorption[48]. This idea is supported by the observation in a prospective study 
of patients (diagnosed with microscopic colitis) treated with budesonide that  SeHCAT retention 
improves [49].   
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1.4.3 Altered BA-FXR-FGF19 signalling in Crohn’s disease 
Rodent gene knockout studies on any part of the BA- FXR –FGF15 signalling pathway from ileum to 
liver reveal the same phenotypic changes in BA homeostasis, which include: 1. Increased CYP7A1 
mRNA expression, 2. Increased BA pool sizes and 3.increased faecal BAs. The gene knockout studies 
that have been performed include intestine  specific FXR -/-, aswell as FGF15 -/-, FGFR4 -/- and SHP -
/-[7, 16, 50]. The intestine specific FXR knockout phenotype was generated by using a ‘floxed’ FXR 
transgenic mouse model. To gain intestine specific knockdown of FXR, homozygous floxed FXR mice 
were crossed with those harbouring cre-recombinase under the the control of the villin promoter to 
inactivate FXR specifically in intestine but not the liver [51].  
Similarchanges in BA homeostasis associated with severe watery diarrhoea, were also shown in a 
primate study of anti-FGF19 antibodies [52]. With the new knowledge of the FXR-FGF15 signalling 
pathway in the mouse, more recent studies have examined how this pathway may be disturbed by 
BAM in humans, particularly in Crohn’s disease. 
The first potential defect in this signalling pathway in CD starts with the decrease in BA uptake into 
the enterocyte within the terminal ileum. Inflammatory ulceration is likely to limit passive diffusion 
of unconjugated BA in addition to the active transport of conjugated BA. Not only do patients with 
CD in remission demonstrate a reduced basal expression of ASBT, but human, rat and mouse ASBT 
expression and affinity is inhibited by inflammatory cytokines via c-fos interactions with the ASBT 
promoter [53]. 
The reduced uptake of BA from the ileum in CD will interfere with FXR binding and activation and 
ultimately transcription of FGF19 within the ileal enterocyte. The baseline expression of transcripts 
from another FXR-responsive gene, SHP, has been shown to be reduced in ileal biopsies from 
patients, in remission, with Crohn’s colitis [54]. Again this was attributed to reduced BA uptake 
within the enterocyte. However another mechanism has been recently discovered. In vitro work, 
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with intestinal cell lines and ex vivo mouse ileum has shown that FXR-target gene transcription 
(FGF15, SHP and IBABP) is repressed by inflammatory cytokines probably through NF-KB[55] .  The 
authors have therefore suggested that the reduced expression of SHP in Crohn’s ileum may also be 
due cytokine mediated inhibition of FXR activation. FXR expression itself is also reduced in biopsies 
from inflamed areas of colon in patients with CD [56]. As one might expect, fasting circulating levels 
of FGF19 are significantly lower in patients with ileitis and resections compared with healthy controls 
[57, 58]. In these patients, levels of 7-hydroxy-4-cholesten-3-one (C4 , a metabolic marker of bile 
acid synthesis) are significantly increased, consistent with a compensatory increase in hepatic de 
novo BA synthesis. 
Another explanation for reduced ileal FXR activation may be related to changes in BA composition. 
With ileal malabsorption of BA, there will be an increase in colonic BAs. Many of the BA entering the 
colon are dehydroxylated to secondary BA (deoxycholic  acid, DCA, and lithocholic acid, LCA) which 
are known to be weaker FXR agonists. Some of these BA that are still in solution in the colon may 
enter the BA pool by passive diffusion from the right colon. If the BA pool is enriched with secondary 
BA then it is possible that there will be a decrease in ileal FXR activation. Although some studies have 
shown that non- resected CD patients with localised ileal disease appear to have an increase in 
ursodeoxycholic acid (UDCA, the epimer of CDCA), the most common observation in resected 
patients is actually a paradoxical decrease in secondary BA[59]. This observation has been attributed 
to a possible change in the composition of commensal bacterial flora. This could involve a reduction 
in 7-dehydroxylating bacteria after ileal resection.   
1.5 Primary Bile acid diarrhoea (PBAD) 
After the first description of cholerheic diarrhoea in post ileal resection patients [60] it became clear 
that a subgroup of patients without CD or resection with chronic diarrhoea also have increased 
faecal BA levels and other markers of excess faecal BA loss such as decreased SeHCAT retention 
levels. A mutation in the SCL10A2 gene encoding the ASBT protein was found in a family of patients 
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with PBAD which led to initial theories of ileal BA malabsorption in the absence of any overt ileal 
inflammation[61] . However, this mutation was found to represent only rare cases of congenital BAD 
and further case-control studies failed to show any significant associations of common 
polymorphisms in the ASBT gene in this condition [62].   
A number of studies have documented BAM in one-third to one-half of patients with chronic 
diarrhea or IBS-D, summarized in a recent systematic review [63]. Overall, the systematic review 
found that BAM was reported in 32% of patients with symptoms consistent with IBS-D, and there 
was a dose-response relationship to treatment with BA binders, based on severity of BAM assessed 
by SeHCAT values. More recent studies have confirmed similar results [64, 65]. It has been suggested 
that BAD could have a population prevelance as high as 1% in western countries [66].  
The PBAD phenotype is remarkably similar to animal models of FGF15/19 deficiency. Increased BA 
synthesis, Increased BA pool size and increased faecal BA losses. It was therefore proposed that 
defective FGF19 signalling could be the cause of the BAD in these patients [58]. Impaired FGF19 
feedback inhibition therefore leads to uncontrolled BA synthesis that exceeds the normal capacity 
for ileal reabsorption, producing diarrhoea. 
Increased faecal BA or seHCAT losses could result from other mechanisms other than ileal 
malabsorption. Rapid transit would result in a reduced time for reabsorption of bile acids in the 
terminal ileum. This would lead to increased BA enterohepatic recycling frequency with 
increased faecal SeHCAT loss[67]. Transit studies in PBAD have failed to demonstrate an 
association with increased small bowel transit [68, 69].  Increased faecal seHCAT loss could also 
result from an increased BA pool size. BA recycling frequency could remain unchanged and the 
quantity of BA absorbed at the ileum could actually increase, but the fractional absorption at 
each pass would be decreased leading to increased SeHCAT loss over 7 days. This would be 
consistent with increased BA pool size observed in one study of PBAD patients [70]. Hence, 
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impaired FGF19 feedback inhibition leads to uncontrolled BA synthesis that exceeds the normal 
capacity for ileal reabsorption, producing diarrhoea.. 
 
In support of this hypothesis, low median FGF19 levels have been demonstrated in these patients 
compared to idiopathic diarrhoea controls patients [71]. This implies that FGF19 levels are not 
simply decreased due to diarrhoea per se. FGF19 levels in this group of patients were also found to 
have an inverse relationship to 7α – hydroxyl-4-cholesten-3-one (C4) levels [72],  a metabolic 
byproduct of bile acid synthesis reflects the rate of new bile acid synthesis [73].  
 
Other potential mechanisms involve the colonic response to BAs. Some patients may be more 
predisposed to the pro-secretory or motility related actions of BAs. Genetic variation in GPBAR1 
gene redisposes to quantitative changes in colonic transit and BA excretion. GPBAR1 encodes 
the TGR5 receptor and is a member of the G protein-coupled receptor superfamily that functions as 
a cell surface receptor for BA [74]. They are abundantly expressed on colonic enterocytes and 
regulate basal and cholinergic-induced secretion in rat colon and influence colonic transit [75, 76]. In 
addition to this genetic variation in the proteins involved in FGF19 mediated feedback regulation of 
bile acid synthesis, specifically KlothoB gene and fibroblast growth factor 4 gene have been shown to 
associate with radiological assessments of colonic transit [77-79].  
 
1.6 Diarrhoea resulting from altered FGF19 signalling in Crohn’s Disease 
Recent in vitro studies demonstrating that certain inflammatory cytokines (TNF-α, IL-1β) profoundly 
inhibit the FXR mediated transcription of FGF15/19 lead us to an interesting potential defect in ileal 
CD[55].Cytokine suppression of FXR activation and FGF19 production may be reduced 
disproportionately to the reduction in FXR activation relating to BAM in early ileal CD.  
Hypothetically speaking , the result would be impaired FGF19 feedback inhibition leading to excess 
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BA synthesis, which would exceed the already reduced capacity for ileal reabsorption, producing BA 
diarrhoea [58] figure 1. A recent study of antibodies directed against FGF-19 in cynomolgus monkeys 
was associated with the development of severe diarrhoea (and high faecal BA concentrations) after 
a single dose[52].  Conversley, in a mouse model of BAM (Involving knockout of the BA transporter 
ASBT) both exogenous FGF15 and FXR agonists greatly reduced faecal bile acids [80]. In human 
studies it would be difficult to separate (almost impossible) the increase in faecal BA resulting from 
impaired FGF19 and BA overproduction from the increase resulting from BAM clinically, but the 
relationship between circulating FGF19 levels and conditions of bile acid diarrhoea is of particular 
interest [25]. 
 
Figure 1. Enterohepatic circulation and BA-FXR-FGF19 signalling. In addition to BAM, faecal bile acids 
may be increased in CD as a result of cytokine mediated suppression of FXR activation. FXR’s 
transcription of FGF15 in mouse ileum has been shown to be impaired by inflammatory cytokines. If 
FGF19 production is impaired by cytokines in CD then dysregulated synthesis and release of BA from 
the liver may occur, further overwhelming the capacity for ileal reabsorption.(Chol = cholesterol, 
CYP7A1 =hepatic cholesterol 7αhydroxlase, C4 = 7α-hydroxy-4-cholesten-3-one, BA=Bile acids, ASBT 
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= apical sodium-linked bile acid transporter, FXR = Farnesoid X Receptor, FGF19 = Fibroblast Growth 
Factor 19, GB = Gallbladder). 
1.7 Bile acids, FXR and intestinal barrier function 
The commensal microbiota of the intestine is several orders of magnitude lower in the small 
intestine compared to the large intestine. There are a number of reasons for this, including small 
intestinal peristalsis, defensin secretions and the ileo-caecal valve. Bile acids are also thought to 
contribute by virtue of direct anti-bacterial effects within the lumen of the small intestinal. In vitro 
studies have demonstrated bacterocidal functions via their effects on pH [81]. Animal models 
involving bile duct ligation display evidence of small intestinal bacterial proliferation.  They also 
display evidence of intestinal mucosal injury, inflammation and bacterial translocation to the 
mesenteric lymph nodes and systemic circulation  [82]. Oral administration of CDCA can limit these 
affects in animal models [83]. Bacteraemia and sepsis from gut derived organisms is also a common 
problem in patients with obstructive jaundice [84]. 
More recent mouse models of BDL have revealed that the increased bacterial proliferation, 
translocation and mucosal injury are prevented by the oral administration of a specific non-steroidal 
FXR agonist GW4064 [10]. In addition to this, these protective effects were lost in FXR knockout 
mice. Microarray analysis of mRNA levels in the ileum reveals the expected upregulation of bile acid 
responsive genes   but also showed an upregulation of many other genes, some of which are thought 
to have roles in epithelial barrier function.  As CDCA is the most potent FXR agonist in vitro it was 
suggested that BA convey anti-bacterial defence through more complex means than simply pH 
effects within the lumen of the small intestine. Intracellular enteroprotective signalling via FXR 
activation has become a target of further investigation.  
Another FXR agonist currently attracting some attention is the semi-synthetic bile acid 6-ECDCA or 
INT-747, now known as obeticholic acid. This is chemically derived from CDCA and is also similar in 
structure to UDCA which has been in therapeutic use for over 30 years. The addition of the 6 ethyl 
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group greatly increases potency for FXR binding and activation. In vitro work shows it to be 100 
times more potent than CDCA [85]. 
1.7.1 FXR agonists protect against chemically induced animal models of colitis 
The importance of FXR activation in the maintenance of intestinal barrier function was first 
demonstrated by Piero Vavassori et al, by carefully observing the intestinal phenotype in FXR 
knockout mice. They demonstrated the following important changes after 14-16 weeks, in 
comparison to FXR wild type mice: 1 Increased colonic mucosal lamina propria (LP) cellular 
infiltration and collagen deposition. 2 A 60 fold increased expression of mRNA from proinflammatory 
and pro-fibrotic  genes (TNF, IL-1β, IFN , TGF1, 1 collagen) using RT-qPCR. 3. Increased basal 
and stimulated inflammatory cytokines from FXR-/- LP-derived monocytes [56].    
The FXR knockout mice developed a more severe phenotype of chemically induced colitis (intrarectal 
administration of trinitrobenzenesulfonic acid (TNBS) ) than FXR wild type mice. Most interesting of 
all however, was that FXR wild type mice fed concomitantly with INT-747 alongside TNBS 
administration were protected from the development of colitis. The protective effect s of INT-747 
were absent in FXR knockout mice.  In vitro, INT-747 also attenuatues Lamina propria (LP) derived 
mouse mononuclear cell (MC) responsiveness and inhibits pro-inflammatroy gene responses to 
lipopolysaccharide (LPS). Again, these responses are not attenuated by INT-747 in FXR knockout 
mice derived MCs.  Some evidence was presented demonstrating that in addition to synthetic FXR 
agonists, endogenous BA can also alter certaininnate immune responses. Using THP-1 cells (a 
leukaemic cell line with upregulated IL-1β expression) LPS stimulated induction of IL-1β mRNA was 
inhibited by pretreatment with CDCA but not by the weaker endogenous FXR ligand LCA[56]. 
Gadaleta et al have also demonstrated the protective effects of INT-747 in chemically induced 
mouse models of colitis. Mice fed with INT747 during intestinal dextran sodium sulphate (DSS) and 
TNBS administration are protected against chemically-induced colitis[86]. Again using FXR-knockout 
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mice the protection was shown to be FXR dependent. They also demonstrated INT-747 limited 
chemically induced increases in intestinal permeability, and limited the induction of several key pro-
inflammatory genes in intestinal tissue (IL-1β, mcp-1, IL-6). They went further to note an induction of 
certain genes which may be important in mucosal protection (iNOS + cathelicidin in colon and ANG1 
in ileum). In vitro studies from this group revealed that culturing human stimulated  peripheral blood 
mononuclear cells (PBMC) and gut-derived lamina propria mononuclear cells (LPMC,from 4 patients 
with IBD) with INT-747 significantly inhibited the release of TNF (measured by ELISA). With PBMC, 
10uM of endogenous BA CDCA showed some evidence of attenuating cytokine release but in 
comparison to 1 – 10uM of INT-747, this did not achieve significance. This is likely to relate to the 
relative potency of INT-747 compared to CDCA with regards to FXR binding and activation[86].  
1.7.2 The vicious cycle: FXR activation is repressed by inflammatory cytokines, and 
inflammatory cytokine expression is repressed by FXR 
Many of the pro-inflammatory genes shown to be downregulated by FXR activation by INT747 (TNF-
a, IL-1β) have their expression upregulated by another key transcription factor, Nuclear factor kappa 
– B (NF-kB). Mutual antagonism between these two pathways has been demonstrated. FXR can 
inhibit the transcriptional activity if NF-kB and, conversely, NF-kB can inhibit the transcriptional 
activity of FXR. Fiorruci’s group have highlighted, in vitro, possible mechanisms underlying FXR 
induced inhibition of NF-kB. In THP-1 cell cultures FXR INT-747 activation was shown to promote the 
transcriptional silencing of IL-1β by stabilising nuclear receptor corepressors (NCoR)[56]. Conversly, 
Van Mil’s group have explored possible mechanisms underlying NF-kB induced inhibition of FXR.  In 
cultured ex vivo mouse ileal tissueFXR BA responsive target genes IBAP,SHP and FGF15 revealed 
significantly reduced transcription upon stimulation with GW4064 in the presence of TNFα or IL-1β. 
Reporter assays overexpressing the NF-kB subunits p50 and p65 also completely abolished GW4046 
mediated stimulation of target FXR target genes SHP and IBABP. [55].  
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If BA have anti-inflammatory properties within the intestinal cells, one hypothesis worth exploring in 
the future is whether reduced BA absorption into intestinal cells contributes to the upregulated 
inflammatory signals associated with Crohn’s disease. A vicious cycle may exist where reduced BA 
uptake into cells leads to impaired FXR activation leading to disinhibition of inflammatory cytokine 
production. Increased inflammatory cytokines may repress FXR activation further. Reduced FXR 
target gene transcription would also lead to reduced expression of FGF19, Figure 3.  
 
Figure 1.2. Vicious cycle of repressed FXR activation within epithelial enterocytes: Reduced uptake of 
BA will lead to reduced FXR activation. FXR activation is further restrained by basally upregulated 
inflammatory cytokines in Crohn’s disease. NF-kB pathways will be further disinhibited by impaired 
FXR activation allowing for further unrestrained transactivation of inflammatory cytokines. 
Inflammatory cytokines have also been shown to impair the activity of the bile acid uptake 
transporter ASBT. Hence a self perpetuating cycle of impaired FXR activation and upregulation of the 
NF-kB pathway ensues (BA=Bile acids, ASBT = apical sodium dependent bile acid transporter, NF-kB = 
Nuclear factor Kappa B). 
  
30 
 
1.8 FXR agonists and a therapeutic role in SBAD of Crohn’s Disease 
We hypothesized that, if potent FXR agonists such as OCA were able to stimulate FGF19 in patients 
with BAD, this would reverse the impaired regulation of BA synthesis and, by reducing BA 
production, would lead to clinical improvement.  The effect may be most marked in primary BAD and 
impaired BA absorption could limit the effect in secondary BAD but the potency as an FXR agonist 
may overcome this in SBAD. The addition to the CDCA by the addition of the 6 ethyl group 
dramatically increases the bile acids binding and activation of FXR. The importance of FXR signaling 
in BA homestasis and colonic function is already hinted at from the observation that constipation  
was a side effect in prior human studies of obeticholic acid [87] whereas CDCA has been used to 
treat constipation due to its secretory effects in the colon in others [78] . 
Additional benefits may arise from the demonstrated anti-inflammatory effects of FXR agonists 
observed in animal studies and cell lines [56, 86, 88]. In vitro, the most potent natural ligand for FXR 
is CDCA [9].  There is some evidence to suggest  that FXR activation is impaired in human ileum in CD 
[54]. The mechamism underlying this finding may be due to malabsorption of BAs (specifically CDCA) 
or directly resulting from  cytokine suppression of FXR. If FXR activation maintains intestinal barrier 
function it is theoretically possible that impaired FXR activation may contribute to the 
aetiopathogenesis of ileal Crohn’s disease. Initiating events in the early pathogenesis of IBD are 
thought to be related to inappropriate activation of  (Pathogen Pattern Recognition )PPR receptors 
in response to translocating bacterial antigens with activation of NF-kB pathways. It is possible that 
in the normal ileum, BA-induced FXR activation contributes to the restraining of this pathway via its 
antagonistic effects on NF-kB . Impaired ileal BA transport and FXR activation may contribute to the 
Crohn’s disease predilection for localised ileal inflammation. Again it is interesting to speculate 
whether budesonide and other corticosteroids may have anti-inflammatory effects in part 
attributable to enhanced BA uptake and possibly increased FXR activation.   
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FXR agonists have shown protective effects in chemically induced colitis but perhaps their most 
relevant application in human inflammatory bowel disease will be in ileal Crohn’s disease, as this is 
physiologically where the most significant defect in intestinal FXR activation is likely to occur .  In the 
normal intestine, the protective effects of FXR activation in the colon are probably less important as 
most of the BA in the colon are either secondary bile acids (which are only weak FXR agonists, in 
vitro) or not in the aqueous phase.  Also reduced fasting circulating FGF19 levels may act as a 
biomarker of patients in whom ileal FXR activation is most deficient. Fasting FGF19 levels have been 
shown to increase significantly in patients taking FXR agonists in clinical trials where it is being used 
in liver disease [89].  This observation confirms that ileal FXR activation is certainly enhanced in this 
group of patients. Enhanced ileal expression of BA-responsive target genes has also been 
demonstrated recently in patients with Crohn’s colitis after the oral administration of CDCA[25]. This 
confirms that ileal FXR activation is possible in CD despite the known defects in ileal BA absorption.  
The next step is to test whether the FXR agonists produce symptomatic improvement in SBAD, 
followed by further studies in the future regarding the potential anti-inflammatory effects 
specifically in ileal CD. 
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1.9 Genotype phenotype relationships in bile acid homeostasis, colonic function 
and PBAD 
 
Candidate gene studies in patients with PBAD have centred on genes with established roles in bile 
acid transport and metabolism and the FXR-FGF19 pathway. As previously described the FXR-FGF19 
pathway exerts a negative feedback signal to hepatic BA synthesis in response to ileal absorption of 
BA. After uptake of BA into the ileal enterocyte BAs act as the ligand to bind and activate the nuclear 
receptor FXR. Ligand bound FXR then upregulates the transcription of FGF19. Receptors specific for 
FGF19 protein, referred to as FGFR4 are expressed predominantly on hepatocytes in association with 
a co-receptor klothoB. FGFR4 and klothoB activation downregulates CYP7A1 expression.  
A study of 435 IBS patients and 279 healthy subjects testing 15 common SNPs from 7 genes involved 
in BA homeostasis and associated a Klotho β variant (SNV rs17618244) with accelerated colonic 
transit in IBS predominant diarrhoea patients [79]. Previous work by this group examined the use of 
chenodeoxycholate in females with IBS and constipation on colonic transit and ascending colon 
emptying which were significantly increased compared with placebo 121. Stool frequency increased 
and stool form became looser. There was a significant association between fasting C4 levels and 
bowel transit, although no association with FGF19 was found. It was found that a SNP in the FGFR4 
gene and the same SNP in klotho B gene rs17618244 was associated with increased transit with the 
2 different doses of CDCA administered. The authors concluded that patients with this genotype may 
be more susceptible to the effects of exogenously administered BAs[78].  
Recently described exploratory studies of certain functional genetic variants including those which 
have been identified in the FXR gene (NR1H4) [90, 91] which might affect FGF19 production have 
also been described.  This research group has also looked at variants in the FGF19 gene in the 3’-
untranslated region which could affect transcript stability.  Other candidate genes were explored 
where variation could affect intracellular bile acids and FGF19 expression include the ileal bile acid 
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transporters ASBT (SLC10A2) and OSTα (SLC51A). No associations of variants in these key genes were 
identified to associate with PBAD patients compared to healthy control patients. 
1.9.1 DIET1 single nucleotide variant: rs12256835  
For the purposes of this thesis we became interested in another gene known as DIET1. The Diet1 
gene locus was first localised in a substrain of C57BL/6 (C57BI/6ByJ (B6By)) mice with low cholesterol 
levels and resistance to atherosclerosis when fed a high fat diet [92]. The investigators had 
hypothesized that the atherosclerosis resistant phenotype of this mouse substrain was due to a 
mutation in an uncharacterized gene diet1 and was associated with increased BA synthesis [93]. The 
Diet1 gene locus was localised to chromosome 2 and genes in this area were known to affect plasma 
lipid levels and atherogenesis. 
FGF19 secretion is poorly understood but a novel protein, DIET1, has been identified as a key 
regulator. Diet1 in the mouse is a 236kD protein and promotes FGF19 secretion. The responsible 
mutation in the mouse diet1 gene was associated with differences in BA metabolism analogous to 
PBAD with reduced FGF15 expression, increased BA synthesis and pool size and increased faecal BA 
levels. Diet 1 is localised to intestinal epithelial cells in the mouse small intestine with increasing 
expression towards the ileum. Diet1 expression levels in mouse intestine, and DIET1 expression 
levels in cultured human enterocytes, correlate with FGF15/19 protein production. Diet1-deficient 
mice have reduced FGF15/FGF19 levels in the ileum, impaired feedback regulation of hepatic bile 
acid synthesis, and increased bile acid synthesis, an increased BA pool and increased BA excretion 
[94].  In the same diet1 deficient mice, transgene expression of diet1 normalized hepatic bile acid 
synthesis and Fgf15 expression, confirming that a key function of Diet1 is to promote FGF15 
production. HT-29 cells transfected with a Diet1 expression vector increased FGF19 mRNA levels 
slightly (∼30%) and increased FGF19 protein secretion into the culture medium by 3-fold. Diet1 
therefore enhances FGF15/FGF19 expression and secretion.   Karen Reue et al have since performed 
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pilot studies on DNA samples from previously recruited patients with PBAD and healthy controls to 
sequence the DIET1 gene for variation which may be associated with PBAD (unpuplished work) and 
is further described in chapter 8.   
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Hypothesis: 
The general hypothesis of this thesis is that ileal FGF19 production is suboptimal and causes 
diarrhoea due to dysregulated BA production leading to increased faecal BA levels and secretory 
diarrhoea, in patients otherwise described as suffering from ‘bile acid diarrhoea’. This hypothesis can 
be further subdivided into 3 main propositions for investigation in this thesis: 
(1) Ileal FGF19 expression is altered in both CD and PBAD;  
(2) Serum FGF19 is related to ileal resection length and symptoms of diarrhoea in CD and therefore 
could have utility as a biomarker of BAD in CD;  
(3) Stimulating FGF19 with a BA analogue in patients with CD and SBAD will have beneficial 
symptomatic effects 
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2. Materials and Methods: 
2.1 Ethical considerations, patient recruitment and consent 
The FGF19 expression studies (Chapter 3-6, 8)were approved by the local Institutional Review Board, 
the Hammersmith, Queen Charlotte's, and Chelsea Hospitals' Research Ethics Committee. REC 
reference number 2000/5795, UKCRN ID number 7024. The clinical trial in Chapter 7, OBADIAH1 was 
sponsored by Imperial College London and Imperial College Healthcare NHS Trust and registered 
with EudraCT (2011-003777-28) and ClinicalTrials.gov  (NCT01585025).  The drug was provided by 
Intercept Pharmaceuticals, Inc. (San Diego, CA).  Ethical approval was obtained from National 
Research Ethics Service Committee London Brent (REC reference 12/LO/0123). 
2.2 Serum FGF19 studies. 
Described in chapter 3, fifty-eight patients with a diagnosis of Crohn’s disease were recruited 
prospectively from the gastroenterology outpatient clinics, inflammatory bowel nurse specialist 
clinics and gastroenterology wards from 3 sites at Imperial College Healthcare trust. This included 
Charing Cross, Hammersmith and St Mary’s hospital.  Written informed consent was obtained and 
venous blood samples were collected in serum separator tubes. These were then centrifuged at 
3000rpm for 10mins and aliquoted for storage at -80°C for subsequent FGF19 assays. Some patients 
also had 5mls of whole blood collected in an EDTA tube for storage at -20 and later DNA extraction. 
The diagnosis of Crohn’s had been histologically confirmed in all patients.  Twenty-three patients 
had undergone previous ileal resection (IR-CD) and 35 had no previous intestinal resections (non-
resected CD, ‘NR-CD’).  In 18 of the 23 IR-CD patients the precise length of ileum resected was 
available according to macroscopic surgical specimen descriptions.   
Stool frequency, and Bristol Stool Form Scale (BSFS) were recorded for all patients.  Disease activity 
was assessed using the Harvey Bradshaw Index (HBI)[95] and CRP in those with CD. Some patients 
also gave stool samples for storage at -80 for later analysis of faecal calprotectin. For comparisons 
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between patient groups, diarrhea was arbitrarily defined as a stool frequency of ≥3, with stool form 
of 6 or 7 as in previous studies[71].  A Stool Index (SI) was calculated as (daily stool frequency x BSFS) 
+ loperamide use (mg*3).[96] None of the NR-CD patients were laking loperamide during this study. 
Distribution of CD was assessed using standard endoscopic and radiological techniques. Of the NR-
CD patients, 21 had evidence of ileitis (10 ileal, 11 ileo-colonic CD) and 14 had disease affecting the 
colon only (colonic CD).  Details of the patients are shown in Table 1.   
Eleven patients (6 with ileitis and 5 colonic) with active disease (HBI≥5) requiring treatment (6 
corticosteroids and 4 biologics) to induce remission were part of a longitudinal study.  Repeat fasting 
samples were taken following resolution of diarrhea during a period of medically induced remission 
(HBI<5).  Where possible, samples were taken before the start of treatments used for inducing 
remission in patients with active disease.  This was possible in all patients starting biologics and 
three of the six starting corticosteroids.  The three patients who were already commenced on 
corticosteroids during active disease had been on these for no longer that 48h. 
Three patients with CD and ileal resection or inflammation (one NR-CD with ileal involvement, and 
two IR-CD) underwent serial blood sampling for FGF19 pre and post standardized breakfast and 
lunch.  
2.2.1 FGF19 and C4 assays. 
Including samples from chapter 3 and 7, blood samples were separated, aliquoted and stored 
at -80deg C.  Assays were performed by operators who were unaware of the clinical conditions of 
the patient providing the sample.  FGF19 was measured by ELISA sandwich assay (FGF19 Quantikine 
ELISA kit; R&D Systems, Minneapolis) according to the manufacturer’s protocol. 100μl samples of 
serum were assayed in duplicate. The assay is linear between 16 and 1000pg/ml. The intra-assay 
and inter-assay coefficients of variance are about 4-6% (manufacturer’s data, confirmed in the 
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laboratory). All assays were run with mid pool samples (previously collected with known FGF19 
levels) to ensure consistency and observe the inter-assay variation. 
2.2.2 C4 and BA assays. 
Serum 7α-hydroxy-4-cholesten-3-one (C4) levels from the clinical trial described in chapter 7 were 
determined by the previously documented procedure in the Clinical Chemistry Department, Western 
General Hospital, Edinburgh [73].  Following solid phase extraction, samples were analyzed by  high 
performance liquid chromatography.  Total serum BA were measured by an enzymatic colorimetric 
method using 3α-hydroxysteroid dehydrogenase.   
2.3 Ileal FGF19 expression studies: 
2.3.1. Sampling during routine colonoscopy  
Endoscopically obtained intestinal biopsies were used to study the expression of FGF19 transcripts. 
Biopsies were to be taken at colonoscopy. Colonoscopy was performed after bowel preparation and 
fasting for at least 6h. The bowel preparation used is Senna granules and magnesium citrate . The 
bowel purgative includes magnesium carbonate and citric acid. This reacts within the intestinal 
lumen to form magnesium citrate which exerts an osmotic effect on cells within the intestine. This 
leads to secretion of water and stimulation of GI motility. This clears the colon of any stool prior to 
colonoscopy and biopsies.  
During colonoscopy,endoscopic mucosal biopsies were taken by an endoscopist using standard 
endoscopic radial jaw biopsy forceps (Boston Scientific, M005133300). The first two ileal and/or 
colonic biopsies were placed in formalin for histological examination. Then 2 – 9 biopsies were taken 
for research purposes to be used for basal expression studies or ileal explant incubations. 
2.3.2 General recruitment and selection of healthy controls and patients 
Patients for this part of the study were screened and recruited prospectively whilst attending for 
routine outpatient colonoscopy. Patients aged 18-80 were included. Patients were excluded if they 
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were taking anti-coagulants, dual anti-platelet therapy or any other bleeding risks including the need 
for polypectomy of a polyp ≥1cm. They were given a patient information sheet whilst they were 
being pre-assessed for colonoscopy. If interested in taking part,  written, informed consent was 
obtained to undergo 2-9 research biopsies in addition to clinical biopsies.  
In all patients symptoms of diarrhoea were recorded including the presence or absence of liquid 
stool and average stool frequency in 24hrs. Drug history and where possible wt, height and BMI 
were also recorded. Each of the patient groups studied are described in the specific methods of 
chapters 4,5 and 6. Colesevelam was stopped 48hrs prior to samples in BAD patients. 
2.3.3 Samples from retrospective cohort of patients with chronic diarrhoea 
 
Historical stored ileal biopsy samples from a previously recruited cohort of 15 patients was also 
included in baseline intestinal FGF19 expression studies [71]. These patients had been investigated 
for chronic diarrhoea (an average of 3 loose, type 6 or 7 stools per day for greater than 3 months) 
with colonoscopy and SeHCAT scanning. 3-6 ileal biopsies had been taken at colonoscopy and stored 
in RNA later and immediately frozen and stored at -80 for later processing.  
2.3.4 Samples for basal ileal FGF19 transcript expression studies  
For this part of the study, groups of 3 mucosal biopsies were taken from the following anatomical 
regions; terminal ileum, proximal and distal colon. From each region the 3 mucosal biopsies were 
pooled and placed together in 400ul of RNAlater in separately labelled sterile RNAse free, 1.5ml 
microcentrifuge tubes. Distal colonic biopsies were taken from the sigmoid colon just above the 
rectosigmoid junction. For each patient, separately labelled ileal, proximal and distal colonic biopsies 
were then transferred to a -80 freezer for storage and subsequent processing for the analysis of 
baseline gene expression.  Intestinal samples taken from prospectively recruited patients were 
thawed and processed within 6 months of sampling. The 15 historical ileal samples were thawed and 
processed as part of this thesis 2 years after the samples were taken at colonoscopy. 
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2.3.5 Explant incubations and bile acid preparations: 
Patients were screened and consented as described above 2.3(a). Two to eight ileal mucosal biopsies 
were placed in pre-oxygenated Dulbecco Modified Eagle's Medium (DMEM, PAA systems E15-843) 
on ice for immediate transfer (5-10 mins) to culture media in an incubator at 37°C 5% CO2 in a 
primary cell culture lab for 6 hour incubations. 
Culture wells were pre-filled with ‘complete culture media’ from 6 well culture plates (NunclonTM Δ 
Surface multidishes, ThermoScientific 140685). Complete culture media was prepared by 
supplementing DMEM with 10% heat-inactivated fetal calf serum, 100 units/ml penicillin, 100 µg/ml 
streptomycin, 50 µg/ml leupeptin, 50 µg/ml soybean trypsin inhibitor, and 1 mM 
phenylmethylsulfonyl fluoride (PMSF). The media was also aliquoted to be stored at -20°C for future 
use. On the day of an incubation frozen culture media was thawed and brought to 37°C (in a water 
bath) prior to obtaining biopsies. All culture media had high concentration oxygen (95%O2 and 
5%CO2) bubbled though it with sterile tubing for 5 seconds.   
The culture well in the first position of the 6 well dish was always designated a substrate free well 
(negative control), containing culture media only +/- vehicle. The other wells contained the substrate 
of choice (a BA or BA analogue). For incubations six or eight terminal ileal biopsies were usually 
obtained from an individual patient. Groups of 2 or 3 explants (from the pool of 6-9 ileal biopsies 
from an individual patient) were then placed into each well depending on how many conditions 
were being studied in parallel (figure 4).  
 
 
 
Susbtrate free, 
unstimulated explants: 
culture media only 
vehicle 
BA stimulated 
explants: Culture 
media + CDCA 
50µM 
BA stimulated 
explants: Culture 
media + GCDCA 
50µM 
Oxygen inlet 
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Figure 2.0. An example of an incubation of 6 terminal ileal biopsies (explants) from one patient. 
Groups of 2 biospsies maintained in 3 parallel culture wells in 3 separate conditions. Each culture 
dish contained 2mls of complete media.  Bile acids (CDCA = Chenodeoxycholic acid, GCDCA = Glyco-
chenodeoxycholic acid) were usually added to stimulate BA regulatory genes. Transcriptional gene 
expression in stimulated explants was then compared to control ‘unstimulated’ explant expression. 
Stock solutions of bile acids were made to 10mM and the different BA and concentrations used are 
shown in table 2.1. Small aliquots were frozen at -20 for single use aliquots to prevent repeated 
freeze thaw cycles. The conjugated BA, GCDCA was dissolved directly into DMEM and the 
unconjugated BAs studied were dissolved in a solvent vehicle, dimethyl sulfoxide DMSO (Sigma UK, 
D8418) or ethanol. The addition of 10µl of BA to the total volume of 2mls culture media was then 
required to obtain a concentration of 50µM.  This concentration was used most often as it was also 
used in cell and non cell based FXR activation assays[9]. BA aliquots amounted to no more than 0.5% 
of the total volume of culture fluid. 
Bile acids / BA analogue Concentration in µM used 
in explant incubations 
Manufacturer 
Glyco-chenodeoxycholic acid 
(GCDCA) 
1-100 Sigma UK 739715 
Chenodeoxycholic acid 
(CDCA) 
1-100 VWR A1690 
Cholic acid (CA) 50 Sigma Uk C1129 
Deoxycholic acid (DCA) 50 Sigma Uk D2510 
Lithocolic acid (LA) 50 Sigma Uk L6250 
6-ethyl-3,7-dihydroxy-5-
cholan-24-oic acid, 
Obeticholic acid, INT 747 
(OCA) 
1-20 Gift from Intercept 
pharmaceuticals, San Diego, 
USA 
 6-ethyl-3,7,23-trihydroxy-24-
nor-5-cholan-23-sulfate 
sodium salt, INT 767 
1 Gift from Intercept 
pharmaceuticals, San Diego, 
USA 
 
Table 2.1. (BA) Bile acids and BA analogues and the concentration ranges studied in explant 
incubations with abbreviations and/or synonyms and manufacturers. 
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The culture plates were then placed in a sealed plastic container with a small inlet valve allowing for 
oxygen tubing to be attached allowing for oxygenation intermittently. The container was placed in 
the incubator at 37°C and 5%CO2 and oxygenated for 30 seconds at the start and at 2 hourly intervals 
during each 6 hour incubation. At the end of the incubation, biopsies were placed in RNAlater and 
stored at 4 °C overnight, then transferred the next day to be stored at -80 °C prior to RNA extraction. 
Culture fluid from the 6 well plates was also collected and immediately frozen in 500ul aliquots at -
80 for later analysis. This experimental set-up is similar to a previous successful set-up described by 
Balesaria et al for human duodenal transcriptional responses to stimulation by Vitamin D[97].  
2.3.6 Tissue disruption, lysis and RNA extraction 
Stored biopsies from explant incubations or basal expression samples were thawed suspensed in 
RNAlater to preserve RNA from environmental RNAses. Upon thawing of samples they were 
immediately transferred to eppendorfs containing lysis buffer including dithiothreitol (DTT) at 40mM 
concentration. Phyisical tissue disruption of biopsies was performed using a mechinal rotostator or 
hand held (RNAse free) pestle and mortars (VWR) for each group of explants. When hand hand held 
pestle and mortar was used for tissue disruption, an additional step was used to enhance tissue 
discruption and minimise residual tissue debris. This involved centrifuging the lysate through a 
biopolymer-shredding system in a microcentrifuge spin-column format (QIAshredder, QIAGEN, 
70565).  
The lysate was then processed using silica membrane based spin columns using the RNeasy Mini kit 
(Qiagen 74106) according to the manufacturer’s protocol to isolate total RNA.  To minimise genomic 
DNA contamination, further RNA purification was performed on-column using a RNase-free DNase 
set (Qiagen 79254). At the end of the protocol total RNA was eluted in 50µl nuclease free sterile 
water. RNA concentration of the ‘eluate’ and purity obtained was then assessed using a 
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ThermoScientific NanoDrop 1000 Spectrophotometer, and then stored at -80’C. Nanodrop RNA 
concentrations were expressed as ng/ul.  
2.3.7 cDNA synthesis 
Synthesis of cDNA from RNA was carried out using a SuperScript kit (Invitrogen 11904-018). To 
control for any differences in RNA yield or amount of tissue between specimens, all RNA was diluted 
to obtain 1ug.  Reaction volumes of 20 µl were used. The first step was to combine 1 µl dNTP mix 
(10 mM) and 1 µl random hexamers (50 ng/µl), with the RNA eluate and DEPC treated water to 
obtain  1 µg RNA to an initial volume of 10ul.  
This would mean that RNA eluate of concentrations of 125ng/ul would require the addition of 8ul 
RNA eluate without dilution + 1ul dNTP mix and 1ul random hexamers. Concentrations above 
125ng/ul were diluted with DEPC to achieve a final RNA concentration of 1ug  (eg 331.18ng/ml 
required 3.02uls of RNA eluate and 4.98 uls of DEPC treated water within the 8ul reaction volume) .  
This 10ul initial reaction volume was followed by  the addition of 2 µl 10X RT buffer, 4 µl MgCl2 
(25 mM), 2 µl DTT (0.1 M), 1 µl RNaseOUTTM (40 U/µl), 1 µl SuperScript II RT (50 U/µl). Reverse 
transcription was performed at 42 ºC for 50 minutes according to the manufacturer’s instructions. 
The reaction was terminated at 70°C for 15 minutes.  Minus reverse-transcriptase controls were 
included, where SuperScript II RT was replaced with 1 µl DEPC-treated water. The RNA template 
from the RNA:cDNA hybrids were removed by treatment with 1 µl E.coli RNase H (2 U/µl) for 
20 minutes at 37 ºC .  
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2.4 Quantitative real-time reverse-transcription PCR (RT-PCR) 
2.4.1 Primer design 
Primer sequences and characteristics are summarised in Table 2.2. FGF19 primers were designed 
using the following criteria: primer length of 18-22 base pairs (generally accepted as optimal), similar 
melting temperatures (Tm), similar G-C content, no more than 3 consecutive identical nucleotides, 
presence of G-C clamping and amplicon size between 85 and 150 base pairs. For the endogenous 
control, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were used, as described 
previously [98], and although amplicon size is >150 base pairs, the primers had amplified successfully 
in this previous study. For both primer pairs, BLAT (http://genome.ucsc.edu/) was used to verify 
primer specificity and to check that amplicons span at least 2 exons (to prevent genomic DNA 
amplification). In silico PCR methods were also used to obtain melting temperatures. 
Primer Sequence (5’-3’) Position Primer 
melting 
temperature 
(Tm, ºC) 
G-C 
content 
(%) 
Amplicon 
size (base 
pairs) 
Human 
FGF19, 
forward 
CGG TAC CTC TGC ATG GGC chr11: 
69,518,053-
69,518,070 
62.6 67 95 
Human 
FGF19, 
reverse 
CCA TCT GGG CGG ATC TCC chr11: 
69,514,292-
69,514,309 
64.0 67 
Human 
GAPDH, 
forward 
CGA CCA CTT TGT CAA GCT CA chr12: 
6,647,136-
6,647,155 
60.0 50 203 
Human 
GAPDH, 
reverse 
AGG GGA GAT TCA GTG TGG TG chr12: 
6,647,423-
6,647,442 
60.0 55 
Table 2.2. FGF19 and GAPDH primer sequences. 
2.4.2 RT-PCR protocol 
Amplification of cDNA was performed using SYBR Green JumpStart Taq Ready Mix (Sigma-Aldrich, 
UK) in an Applied Biosystems 7900HT Fast cycler. Singleplex RT-PCR assays were performed in 
triplicate in 25 µl reaction volumes, using MicroAmp® Fast Optical 96-well reaction plates (Applied 
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Biosystems, UK) or in 8 µl reaction volumes using MicroAmp® Optical 384-Well reaction plates 
(Applied Biosystems, UK). Final cDNA dilution in each well was 1in 25 and final primer concentration 
was 0.4µM. 
Each plate was run with minus reverse-transcriptase controls, and PCR controls (1 in 25 volume of 
DEPC-treated water added to a triplpicate of reaction wells instead of 1 in 25 volume cDNA). The 
thermal cycling programme was as follows: 10 minutes of 95 ºC (to activate Taq polymerase), then 
40 cycles of 15 seconds at 95 ºC, 1 minute at 60 ºC, and 1 minute at 72 ºC, ramping at 1.4 ºC / sec 
between each step of the cycle. Dissociation-curve analysis to determine melting temperatures (Tm) 
of nucleic acids was performed to check for product specificity [99] using the same Applied 
Biosystems 7900HT Fast cycler, with a temperature range of between 60 ºC and 95 ºC, ramping at a 
rate of 0.3 ºC / 10 sec. 
Results were excluded according to the following exclusion criteria:  
1. Any samples where amplification revealed a Ct > 35 cycles. 
2. Where the standard deviation of the mean delta Ct (∆Ct) from triplicate samples was >0.3 
3. If amplification curves of triplicate samples revealed more than one outlier (>0.5 cycle) 
4. Dissociation curve analysis showed more than one specific product. 
Results were analyzed using relative quantification methods. Basal expression of target gene 
transcript levels were calculated by converting delta Ct values to the linear form using the 
calculation 2 (-dCT) (See specific methods, chapter 4). For stimulated explants studies, the comparative 
Ct method was used to give fold changes of FGF19 expression relative to the ‘calibrator’ control 
sample in each patient (see specific methods Chapter 5).  
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Primer sequences and characteristics of other genes are summarized in table 2. Other primer 
sequences were taken from other previously published human studies using SYBR green assays  
 
Primer Sequence (5’-3’) 
Human FGF19, forward CGG TAC CTC TGC ATG GGC 
Human FGF19, reverse CCA TCT GGG CGG ATC TCC 
Human GAPDH, forward CGA CCA CTT TGT CAA GCT CA 
Human GAPDH, reverse AGG GGA GAT TCA GTG TGG TG 
Human ASBT, forward GCC CCA AAA AGC AAA GAT CA 
Human ASBT, reverse GCT ATG AGC ACA ATG AGG ATG 
Human IBABP, forward TCA GAG ATCGTG GGT GAC AA 
Human IBABP, reverse TCA CGC GCT CAT AGG TCA 
Human SHP, forward AGG GAC CAT CCT CTT CAA CC 
Human SHP, reverse TTC ACA CAG CAC CCA GTG AG 
Human FXR, forward AGG ATT TCA GAC TTT GGA CCA TGA 
Human FXR, reverse TGC CCA GAC GGA AGT TTC TTA TT 
Human OSTα, forward AGA TTG CTT GTT CGC CTC C 
Human OSTα, reverse ATT CGT GTC AGC ACA GTC ATT 
Human OSTβ, forward CAG GAG CTG CTG GAA GAG AT 
Human OSTβ, reverse GAC CAT GCT TAT AAT GAC CAC 
 
Table 2.3. Primer sequences used in chapters 4-6. 
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2.5 Statistical analysis and interassay variability 
In the serum studies of chapter 3 results will be analyzed by comparing groups of patients with 
active and inactive Crohn's.  17-18 patients in each group will have 80% power to detect a difference 
equal to the SD of the sample at the 0.05 level.  Sequential samples will be compared in patients 
before and after response to treatment with corticosteroids and anti-TNF.  In these paired 
comparisons, 10 patients will give similar power. Non parametric Mann Whitney tests will be used to 
compare cross sectional comparisons of patients from the serum studies and paired non-parametric 
Wilcoxon paired test for the 10 patients before and after treatments. Spearmans rank correlation 
coefficients will be used to assess relationships between FGF19 levels and clinical variables.  
In the explant studies of Chapters 4,5 and 6. Non-parametric Mann-Whitney tests and Spearman’s 
rank correlations were also used. Corrections for multiple correlations were not applied in Chapter 4 
as this is a relatively small group of patients and the comparisons in Chapter 4.4.4 and 4.4.5 are 
exploratory in nature. 
For PCR assays, baseline expression studies all samples were assayed on the same plate. For 
Stimulated expression studies a positive control was included in each assay to ensure that the 
GAPDH Ct was within one cycle of previous measurements. All ELISA assays were run with mid pool 
samples (previously collected with known FGF19 levels) to ensure consistency and observe the 
inter-assay variation. 
2.6 Culture fluid ELISA for FGF19 
Culture fluid collected at the end of each incubation for both BA free explants and BA stimulated 
explants were analysed and compared. Frozen aliquots of culture fluid were thawed at room 
temperature. The Quantikine Elisa Assay was used to measure FGF19 in culture fluid using the same 
ELISA as described previously. Standards are prepared in the same medium as culture fluid to 
exclude any binding differences. The measured concentrations (in pg/ml) were normalized according 
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to whether the culture plate well had contained 2 or 3 biopsies and the FGF19 concentration was 
expressed as pg/explant. 
2.7 DIET1 genotyping study: Allelic discrimination assay. 
Previously extracted genomic DNA was studied for the  rs12256835 SNP in a cohort of patients who 
have been previously described [71]. This cohort consisted of 78 prospectively recruited patients 
with chronic diarrhoea who underwent SeHCAT testing and fasting FGF19 serum sampling. Other 
intestinal diseases such as IBD or coeliac disease had been excluded from this cohort and the ethnic 
origin was predominantly caucasian. The 1000 genome project had revealed a rs12256835 minor 
allele frequency (MAF) of 0.28 [100]. We assumed a similar MAF of 0.28 in the diarrhoea control 
patients from this study. On the basis of recent findings  of lower prevelance of the minor allele in 
PBAD patients, power calculations were therefore designed to detect a low frequency of 0.05. For 
90% probability at detecting a significant difference between a prevalence of 0.28 and 0.05 we 
would need 64 alleles (32 patients) in each group (diarrhoea controls vs PBAD). 50 alleles (25 
patients)  in each group would have an 80% probability.  
 
Genotyping for the rs12256835 variant was performed using an end point TaqMan allelic 
discrimination assay (Life Sciences, CA, USA) on each of the 78 patient DNA samples. PCR was 
performed on 96 well reaction plates and analyzed using a StepOnePlus RT-PCR machine (Life 
Sciences, CA, USA). 
Reaction volume was 15µl per well including 7.5µl TaqMan genotyping Master Mix (2X), 0.375µl SNP 
Assay mix (40X), 6.125 nuclease free water and 1µl genomic DNA. Standard PCR conditions were: 
95ºC for 10 minutes, followed by 40 cycles of amplification at 95ºC for 15 seconds and 60ºC for 1 
minute, followed by 60ºC for 30 seconds. 
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The SNP assay consisted of a custom Taqman  rs12256835 genotype assay involving  primer/ probe 
pairs using Minor Groove Binders (MGB) as the  Non –Fluorescent Quencher (NFQ). The probe for 
allele T was labelled with VIC dye and the probe for allele G was labelled with the FAM dye (Life 
Sciences, CA, USA, assay ID C__32112379_10). The TaqMan genotyping Master Mix contained 
AmpliTaq Gold® DNA Polymerase with 5’ exonuclease activity (Life Sciences, CA, USA Catalog 
Number 4371353).  Allele 1: VIC/MGB-NFQ, T major allele, Histidine residue position 1721. Allele 2: 
FAM/MGB-NFQ, G minor allele, Glutamine residue position 1721. 
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2.8 Clinical trial: Obeticholic Acid in Bile Acid Diarrhoea: Obadiah1: 
2.8.1 Study design 
This was an open-label, single-center observational study of mechanisms, safety and symptom 
response of obeticholic acid treatment in patients with BAD.  Use of OCA was approved by the 
Medicines and Healthcare Regulatory authority (MHRA, London, UK).  Written informed consent was 
obtained from all subjects who were fully briefed that they were free to withdraw at any point in the 
study.  The study was conducted according to Good Clinical Practice guidelines.  All authors had 
access to the study data and approved the final manuscript. 
The design of the trial is shown in Figure 6.  This lasted six weeks, consisting of a two-week run-in 
period (weeks 1 and 2), two weeks of treatment with oral OCA 25mg daily (weeks 3 and 4) and a two 
week follow-up period off OCA (weeks 5 and 6).  Treatment with bile acid sequestrants was 
discontinued at the start of the trial; loperamide (up to 16mg/d) was allowed as rescue therapy.  
Daily symptom diaries were used to record stool frequency, stool  form (type) using the 7-point 
Bristol Stool Form Scale (BSFS)[101], loperamide usage, and abdominal pain, urgency and bloating 
scores on a 10-point scale, ranging from none to moderate to severe.  Hours of pain were also 
recorded.  Patients were asked to record any adverse events in their symptom diaries.  Week 5 and 6 
diaries were not returned by several patients. 
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Figure 2.2. Design of the OBADIAH1 study. Three groups of patients were studied over 6 weeks.  OCA 
was given in weeks 3 and 5 with fasting and serial blood sampling at the beginning and end of this 
period on D0 and D14 
Subjects attended on the first and last days of the two week treatment period (D0 and D14), having 
been asked to fast from 9pm the night before.  Blood was taken in the fasting state and then OCA 
was given on those days.  Subjects were then given a standard mixed content breakfast.  Further 
serial postprandial/OCA blood samples were taken at 1-hourly intervals for 6h; a standard mixed 
content lunch was consumed after 3h. 
2.8.2 Subjects 
Twenty-three patients were initially recruited from gastrointestinal clinics at the hospitals of 
Imperial College Healthcare NHS Trust.  They were aged 18 – 80y and all had described symptoms of 
passing an average more than 3 soft or watery stools per day for at least the past three months.  
Patients recruited into the idiopathic diarrhea control group  had received standard investigation for 
diarrheal symptoms prior to enrolment; other causes of diarrhoea such as colorectal neoplasia, 
ulcerative colitis, ceoliac disease, chronic pancreatitis, drug-induced diarrhoea,  active infection or 
lactose intolerance had been excluded.  The patients in the secondary BAD group had Crohn’s 
disease and/or ileal resection. Patients were excluded if they were receiving concomitant 
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corticosteroids.  Patients with clinically significant other disorders including liver disease were 
excluded. 
Work undertaken by others, not included in this thesis also involved recruiting 10 patients with a 
diagnosis of PBAD. The SeHCAT test was used for a diagnosis of BAD.  Patients with primary BAD all 
had SeHCAT 7d retention ≤ 10%.  In the secondary BAD group, SeHCAT was not required, as previous 
studies have shown that over 90% of patients with Crohn’s disease, ileal resection and chronic 
diarrhoea have a SeHCAT ≤ 10% [36, 37].  Two secondary BAD patients with Crohn’s disease did not 
have resections but had SeHCAT tests with retention values of 10% and 4%.  The median ileal 
resection length was 33.5cm, range 0 – 71cm.  Several patients also had short colonic resections.  
Patients in the control group with idiopathic chronic diarrhoea all had normal SeHCAT 7d retention 
of greater than 15%. 
2.8.3 Statistical analysis 
The primary endpoint was the change in fasting FGF19 in each group between the samples taken 
before the first dose of OCA (D0) and after 2 weeks (D14) before the last dose.  Secondary endpoints 
included changes in fasting C4 and BA, liver enzymes, lipids and in clinical symptoms.  Peak values 
during the serial sampling (usually at 5 or 6h) were identified and 0-6h integrated responses (area-
under-curve; AUC) values for FGF19 and BA were compared on D0 and D14. 
Symptoms recorded in the patient diaries were analyzed as total weekly stool frequency and mean 
weekly BSFS.  Total weekly loperamide use (in mg) was calculated.  As patients responded in 
different ways, to detect a global improvement involving changes in any of these parameters, a 
weekly diarrhea index (stool index) was calculated using the formula ([weekly stool frequency * 
mean BSFS] + loperamide use [weekly mg*3]).  This equates one 2mg dose of loperamide to one 
type 6 stool.  Comparisons were made between data for W2, the second week of the run-in period 
off specific treatment, with data for  W4, the second week of OCA treatment. 
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Data are usually reported as medians and interquartile ranges (IQR).  Nonparametric tests were used 
to look for treatment effects between the two groups, Mann-Whitney U unpaired or Wilcoxon 
paired rank tests and Spearman rank correlations.  Statistical analyses were performed using 
GraphPad Prism 5, Ca, USA.  P values <0.05 were considered significant. 
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Chapter 3: Diarrhoea in Crohn’s disease: investigating the potential role of the ileal 
hormone fibroblast growth factor 19 
 
Abstract 
Background: Bile acids (BA) are usually reabsorbed by the terminal ileum, but this is frequently 
abnormal in Crohn’s disease (CD).  BA malabsorption occurs and excess colonic BA cause secretory 
diarrhea.  Furthermore, the hormone Fibroblast Growth Factor 19 (FGF19) is synthesized in the 
ileum in response to BA absorption and regulates BA synthesis. We hypothesized that reduced 
serum FGF19 levels will be associated with diarrheal symptoms and disease activity in both ileal-
resected (IR-CD) and non-resected CD (NR-CD) patients. 
Methods:  Fasting serum FGF19 levels were measured in 58 patients (23 IR-CD patients and 35 NR-
CD patients).  Disease activity was assessed using the Harvey Bradshaw Index and CRP. Stool 
frequency, Bristol stool form scale and length of previous ileal resection were recorded.  FGF19 
levels were also compared to healthy and diarrhea control patients.  
Results: FGF19 levels were inversely correlated with ileal resection length in IR-CD patients (r=-0.54, 
p=0.02, n=18). In NR-CD patients, median FGF19 levels were significantly lower in patients with 
active disease compared to inactive disease (103 vs 158 pg/ml, p=0.04) and in those with symptoms 
of diarrhea compared to those without (86 vs 145 pg/ml, p=0.035).  FGF19 levels were inversely 
correlated (r =-0.52, P=0.02) with stool frequency, Bristol stool form and CRP in NR-CD patients with 
ileitis.  
Conclusions: Reduced FGF19 levels are associated with diarrhea and disease activity. FGF19 may 
have utility as a biomarker for functioning ileum in CD. This study supports a potential role of FGF19 
in guiding treatments for diarrhoea in Crohn’s disease. 
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3.1 Background 
Diarrhoea is a major feature of active disease in Crohn’s disease (CD) and a major influence on the 
ill-health experienced by patients.  Clinical disease activity scores are heavily influenced by the 
frequency of liquid stools.[95]  Stool frequency and form are among the least subjective components 
of the symptomatic scores but do not necessarily reflect active inflammatory disease.   
The pathophysiology of diarrhoea in CD is multifactorial but there are two key factors.  Colonic water 
and electrolyte absorption can be impaired directly by colonic inflammation,[102] or indirectly  by 
increased concentrations of bile acids (BA) having secretory effects, [103, 104] referred to as BA-
induced diarrhoea (BAD).  In healthy subjects, approximately 95% of luminal BA within the small 
intestine are reabsorbed at the terminal ileum, with only small amounts entering the colon.  In CD 
patients, increased colonic BAs result from impaired reabsorption of BAs at the terminal ileum.  This 
can be either due to ileal inflammation or resection, and may also relate to reduced expression of 
the ileal apical sodium dependent bile acid transporter (ASBT).[41, 46, 53]  This bile acid 
malabsorption (BAM) can be regarded of as part of the usual phenotype of CD. 
Options for diagnosing  bile acid malabsorption have recently been reviewed[105]. The gold 
standard test for diagnosing BAM is the measurement of increased concentrations of fecal BA.  This 
is not commonly done as it is unpopular for patients and lab staff.  Other more indirect markers for 
BAM are measures of BA retention (SeHCAT scan).[106]  This involves the oral administration of a 
radiolabelled BA (SeHCAT) and measurement of its retention within the enterohepatic circulation.  
Seven day retention is usually reported and reduced retention levels reflect increased losses of BA 
into the feces. Reduced SeHCAT retention levels are associated with chronic diarrhoea in quiescent 
CD in the vast majority (90%) of patients with previous ileal resection and as many as 50% of those 
patients without previous ileal resections[36] [37]. As many as 30% of those previously regarded as 
having IBS-D also have reduced SeHCAT retention [63] . The majority of these patients gained 
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symptomatic benefit from BA sequestrants, such as cholestyramine.  More recent studies using a 
newer BA sequestrant, colesevelam, has also demonstrated positive effects on symptoms of 
diarrhoea in CD.[107] 
Another indirect marker of BAM is the BA precursor 7α-hydroxy-4-cholesten-3-one (C4).  Serum 
levels of C4 are a measure of new bile acid synthesis and increase in response to BA losses from the 
entero-hepatic circulation.[73]  Measuring C4 involves HPLC or tandem mass spectrometry which 
requires specialized techniques.  Increased levels of C4 have been shown to be associated with 
chronic diarrhoea in pediatric CD.[108]  Using older methods markers of BAM were found to relate 
to disease activity in previous studies  
FGF19 is a hormone produced in the enterocytes of the ileum in response to absorbed BAs.[22, 109, 
110]  BAs bind to the farnesoid X receptor (FXR) in enterocytes and increase transcription of FGF19.  
Serum FGF19 levels are thus a direct marker of BA absorption and we have shown they are reduced 
in BA malabsorption.[58] Reduced levels of FGF19 have been demonstrated in patients with both 
ileal resected and non-resected CD.[72] [57, 111] FGF19 is easily measured using commercially 
available ELISA.  FGF19 levels and C4 are inversely correlated in several groups including CD.   ROC 
curve analysis has revealed that the optimal level of FGF19 for predicting severe BAM (defined by 
C4>50ng/L )was <60pg/ml with a 80% sensitivity and 68% specificity in CD.[57] We have previously 
shown an optimal level of FGF19 at <145pg/ml has a sensitivity of 58%  and a specificity of 79%  to 
detect C4 levels of >28ng/ml in a cohort of BAD patients including CD.[72]  
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3.2 Aims 
(1) We aimed to investigate the relationship between serum FGF19 levels and CD disease activity 
scores, and in particular symptoms of diarrhoea (the main symptomatic consequence of BAM) in 
patients with CD.  
(2) We aimed to study the relationship between serum FGF19 levels and length of previous ileal 
resection in patients. 
(3) To study how FGF19 levels are influenced by anti-inflammatory treatments used to treat patients 
with diarrhoea and active disease. 
3.3 Specific methods 
 
Described in serum FGF19 studies Chapter 2.2 
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3.4 Results: 
3.4.1 Patient demographics 
 
 NR-CD IR-CD Idiopathic* 
diarrhea 
Healthy* 
controls 
Ileal disease Colonic 
Number 21 14 23 68 19 
  Median Age 35 (25-40) 38 (29-55) 50 (39-67) 50 (33-61) 47 (23-61) 
Gender  
  Female 
  Male 
Clinical indices 
 
10 (48%) 
11 (52%) 
 
10 (71%) 
4 (29%) 
 
12 (52%) 
9 (48%) 
 
46 (68%) 
22 (32%) 
 
     9 (47%) 
10 (53%) 
  CRP mg/dL 10 (2-24) 5 (2-27) 3 (1-9) - - 
  HBI 6   (3-7) 4 (0-6) 4 (2-6) N/A N/A 
  Stool Freq 3   (1-3) 3 (1-4) 4 (2-5) 5 (4 -8) 1 (1-1.5) 
  BSFI 
Median Resection length(cm) 
Resection length range (cm) 
Current medications 
5   (2-6) 5 (3-7) 6 (5-6) 
40  
10-96 
6.5 (6-7) - 
  5-ASAs 4 (20%) 3 (20%) 3 (13%) - - 
  Immunomodulators 7 (33%) 4 (29%) 8 (34%) - - 
  Biologics 4 (20%) 2 (14%) 0 - - 
  Corticosteroids 5 (24%) 2 (14%) 1 (5%) - - 
  No Medication 7 (33%) 5 (36%) 11 (48%) - - 
 
Table 3.1 *These results are from previously studied patients for comparison only and were not 
recruited as part of this PhD. Medians and Interquartile ranges are shown. Percentages are shown 
where indicated. For comparisons, additional results are included from sixty-eight previously studied 
[71] patients with idiopathic chronic diarrhea (without evidence of inflammatory bowel disease, 
previous resections or bile acid diarrhea  and SeHCAT >15%) as an ‘idiopathic diarrhea control’ 
group.  Nineteen previously studied healthy control subjects were also included.[58] 
3.4.2 FGF19 levels in Ileal resected (IR)-CD patients: 
FGF19 levels were lower in IR-CD patients (median 68pg/ml) than in the previously described healthy 
controls (231 pg/ml; p=0.0002) [Walters CGH] confirming previous findings.[57, 72]  We found a 
significant inverse correlation between the recorded length of ileum resected and the fasting serum 
FGF19 in IR-CD patients (Spearman r = -0.55, P = 0.02, Figure 3.1). Over half of the IR-CD patients, 14 
/ 23 (60%) were suffering from symptoms of diarrhea.  Five of these patients were taking regular BA 
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sequestrants and 4 others were unable to tolerate them.   There was a trend towards lower FGF19 
levels in those patients suffering from chronic watery diarrhea compared to those without (P = 0.09).  
 
 
 
Figure 3.1. Significant inverse correlation between fasting FGF19 vs previous ileal resection length 
obtained from surgical records. Spearman’s rank correlation coefficient (r) is shown. NR-CD = Non 
resected Crohn’s disease. 
 
 
3.4.3 FGF19 levels in Non-Resected CD patients 
The median FGF19 levels in NR-CD (112 pg/ml) were 52% lower than in previously described healthy 
controls (p <0.0001).  Comparisons with previously described diarrhea controls were also highly 
significantly different. Median FGF19 levels were similar in healthy control patients and diarrhea 
control patients (231 and 237pg/ml). Within the cohort of NR-CD patients, those with diarrhea had 
median FGF19 levels 41% lower than those without diarrhea (86 vs 145pg/ml, p = 0.035, Figure 3.2). 
Median FGF19 levels were 35% lower in patients with NR-CD and active disease (as shown by the 
HBI) compared to those with inactive disease (103 vs 158 pg/ml, P=0.04, Figure 3.3)  
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Figure 3.2. Fasting levels of FGF19 in groups of patients with and without diarrhea (stool frequency 
≥3, BSFS > 5).  NR-CD = Non-resected Crohn’s disease, IR-CD = Ileal resected Crohn’s disease. Median 
and Inter Quartile Ranges are shown; Mann Whitney U test was used for comparisons. 
 
 
 
 
Figure 3.3. Fasting FGF19 levels are significantly 
lower in NR-CD patients with disease activity 
(HBI>4) than those in clinical remission (HBI≤4).  
HBI = Harvey Bradshaw Index. Mann Whitney U 
test, Medians and Interquartile ranges shown. 
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Of the 19 NR-CD patients with active disease at the time of sampling, 11 of these patients were 
suffering from diarrhoea. Symptoms of diarrhoea were present in both colonic CD (5 /6 patients) and 
in those with ileal involvement (6/13 patients). In the patients with ileal involvement, median FGF19 
levels were 71% lower in patients with diarrhoea than those without (40 vs 177 pg/ml respectively). 
The similar trend in the patients with colonic CD was non-significant (Figure 3.4). Patients with ileal 
involvement and diarrhoea had significantly lower median FGF19 levels than those with colonic CD 
and diarrhea (P=0.004). Significant inverse correlations between FGF19 levels and stool frequency, 
BSFS, CRP and stool index were found; these inverse correlations were strongest in those patients 
with ileitis (Figure 3.5, table 3.2).  
 
Figure 3.4 Fasting FGF19 levels in NR-CD (Non-resected CD) patients in those with (a) ileal 
involvement and (b) colonic involvement, respectively, according to the presence or absence of 
diarrhoea (Stool frequency ≥3, BSFS > 5).  Line represents an FGF19 level of 60pg/ml. Levels below 
60pg/ml have been shown to be associated with severe BAM (C4 levels >50) in a cohort of CD 
patients from another study.[57]  Mann-Whitney U test, median levels and Interquartile ranges are 
shown. 
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Figure 3.5. Significant inverse correlations between FGF19 levels and a calculated SI (stool index) in 
(A) all patients with NR-CD and (B) in those with ileitis (ileal or ileo-colonic disease). Spearman’s rank 
correlation coefficient (r) shown and regression lines. 
 
 Stool freq/ day BSFS SI HBI CRP (mg/dL) 
NR-CD all (n=35)      
  Spearman r -0.34 -0.36 -0.35 -0.24 -0.37 
  P value  0.04 0.03 0.04 0.15 0.03 
NR-CD ileitis (n=21)      
  Spearman r -0.49 -0.45 -0.52 -0.39 -0.58 
  P value  0.02 0.04 0.02 0.08 0.006 
Diarrhea controls (n=68)      
  Spearman r 0.07 0.04 0.24   
  P value 0.56 0.80 0.07   
 
Table 3.2 FGF19 correlations with clinical indices. Spearman’s rank correlation coefficients shown. 
BSFS = Bristol Form Stool Index. SI = Stool index, HBI = Harvey Bradshaw Index 
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Using a cut-off value of 145pg/ml (previously shown to have a 80% sensitivity and 60% specificity as 
a marker of excess BA losses assessed by SeHCAT retention levels in PBAD[71]), levels below 
145pg/ml were significantly commoner in those with symptoms of diarrhea in all 35 NR-CD patients 
studied (P=0.028, Fisher’s exact test).  Using a lower cut-off value of 60pg/ml (previously shown to 
have a 80% sensitivity and 68% specificity as a marker of more severe BA losses assessed by C4 levels 
in IBD[57]) revealed that levels below 60pg/ml were significantly associated with symptoms of 
diarrhea in the 21 NR-CD patients with ileitis (P=0.046, Fisher’s exact test). 
 
3.4.4 Serial FGF19 levels during the day 
Repeated FGF19 sampling pre and post meals were compared between patients with CD and 
diarrhea control patients. Serial FGF19 levels remained low with no evidence of diurnal variation pre 
and post meals in the 3 CD patients compared to the 4 diarrhea control patients (figure 3.6). 
 
Figure 3.6. Diurnal variation in FGF19 levels in CD patients vs non inflammatory diarrhea control 
patients.  Closed shapes and solid lines = 3 patients with CD and diarrhea (one with ileitis and the 
other 2 with previous ileal resections). Open shapes and dotted lines = 4 idiopathic diarrhea control 
patients (without evidence of Primary BA Diarrhea, SeHCAT retention >10%). Arrows indicate 
standardized meals (9am and 12 midday). 
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3.4.5 Serial FGF19 in NR-CD patients on treatment 
In the longitudinal studies, initial serum FGF19 levels were measured in patients in clinical remission 
on different days to look for intra-individual variability.  There was no significant difference between 
the paired levels (n = 6, Wilcoxon P = 0.68).  Median FGF19 levels were significantly lower in the 
patients with ileitis while their disease was active (median 40 pg/ml, range 3 – 92) compared to 
paired levels taken after medically induced clinical remission and resolution of diarrhea (median 140 
pg/ml, range 106 – 184, P=0.03, paired Wilcoxon).  Median FGF19 levels were not statistically 
different in the 5 patients with colonic CD during active disease (median 113 pg/ml, range 50 – 120) 
compared to paired levels taken during medically induced clinical remission and resolution of 
diarrhea (median 70 pg/ml, range 40 - 120, p=0.5 Wilcoxon, Figure 3.7). The median time interval 
between samples taken during disease activity and medically induced remission was not significantly 
different between these groups (median interval: colonic  98 days, range 28 – 168 vs ileitis 83 days 
range 40 -159, p = 0.66 Mann Whitney U test). 
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Figure 3.7. FGF19 levels during a period of disease activity followed by a repeat sample during 
clinical remission after anti-inflammatory treatments used to induce remission (biologics or 
corticosteroids).   
 
Two out of five patients with colonic CD were treated with corticosteroids and five out of six patients 
with ileitis were treated with corticosteroids.  The remaining patients were treated with biologics 
(infliximab or adalimumab) only.  The open circles represent patients that were still receiving 
corticosteroids when the repeat FGF19 sample was taken (Paired values were compared using the 
Wilcoxon signed rank test). 
 
3.5 Discussion 
 
Overall, significantly reduced median FGF19 levels were associated with active disease and more 
specifically with symptoms of diarrhea in NR-CD. Median FGF19 levels were found to be significantly 
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lower in those patients with ileitis and diarrhea than those with disease restricted to the colon and 
diarrhea.  In addition to this, FGF19 levels increased in NR-CD patients who received anti-
inflammatory treatments leading to clinical remission and resolution of diarrhea in those patients 
with ileitis but not colonic CD. As excess fecal BA are more likely to contribute to the diarrhea of 
patients with ileitis than those with pure colonic disease, these differences support the role of FGF19 
as a marker of both BAD and ileitis in NR-CD. 
 
The association between ileal inflammation and markers of BA malabsorption have previously been 
demonstrated in NR-CD patients using older markers of BA loss techniques.[41] Similar to our 
findings with FGF19, inverse relationships between symptoms of disease activity and SeHCAT 
retention values have also been demonstrated previously in NR-CD.[41, 42] 
 
A significant inverse correlation was found between fasting FGF19 and length of terminal ileal 
resection despite the possible confounding variables that may affect this (such as total small bowel 
length, type of anastomosis, and gut microbial metabolism of bile acids). We also observed a 
complete loss of normal post prandial diurnal variation in FGF19 levels throughout the day in the 
patients with ileal resection or inflammation.  The pattern is similar to those observed in healthy 
controls that remain fasted throughout the day.[22] These findings suggest that the terminal ileum is 
critical to the basal production of serum FGF19.   
 
The higher FGF19 levels post treatment in patients with ileitis may also have been influenced by the 
use of corticosteroids.  Budesonide treatment has been shown to increase the expression of ASBT 
protein in the terminal ileum of healthy volunteers.[46] In vitro reporter assays have revealed a 
Glucocorticoid Receptor (GR) response element within the promoter region of ASBT and various 
animal models have demonstrated an increase in ASBT expression and function after corticosteroid 
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treatments.[46, 112]  Hence, the higher post treatment FGF19 levels seen in some patients in this 
study may have been influenced by corticosteroid induced increases in ASBT expression and BA 
absorption.  
 
It is important to note that FGF19 synthesis occurs after absorbed BAs bind and activate the 
intracellular BA receptor Farnesoid X Receptor (FXR).[113] The most FXR responsive BA regulatory 
gene in human ileum is FGF19. [109] However, FXR activation may also enhance anti-inflammatory 
genes and down regulate pro-inflammatory genes. [56] [86]  Obeticholic acid, a potent, 
semisynthetic FXR agonist has demonstrated anti-inflammatory and anti-fibrotic properties within 
the liver,[114, 115] [87] and possibly within the intestine.  [116, 117] Perhaps the most relevant 
application in human IBD will be in ileal CD, as this phenotype is most likely to be associated with a 
deficit in endogenous intestinal FXR activation.[54]  Hence reduced fasting circulating FGF19 levels 
may also serve as a biomarker of impaired FXR activation.  
 
FXR agonists may therefore have dual functional effects in ileal CD. Stimulating FGF19 may have 
beneficial symptomatic effects by the inhibitory actions on BA synthesis reducing excess colonic BAs. 
The FXR agonist Obeticholic acid has shown positive effects on diarrhea symptoms in an open label 
phase II study of primary and secondary  BAD patients.[96] Additional positive effects on ileal FXR 
mediated barrier function may also result and requires further study. 
  
It has already been established that the majority of patients with chronic diarrhea and previous ileal 
resection are likely to be suffering from BAD and will have symptomatic benefit following treatment 
BA sequestrant therapy.[36]  However, using reduced FGF19 as a marker of BAD in this study has 
revealed that the majority of NR-CD patients with ileitis, disease activity and symptoms of diarrhea 
are also likely to gain symptomatic benefit from treatments for BAD. FGF19 levels may have utility in 
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the work up of a NR-CD patient suffering from an acute flare of disease activity and diarrhea. 
Diarrhea associated with higher levels of FGF19 is more likely to be associated with colonic 
inflammation and less likely to respond to such treatments.  Levels less than 60pg/ml are likely to be 
associated with severe BAM, ileal inflammation and BAD. These patients are likely to benefit from 
BA sequestrants, budesonide or potential future treatments to restore FGF19 levels and reduce 
excess colonic BA such as FXR agonists. 
  
69 
 
Chapter 4: Basal expression of FGF19 and other BA regulated genes in human 
ileum  
 
Abstract 
Background: Animal models of FGF15/19 deficiency develop a phenotype similar to PBAD 
characterized by increased BA synthesis, BA pool size and excess faecal BAs. Primary bile acid 
diarrhoea (PBAD) is a chronic diarrhoeal disease characterized by excess faecal BA loss and reduced 
SeHCAT 7d retention (<15%. The condition has previously been shown to be associated with an 
increased BA pool size and increased BA synthesis. PBAD could result from FGF19 deficiency or ileal 
BA malabsorption. We set out to investigate the normal and PBAD related basal expression of FGF19 
alongside other BA regulated genes (ASBT, IBABP, OSTa/b, SHP, FXR) in human ileum.    
Aim: To determine ileal and colonic transcript expression of FGF19 and genes related to BA 
absorption in healthy controls, CD and patients with chronic diarrhoea and known SeHCAT values.  
Methods: 7 healthy controls, 6 CD patients and 15 patients with undiagnosed chronic watery 
diarrhea (stool >3/d, Bristol stool form scale >5, duration >3 month) who had undergone SeHCAT 
tests were recruited and ileal or colonic biopsies were obtained at routine ileo-colonoscopy after 
standard bowel preparation and > 6h fasting. Biopsies were stored in RNAlater. After RNA extraction 
and cDNA synthesis, transcript levels for FGF19 and GAPDH were measured in all samples and ASBT, 
IBABP, OSTα, OSTβ, SHP, FXR and GAPDH, in the chronic diarrhoea cohort were determined by qRT-
PCR. Data were analysed by Mann-Whitney U and Spearman Rank correlation tests. 
Results: FGF19 transcripts were detected in all ileal biopsies in all patients studied. FGF19 was not 
detected in any of the colonic biopsies. From the chronic undiagnosed diarrhoea cohort, 8 patients 
had SeHCAT values <15% (range 3-13%), diagnostic of PBAD, and 7 had values >15% (“diarrhea-
controls”). Two patients (SeHCAT 5% and 13%) were excluded from further analysis as ASBT, SHP 
and FGF19 values were below detection limits, suggesting a non-ileal source. No significant 
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differences in median gene expression were detected between the groups. Overall, SeHCAT values 
were significantly correlated with FGF19 (r=0.59, p=0.027) and with ASBT (r=0.49, p=0.043) but with 
no other transcripts. FGF19 and ASBT were strongly correlated (r=0.88, p=0.0002), as was IBABP with 
OSTα (r=0.87, p<0.0001) and with ASBT (r=0.63, p=0.01). FXR and SHP were associated with many 
genes (FGF19, ASBT, IBABP, OSTα and each other) but OSTβ did not correlate with any other 
transcript. All associations were stronger in the diarrhoea-controls. In the PBAD group, the 
associations with SeHCAT were absent, and, although the correlation of FGF19 and ASBT remained 
strong, those between FXR and OSTα or IBABP were lost. 
Conclusions: FGF19 is expressed in human ileum but not colon. In patients with undiagnosed chronic 
diarrhoea, SeHCAT values are related to fasting levels of transcripts for both ASBT and FGF19. 
Although expression of many BA-associated genes are closely related, these associations are less 
strong in PBAD, implying impaired basal regulation. Their response to BA absorption may also differ. 
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4.1 Background  
FGF15 mRNA has been detected in relative abundance in mouse ileum but not in other tissues using 
RT-PCR [13]. In-situ hybridization techniques have revealed that transcripts are largely confined to 
the epithelium [7].  The localised ileal expression is a feature unique to FGF15 compared to other 
distal gut peptides such as PYY and GLP-1 which tend to be more widely expressed throughout ileum 
and colon.   
We aimed to study FGF19 transcriptional expression within human intestine. As transcripts have 
been demonstrated in mouse intestinal epithelium we would expect mucosal biopsies obtained at 
ileo-colonoscopy to be sufficient to detect human expression.  Balesaria et al had previously 
confirmed the basal expression of FGF19 in human ileum and duodenum and demonstrated that the 
expression is higher in the ileum than duodenum [118]. However FGF19 expression was detected 
using FGF19 taqman probes and reagents.  We aimed to use SYBR green technology and this would 
require designing new primers as at the time of starting this study there were no published FGF19 
primers for use in SYBRgreen assays.  
The previous study had also investigated BA regulated gene expression in patients with chronic 
diarrhoea. However only a minority of these patients had BA losses quantified with SeHCAT 
scanning. We aimed to investigate the relationship between BA regulated gene expression levels to 
SeHCAT retention levels.  
SeHCAT, selenium homo tauro cholate, is a radiolabelled BA that becomes incorporated into the 
enteroheptic circulation after oral administration and has BA kinetics similar to cholic acid. SeHCAT 
remains in the enterohepatic circulation and is excreted exclusively in the faeces (see chapter 3). 
Patients with PBAD (seHCAT retention levels <15%) have diarrhoea due to the secretory effects of 
increased faecal BA concentrations within the colon. SeHCAT retention levels have been shown to be 
inversely related to faecal BA concentrations 
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SeHCAT retention levels are dramatically reduced in patients with secondary BAD, such as in CD, due 
to terminal ileal resection or inflammation reflecting increased faecal BA losses in these patients. It is 
usually inferred from such studies that SeHCAT retention is largely determined by the re-absorption 
of BA at the terminal ileum.  
However patients with PBAD have an intact terminal ileum and the active uptake of BA into terminal 
ileal mucosa has been found to be normal or increased. Reduced SeHCAT retention may also arise as 
a result of increase in BA synthesis and pool size or enterohepatic recycling frequency. Defective 
production of FGF19, the negative feedback signal to BA synthesis may produce these effects as 
reflected in various animal models.  
The initial aim of this study was to establish an efficient protocol to examine human intestinal FGF19 
transcript expression. This would require successful extraction of enough RNA from small bowel 
endoscopically obtained mucosal biopsies. Then to develop a primer for FGF19 using RT- PCR and 
SYBR green chemistries (which had not been done prior to this work) to enable detection of 
transcripts from these samples. SYBR green chemistries are more cost effective than Taqman based 
primers which have been used to detect FGF19 in human intestine previously [118]. It was important 
to establish the SYBR green technique as we aimed to assess multiple samples between patients 
groups.  
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4.2 Aims: 
(1) To successfully extract RNA from endoscopic mucosal biopsies to detect FGF19 transcripts. 
(2) Establish if FGF19 transcripts are detectable within human ileal mucosal biopsies using RT-PCR 
and SYBRgreen chemistries. 
(3) Establish whetherFGF19 transcripts basally expressed in human colonic mucosal biopsies? 
(4) To perform exploratory studies on basal expression of FGF19 and other BA regulated gene 
transcripts in ileal mucosal biopsies from patients with SeHCAT diagnosed PBAD and CD.  
4.3 Specific methods: 
4.3.1 Prospective study of ileal and colonic FGF19 expression 
In total, 27 subjects were recruited prior to undergoing routine ileo-colonoscopy. 13 of these 
patients were recruited prospectively and gave informed, written consent. All subjects had fasted 
overnight in preparation for colonoscopy and had received bowel preparation, usually with oral 
Senna and magnesium citrate. Exclusion criteria were as follows: patients under 18 yr old, patients 
on anticoagulant or dual-antiplatelet therapy. Intestinal mucosal biopsies were taken with the same 
type of disposable biopsy forceps (radial jaw 3; Boston Scientific, Hemel Hempstead, UK), giving 
standardized mucosal samples. The study was approved by the local Institutional Review Board, the 
Hammersmith, Queen Charlotte’s, and Chelsea Hospitals’ Research Ethics Committee. 
For this part of the study, groups of 3 mucosal biopsies were taken from the following anatomical 
regions; terminal ileum, proximal and distal colon. From each region the 3 mucosal biopsies were 
pooled together in 400ul of RNAlater in separately labelled sterile RNAse free, 1.5ml microcentrifuge 
tubes. Distal colonic biopsies were taken from the sigmoid colon just above the rectosigmoid 
junction. For each patient, separately labelled ileal, proximal and distal colonic biopsies were then 
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transferred to a -80 freezer for storage and subsequent processing for the analysis of baseline gene 
expression.  Intestinal 
4.3.2 Analysis of previously recruited patients with chronic diarrhoea + PBAD 
15 of these 27 patients had been previously recruited and samples taken prior to this PhD and were 
in storage at -80. These ileal mucosal biopsy samples came from patients who have been previously 
described in studies of serum FGF19 levels in PBAD [71]. These patients had been investigated for 
chronic diarrhoea (an average of 3 loose, type 6 or 7 stools per day for greater than 3 months) with 
SeHCAT scanning and serum samples obtained for fasting FGF19. Ileal biopsies (n=3-6 biopsies) had 
been taken at colonoscopy and pooled together in 400ul of RNAlater in individually labelled RNAse 
free 1.5ml microcentrifuge tubes. The samples had been stored at -80 for 2 years prior to the 
processing described below. 
4.3.3 Sample processing and RT-PCR 
RNA extraction and cDNA synthesis was performed according to the manufacturer’s protocols and as 
described in chapter 2.4 – 2.5.  Primers were designed for FGF19 (Chapter 2.6) and otherwise 
included previously published human primer SYBR green sequences for the other genes (GAPDH, 
ASBT, OSTa+b, IBABP, FXR, SHP). RT-PCR was then performed on the cDNA using specific primers at 
400nM in singleplex reactions using SYBR green chemistry according to the manufacturer’s protocol 
(chapter 2.6.2).  
To assess the relative efficiencies of the target amplification and the reference (endogenous control) 
amplification, standard curves were run for each amplicon utilizing the same sample. We aimed to 
cover 5 logs of input cDNA amount to assess the dynamic range of the assay for the FGF19 and 
GAPDH primers. We therefore performed serial 3 fold serial dilutions of the sample template.
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4.3.4 Using RT-PCR relative quantification to compare basal expression levels of FGF19 
between patient groups: 
To explore for possible difference in FGF19 expression in ileum from patients with CD and PBAD we 
used RT-qPCR with relative quantification methods. This method quantifies target gene transcript 
levels relative to a control / reference gene. Uniformity of expression levels in the control gene, 
GAPDH across the samples or patients is assumed using this method.  
Using RT-qPCR 40 thermal cycles are run to achieve standard cycles of denaturing, annealing and 
extension. The sample cDNA is amplified using a solution containing DNA polymerase, nucleotides, 
SYBR green probes and primers that are complementary to the target DNA sequence. When this 
solution is heated the taq polymerase (DNA polymerase) is activated. As the solution cools, the 
primers anneal to the target sequences on the first strand cDNA. The DNA polymerase then forms a 
new strand by extending the primers with nucleotides, creating a complimentary copy of the target 
cDNA sequence and dsDNA. Repeated thermal cycling leads to denaturation of dsDNA, annealing 
and extension. This leads to an exponential increase in the number of target DNA sequences 
referred to as amplicons. During this cycling, SYBR green probes bind to the minor groove of the 
dsDNA. Binding to the minor groove of dsDNA increases the SYBR green fluorescence. The TR-qPCR 
7900 ABS system detects this increasing fluorescence representing increasing PCR product. 
Cycle thresholds (Cts) are calculated as the point at which the fluorescence for a sample becomes 
significantly greater than the background fluorescence. A qPCR curve has typically an exponential 
phase followed by a plateau phase. The Ct measure needs to be taken in the exponential phase, 
where the curve is linear. The horizontal blue line shows the cycle threshold, which can be 
automatically or manually set to any value that is: (1) above background fluorescence, (2) below 
plateau regions, (3) within the geometric phase of amplification. Cycle time (Ct) values can then be 
determined by reading off the cycle threshold, as shown by the dotted black lines (figure 4.1).  
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Figure 4.1 PCR amplification curves with Cts indicated by dashed vertical lines. 
 
The later the PCR cycle threshold is reached (ie the higher the Ct, 30-35) the less the amount of 
starting template within the sample as you need more cycles of amplification for the fluorescence to 
be detected.  If the Ct has a small value (10-15), the gene is highly expressed. The Ct is therefore 
inversely proportional to the quantity of starting template. 
FGF19 transcript levels are therefore expressed relative to GAPDH as ∆Ct values which is calculated 
as: 
Ct target gene – Ct endogenous control 
Target gene Cts values were generally higher than control gene Cts. The mean Ct for FGF19 was 29.9 
and 24 for GAPDH. This means that FGF19 amplification occurs 6 cycles after GAPDH. This means 
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that there is a greater relative abundance of GAPDH than FGF19. Due to the exponential nature of 
PCR this difference represents a mean of 64 times ( 26 ) the abundance of GAPDH template in these 
samples than FGF19 template.  
This equation leads to ∆Ct values that are inversely related to expression levels of target gene 
transcripts. High ∆Ct levels would reflect low relative FGF19 transcript levels. To convert the ∆Ct to a 
linear form the equation 2-(∆Ct) is used and expressed as arbitrary units (AU) for comparisons of basal 
FGF19 expression levels between patients. These arbitrary units are then directly proportionate to 
expression levels, with higher values (AU) reflecting a greater abundance of FGF19 transcript levels. 
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4.4 Results: 
4.4.1 RNA concentrations and purity 
RNA concentrations and purity were within acceptable limits following RNA extraction (table 1). The 
total RNA preparations were diluted to obtain a starting amount of 1ug for each sample. This is well 
within the range of starting RNA amount required for the reverse transcriptase (SuperScript™ First-
Strand Synthesis System for RT-PCR, Cat. No: 11904-018) according to the manufacturer’s protocol 
(range - between 1ng and 5ug total RNA). 
Minus reverse transcriptase controls after cDNA synthesis always revealed flat amplification plots 
after RT-PCR consistent with the fact that the FGF19 primer crosses 2 exons. The GAPDH Minus 
reverse transcriptase controls did reveal some amplification with Cts of 33 or later which was always 
> 10 cycles later than the respective RT +ve sample. This implied approximately 0.1% of the 
amplification in the RT+ve samples was attributable to genomic DNA. This was considered an 
acceptably low level of genomic DNA.  
PCR assays were examined and results were excluded according to the criteria described in Chapter 
3. All PCR assays revealed a specific product for each primer pair (figure 4.2). Interassay variability 
between multiple 96 well plates was considered acceptable if there was no more than 1 cycle 
difference between Cts from 2 separate PCR plates using a pooled positive control sample. Analysis 
of multiple genes on the samples from the 15 previously recruited patients was performed on 2 x 
384 well PCR plates with 2 positive controls on each plate to minimise interassay variability.  
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Figure 4.2 Dissociation-curves show that both the FGF19 primer pair (A) and GAPDH primer pair (B) 
dissociate with only one amplification peak, indicating a pure product. 
 
4.4.2 Validation experiments and primer efficiencies 
For the comparative Ct method to be valid the efficiencies of the target amplification and 
endogenous control needed to be similar. A seven-fold serial dilution of a positive control sample 
was performed in singleplex triplicate reactions for target gene and endogenous control gene. The 
Log10(template concentration) was plotted against the Ct. The gradient of the resulting trend line 
represents a function of the amplification efficiency. A gradient (S) of -3.32 is consistent with an 
efficiency of 100%. Amplification efficiency for each primer was then calculated from the slope with 
the equation: Efficiency = 10(1/-S) . Primer efficiencies shown in figure 4.3. 
 
A B 
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Figure 4.3. Analysis of primer efficiencies. Initial input amount of RNA for cDNA synthesis is 1µg; this 
initial amount is then serially diluted using 3-fold dilutions. RT-PCR is performed to give Ct values for 
the serially diluted samples. Primer efficiencies are calculated using the following equation: 
Efficiency = 10^(-1/gradient) – 1, where the gradient is calculated from plotting Ct against log10 (input 
amount of RNA). Efficiencies are 83% for both FGF19 primer pairs (A) and GAPDH primer pairs (B). 
R2 values are > 0.99 in both graphs, indicating that the estimated values determined by the trendline 
correspond extremely closely with the experimental values.   
 
The variation of ∆Ct (Ct target – Ctendogenous control) according to template dilution was plotted against 
Log10(template concentration). The absolute value of the slope of the ∆Ct vs Log10(template 
concentration) was 0.007. Absolute slopes of the ∆Ct vs Log10(template concentration)  are 
considered to have passed a validation experiment if the slope is <0.1. The primer pairs achieved this 
standard (figure 4.4). 
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Figure 4.4. Validation of primers for the comparative Ct method. Initial input amount of RNA for 
cDNA synthesis is 1µg; this initial amount is then serially diluted using 3-fold dilutions. A gradient of 
<0.1 on a semi-log graph of ΔCt (CtFGF19 minus CtGAPDH) against log10 of the input amount of RNA 
indicates matching primer amplification efficiencies.  
 
4.4.3 FGF19 mRNA is basally expressed in human ileal but not in colonic biopsies obtained 
at colonoscopy 
 
We first set out to compare basal FGF19 transcript levels between terminal ileal and colonic mucosa 
(including proximal and distal colon). Healthy control patients (n=7) and 2 patients with NR-CD  
disease in clinical remission were prospectively recruited whilst attending for colonoscopy (see table 
2.1 and chapter 2.3a(ii) respectively). 8 patients underwent groups of 2-3 biopsies from ileum and 
proximal colon, a further patient underwent colonic biopsies only (table 4.1).  
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N=9 Healthy controls (n=7) NR-CD (n=4) Previous IR (n=2) 
Age 36 (26-46) 26 (23-39) 40 (27-73) 
  Male 6 2 5 
  Female 3 2 4 
Indications for colonoscopy    
  Change in bowel habit (no 
diarrhoeal) 
6 0 4 
  Assessment of Crohn’s disease 1 4 2 
  PR bleed 1 0 1 
  Anaemia 0 0 1 
  Polyp surveillance 1 0 1 
Drug History    
 No medication   2 
 Regular medication 7  6 
   Lactulose 1  1 
   Aspirin 1   
   Immunomodulator 0 4 0 
   Biologic 0 2 0 
Ileal resection length (cm)   51 , 15 
 
Table 4.1 Patient demographics for basal expression studies of FGF19 between ileum and colonic 
samples. NR-CD, Non resected Crohn’s disease; IR, ileal resection. 
After, RNA extraction, cDNA synthesis and RT-qPCR, FGF19 transcript levels were either completely 
undetectable or beyond the limits of reliable quantification (Ct>35 cycles) in the groups of colonic 
biopsies from each patient. This finding was independent of colonic region sampled including 
proximal or distal colon (table 4.2). The mean Ct for GAPDH was 24.1 with a standard error of the 
mean of 0.14 suggesting low variance in the expression levels of the control gene, and there was no 
significant difference between colonic and ileal biopsies. 
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Table 4.2. RNA concentrations and Cycle thresholds results for according to different regions sample 
during colonoscopy. RNA concentrations were adequate for subsequent cDNA synthesis. The higher 
the Ct, the later the amplification, so the lower the gene expression. Dark blue boxes represent 
samples that had no amplification after 40 PCR cycles. Light blue boxes highlight samples which 
amplified at the limits of reliable quantification (>35 cycles). All samples expressed FGF19 at <0.004 
times the expression seen in the ileum of the same patient. 
FGF19 transcripts were reliably detected in all samples from ileum. Cts for FGF19 were higher than 
GAPDH with a mean of 29.9 (reflecting a lower relative abundance of FGF19 transcripts relative to 
GAPDH.  The standard error of the mean for FGF19 ∆Ct values was 1.14 again suggesting that the 
ileal samples from different patients had a low variability of up to twofold difference in basal FGF19 
expression. 
Patient Biopsy site GAPDH mean Ct FGF19 Mean Ct (RNA) ng/ul Purity 260/280
Pt A Ileum 24.48 29.14 432.52 2.04
Ileum 23.53 29.15 300.32 2.07
Prox colon 24.25 > 40 1057.81 2.07
Ileum 23.13 25.43 390.87 2.04
Dist colon 23.45 36.14 395.32 2.05
Ileum 24.39 29.22 189.59 2.09
Prox colon 23.82 36.86 249.37 2.08
Ileum 24.15 32.74 279.52 2.08
Prox colon 25.21 > 40 848.48 2.06
Dist colon 24.13 36.87 415.16 2.04
Ileum 24.59 32.54 655.71 2.10
Prox colon 22.96 > 40 681.67 2.10
Dist colon 23.06 37.25 618.19 2.09
Ileum 24.54 30.64 394.48 2.06
Prox colon 23.54 > 40 939.50 2.08
Dist colon 24.13 > 40 330.75 2.05
Prox colon 24.12 > 40 946.11 2.05
Dist colon 23.57 38.15 743.15 2.04
Ileum 24.91 30.62 591.55 2.07
Prox colon 24.72 > 40 750.86 2.05
Dist colon 24.81 > 40 738.73 2.07
Pt H
Pt I
Pt E
Pt F
Pt G
Pt B
Pt C
Pt D
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4.4.4 Ileal transcript expression levels of FGF19 and ASBT are related to SeHCAT retention 
levels in a cohort of patients with chronic diarrhoea 
 
Expression of FGF19 and other relevant transcripts was studied in ileal biopsies from the cohort of 
15 patients (see 2.3(a)) with chronic diarrhoea who also underwent SeHCAT testing. Patient 
demographics are shown in table 4.3. Eight patients had PBAD with SeHCAT values <15% (3 to 13%) 
and 7 were ID controls (values >15%).  Two patients (SeHCAT 5% and 13%) were excluded from 
further analysis as FGF19 and ASBT transcript values were outside the limits of reliable quantification 
with no amplification in one sample and a Ct of 36 in another. This could have been due to a non 
ileal source of biopsy.   
 Age  PMH DHx bmi FGF19 seHCAT 
BD72 67 f Hypothyroid Enalapril, 
thyroxine 
29 263 90 
BD13 49 m   25 489 59 
BD84 44 m  Statin 32 281 48 
BD21 51 f   22 178 39 
EX45 38 m      
BD10 56 f   29 288 23 
BD87 41 m Depression Quetiapine, 
diazepam, 
loperamide 
24 368 19 
BD115 72 f Cholecystectomy, 
osteoporosis 
allendronate 34 206 13 
BD46 57 f Thyroidectomy Thyroxine, 
enalapril, 
lipitor 
26 227 12 
BD52 48 f Hypothyroid, 
Chol 
Thyroxine, 
simvastatin 
 50 9 
BD25 38 f   22 146 7 
BD06 38 f   32 56 5 
BD37 29 f   28 68 5 
BD51 48 m  aspirin 23 349 4 
BD75 55 m   26 129 3 
Table 4.3. Patient demographics from a cohort of patients previously recruited and described 
elsewhere [71]. Bmi, body mass index; PMH, past medical history; DHx, drug history; seHCAT, tauro-
selenium cholic [75 selenium] acid retention level at 7 days (% retention shown). 
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A further 2 samples were also excluded from analysis of FGF19 expression as the ∆Ct SD values for 
FGF19 obtained were >0.3. On these 2 samples small peaks were also seen on the dissociation curve 
analysis for FGF19 at 80’C rather than the usual 85’C which implied possible primer dimer formation. 
Pipetting error may also have affected these results. For these 2 samples however, ∆Ct SD and 
dissociation curves were adequate for all other genes analysed leaving 13 patients for further gene 
analysis. 
Values obtained for GAPDH had low variability across this cohort of patients. RNA concentrations 
and purity were adequate. Even in this small cohort of patients the median serum FGF19 levels were 
significantly lower in the PBAD patients compared to the ID controls ( 117, IQR 55- 197 vs 368, IQR 
285-537, p=0.02). No significant differences in median target gene expression levels were detected 
between the two groups.   
There were no significant correlations between serum FGF19 levels and transcript expression levels 
or SeHCAT levels. However, SeHCAT values were significantly associated with FGF19 (rs = 0.59, p = 
0.03, n= 11) and with ASBT (rs = 0.49, p = 0.04, n= 13) but not with the other transcripts (table 4.4).  
Expression of FGF19 and ASBT were strongly correlated (rs = 0.88, p = 0.0002).  Additionally IBABP 
correlated with OSTα (rs = 0.87, p < 0.0001) and IBABP with ASBT (rs = 0.63, p = 0.01).  FXR and SHP 
expression were associated with many genes (FGF19, ASBT, IBABP, OSTα and each other) but OSTβ 
did not correlate with any other transcript.  
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 All Subjects 
  
Serum 
FGF19 
SeHCAT FGF19 ASBT IBABP OSTα OSTβ SHP 
SeHCAT rs 0.56        
 p 0.08        
FGF19 rs -0.15 0.59       
 
p 0.67 0.03 
      
ASBT rs -0.05 0.49 0.88      
 
p 0.88 0.04 <0.001 
     
IBABP rs 0.20 0.35 0.41 0.63     
 
p 0.53 0.12 0.11 0.01 
    
OSTα rs 0.42 0.24 0.32 0.37 0.87    
 
p 0.17 0.22 0.17 0.10 <0.001 
   
OSTβ rs -0.05 -0.08 0.18 0.08 -0.11 -0.02   
 
p 0.87 0.40 0.30 0.40 0.36 0.47 
  
SHP rs -0.14 -0.04 0.61 0.53 0.55 0.51 -0.05  
 
p 0.64 0.44 0.02 0.03 0.02 0.04 0.44 
 
FXR rs -0.06 0.31 0.67 0.79 0.61 0.43 -0.18 0.54 
 
p 0.84 0.15 0.01 <0.001 0.01 0.07 0.28 0.03 
 
Table 4.4 Correlations between basal expression levels of ileal transcript and SeHCAT levels / serum 
FGF19 in patients with chronic diarrhoea assessed by SeHCAT retention. Spearman rank correlation 
coefficients (rs) and p values are shown.  Significant p values (<0.05) are shown in bold with 
significant correlation coefficients in bold red. 
 
4.4.5 Reduced coexpression of ileal transcript levels in BA regulated genes in PBAD 
Associations between ileal transcript expression levels were stronger in the ID controls.  In the PBAD 
group, the positive correlations between FGF19 and ASBT with SeHCAT were absent.  Although the 
correlation of FGF19 and ASBT remained strong, those between FXR and OSTα or IBABP were lost 
(table 4.5 and 4.6). 
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  PBAD n = 6 
  SeHCAT FGF19 ASBT IBABP OSTa OSTb SHP FXR 
FGF19  rs -0.20              
 
p 0.35              
ASBT rs -0.14 0.94            
 
p 0.38 0.00            
IBABP rs 0.07 0.26 0.18          
 
p 0.44 0.31 0.35          
OSTa rs 0.14 -0.09 -0.21 0.75        
 
p 0.38 0.44 0.32 0.03        
OST b  rs -0.04 0.77 0.50 0.36 0.32      
 
p 0.47 0.04 0.13 0.22 0.24      
SHP  rs 0.18 0.60 0.71 0.61 0.14 0.43    
 
p 0.35 0.10 0.04 0.07 0.38 0.17    
FXR  rs 0.07 0.43 0.61 0.00 -0.21 -0.29 0.39  
 
p 0.44 0.20 0.07 0.50 0.32 0.27 0.19  
 
Table 4.5 Correlation of basal levels of ileal transcript expression in BA regulated genes in patients 
with PBAD, primary bile acid diarrhoea (SeHCAT >15%). Spearman rank correlation coefficients (rs) 
and p values are shown.  Significant p values (<0.05) are shown in bold with significant correlation 
coefficients in bold red. 
 
  ID controls n = 7 
  SeHCAT FGF19 ASBT IBABP OSTa OSTb SHP FXR 
FGF19  rs 0.49              
 p 0.16              
ASBT rs 0.29 0.77            
 p 0.27 0.04            
IBABP rs 0.11 0.77 0.93          
 p 0.41 0.04 0.00          
OSTa rs -0.07 0.83 0.79 0.93        
 p 0.44 0.02 0.02 0.00        
OST b  rs 0.32 -0.09 0.07 -0.14 -0.21      
 p 0.24 0.44 0.44 0.38 0.32      
SHP  rs -0.54 0.66 0.61 0.71 0.82 -0.14    
 p 0.11 0.08 0.07 0.04 0.01 0.38    
FXR  rs 0.29 0.77 1.00 0.93 0.79 0.07 0.61  
 p 0.27 0.04 0.00 0.00 0.02 0.44 0.07  
 
Table 4.6. Correlation of basal levels of ileal transcript expression in BA regulated genes in ID, 
idiopathic diarrhoea controls (SeHCAT >15%). Spearman rank correlation coefficients (rs) and p 
values are shown.  Significant p values (<0.05) are shown in bold with significant correlation 
coefficients in bold red.
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4.4.6 FGF19 ileal transcript levels in patients with Crohn’s disease  
Exploratory studies to investigate basally expressed ileal FGF19 in patients with Crohn’s disease and/  
or ileal resections were also performed. FGF19 was basally expressed in neo-terminal ileal samples 
from 2 patients with previous ileal resections (one patient had Crohn’s disease) and in ileal samples 
from 4 patients with NR-CD.  There was no significant difference in transcript expression levels 
between these patients and the 6 healthy control patients (figure 5.3). 
 
Figure 4.5. Basal expression of FGF19 in healthy control patients compared to NR-CD (non-resected 
Crohn’s disease and IR- ileal resected patients. The quantity of FGF19 mRNA relative to GAPDH has 
been calculated using the equation 2-(∆Ct) and expressed as AU, arbitrary units. 
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4.5 Discussion: 
In this study we have confirmed the presence of FGF19 gene expression within human ileal tissue in 
healthy control patients.  FGF19 transcript levels were lower relative to the expression of the 
endogenous control gene GAPDH and other BA regulated genes. FGF19 transcripts are not basally 
expressed in the human colon.  
These results suggest that the colon is unlikely to be important in intestine-liver hormonal signaling 
for the maintenance of BA homeostasis.  FXR is expressed in more locations in the gastrointestinal 
tract than FGF19, including the colon [119], indicating that other factors must be involved in the 
transcriptional control of FGF19 in ileum.  Other transcription factors which may be candidates for 
regulating the distribution of FGF19 expression include homeobox transcription factors and GATA4 
[120-124] 
Although FGF19 is not basally expressed in colonic biopsies from patients that are fasted and have 
received bowel laxatives prior to sampling, it is possible that FGF19 expression may be induced by 
exposure to increased BA concentrations. Induction of expression of colonic fgf15 expression has 
been demonstrated in mice that have undergone ileo-ceacal resection[125]. This would lead to 
higher colonic concentrations of BA. BA stimulated induction of FGF19 in the human colon is 
explored further in chapter 5.  
The transcript expression studies from ileal mucosal biopsies in the group of patients with chronic 
diarrhoea who had undergone SeHCAT testing is particularly informative. FGF19 transcripts are 
significantly lower in basal, unstimulated, fasting samples from patients with lower SeHCAT values.  
However ASBT transcripts are also lower; if ASBT protein levels are also reduced, it could be that this 
results in reduced bile acid uptake and consequently reduced bile acid/FXR-dependent stimulation 
of FGF19 transcription. This finding is not consistent with previous findings of normal or enhanced 
ileal active uptake of BAs from patients with PBAD diagnosed by low SeHCAT levels [126-128].  
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There is some evidence to support a potential negative feedback influence of BA on ASBT expression 
within the terminal ileum [129, 130].  If reduced FGF19 expression is the primary defect in patients 
with PBAD, with excessive BA synthesis and an enlarged BA pool then the terminal ileum would be 
exposed to increased levels of BA.  This could lead to inhibition of ASBT expression in a homeostatic 
attempt to re-set the BA pool size by increasing faecal BA losses.  
It is also important to observe that the non-significant positive correlation in ASBT and FGF19 to 
SeHCAT retention is absent in the PBAD patients. This could suggest FGF19 expression is not simply 
related to ASBT and BA uptake into cells in PBAD but may influenced by other factors. In addition to 
this, co-expression between the BA activated transcription factor FXR and known FXR responsive 
gene transcripts for FGF19, ASBT, IBABP and OSTa was lost in patients with PBAD. This implies 
impaired basal regulation of BA associated genes via FXR. Such a finding could reflect defects in BA 
binding and activation of the transcription factor FXR. Regulatory cross talk between nuclear 
transcription factors and FXR have been described [55, 131, 132]and are discussed further in 
Chapter 5 and 6. 
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Chapter 5: Stimulation of fibroblast growth factor 19 expression in the 
human ileum by bile acids 
Abstract 
Background: Fibroblast growth factor 19 (FGF19) is proposed to be a negative feedback regulator of 
hepatic bile acid (BA) synthesis.  We aimed to investigate human ileal ex vivo bile acid stimulated 
FGF19 expression in a novel ileal explant system.   
Methods:  Ileal biopsies were obtained at colonoscopy and ileal explants were incubated with 
physiological concentrations of various BA for up to 6h, and expression of FGF19 and other genes 
was determined.   
Results: FGF19 mRNA levels remained stable  in the control explantincubations.  Ileal FGF19 
transcript expression was induced 350-fold by 50µM chenodeoxycholate (CDCA, n=24, p<0.0001) 
and 161-fold by 50µM glycochenodeoxycholate (GCDCA, n=12, p=0.0005).  The response of other 
genes to CDCA or GCDCA (50µM) were smaller: median increases of IBABP, OSTα, OSTβ and SHP 
were 2.4 to 4.0-fold; ASBT and FXR showed little change.  The EC50 for FGF19 transcript induction by 
CDCA was 20µM.  FGF19 protein concentrations were significantly higher in the culture fluid from 
BA-stimulated explants.   FGF19 induction with cholate was 81% of that found with CDCA, but 
deoxycholate (40%) and lithocholate (4%) were significantly less potent.  The synthetic FXR agonist 
obeticholic acid was much more potent with 70-fold FGF19 stimulation at 1µM.   
Conclusions:  FGF19 expression in human ileum is very highly responsive to BA.  Changes in ileal 
FGF19 induction are likely to be important in disorders of BA homeostasis.  
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5.1 Backround  
 
Bile acids (BA) undergo an enterohepatic circulation.  They are synthesized in the liver, secreted into 
the duodenum, reabsorbed in the terminal ileum, and recirculated back to the liver via the portal 
vein.  Enterocytes in the terminal ileum naturally express ASBT in both human and mouse ileum and 
mediate its functional specialization within the intestine for the process of a highly efficient BA 
reabsorption into the enterohepatic circulation. This ensures up to 95% of BA are retrieved from the 
lumen of the terminal ileum leaving only small amounts entering the colon to be lost in the feaces.  
 
BA themselves can exert negative feedback on BA uptake and increase export from hepatocytes via 
the binding and activation of the ‘farnesoid X receptor’ FXR. Transcriptional changes in FXR target 
gene expression has been well studied in human liver and mouse liver and ileum [7, 133]The most 
responsive gene in mouse ileum was found to be FGF15. FGF15 is a fibroblast growth factor which 
lacks the usual heparin binding sites that usually mediate tissue binding of the growth fact. This 
means it can exert effects systemically rather than simply in a paracrine fashion. 
 
In the mouse, FGF15 transcript and protein expression is abundant in ileum[134], and, except for a 
small amount of FGF15 expression in jejunum, it is undetectable in other tissues.  In human 
intestinal studies, FGF19 the human homologue, expression was reported in ileum, but was not 
reliably detected in duodenum [118].  Recently, FGF19 expression has also been reported in human 
gall bladder and biliary tissues [135]. 
 
The farnesoid X receptor (FXR, NR1H4) was previously classed as an orphan nuclear receptor. The 
natural ligand was initially unknown and Farnesoid was shown to activate the receptor. The natural 
ligand to FXR was found to be CDCA in 1999 [136] .  Concentrations of unconjugated 
chenodeoxycholic acid (CDCA) ranging from 3 – 100 µmol/l have been demonstrated to be effective 
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in binding, activating FXR and inducing transcription responses in reporter assays in human CV-1 cell 
lines [9, 136, 137].  However FXR reporter transcription was only observed with taurine- and glycine-
conjugated BA when cell CV-1 cell lines were also transfected with ASBT. ASBT is thought to mediate 
the uptake of these more polar hydrophilic BAS into these cell lines for FXR binding and activation to 
occur.  
 
Transcriptional changes in FXR target gene expression has now been well studied in mouse ileum 
with the most responsive gene found to be FGF15.  84 fold increases in FGF15 transcripts after have 
been shown after 24hrs of feeding FXR agonist GW4046 in mice [10]. Authors investigating FGF15 in 
the mouse proposed that this gut peptide represented a negative feedback signal via its inhibitory 
effects on CYP7A1 the rate limiting enzyme of new BA synthesis. It was described as an 
‘enterohepatic signal regulating BA homeostasis’.  
 
The authors investigating FGF15 have based this hypothesis on observations from FGF15 gene 
transcription studies. FXR -/- and FGF15-/- both lead to increased expression of CYP7A1 with an 
increase in the BA pool size and increased faecal BAs. On the converse, mice fed with the FXR agonist 
GW4046 have reduced expression of CYP7A1 and reduced pool size and faecal BAs which is 
dependent on FXR expression. The authors have demonstrated secretion of FGF15 protein from 
Caco-2 cells transfected with adenovirus expressing a recombinant FGF15 protein.  However, in 
these animal models, confirming this pathway by measuring circulating FGF15 protein in the blood 
has been difficult and has only recently been confirmed with a combination of assay techniques 
[138]. 
 
In humans, FGF19 can be easily detected and measured and a commercially available ELISA is in 
common is studies on FGF19. Human studies reveal that serum FGF19 protein levels are probably 
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dependent on the trans-intestinal flux of BA, based on the serum peaks observed 90 -120 minutes 
after the postprandial rise in serum BA.  In support of this, serum FGF19 was found to decrease after 
the treatment with an intestinal BA-binding resin and to increase upon oral administration of CDCA 
[22].  
 
Homeostatic regulation of the enterohepatic circulation of BA occurring at human terminal ileum is 
ill defined. Some Authors have observed small BA induced transcriptional changes in ASBT, IBABP, 
OST a/b in  rodent studies [53] 
We therefore hypothesized that FGF19 is also the most responsive BA responsive target gene in 
human ileum as it is in mouse. This would support the notion that BA homeostasis is achieved from 
the ileum by signaling to the liver rather than regulating intestinal BA uptake and transport.   
Our ultimate aim from this research was also to set up a system of stimulating FGF19 gene 
expression with BAs in human ileum to enable us to compare responses in patients with PBAD and 
CD to healthy controls. 
 
This research group has previous experience in measuring intestinal (duodenal) transcriptional 
responses and we aimed to use similar techniques to investigate FGF19 transcriptional response 
[97]. The techniques included incubating duodenal mucosal biopsies in tissue culture for 6 hours. 
Similar techniques have also been used in animal intestinal samples [139]. In these experiments the 
intestinal biopsies were stimulated with vitamin D and TRV6 transcripts were measured. We would 
use the endogenous primary BAs CDCA and GCDCA, to attempt to stimulate FGF19 transcription in 
human ileal tissue in a similar set up. CDCA and GCDCA are the most potent natural FXR ligands and 
are therefore most likely to induce a response.   
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BA can be toxic in high doses. Previous experiments have used BA in concentrations ranging from 1-
100µM in human cell lines / hepatic tissue. This is within the range of physiologic concentrations of 
individual BAs within terminal ileal effluent [140]. Using both conjugated and unconjugated BA to 
stimulate FGF19 is also consistent with normal physiology as small bowel luminal contents have 
been shown to consist of equal amounts of both conjugated and unconjugatedBA at the terminal 
ileum due to bacterial de-conjugation [130, 140, 141]. These human intestinal catheter perfusion 
studies have shown that GCDCA absorption displays active, saturable dose response kinetics 
dependent on the active transporter (ASBT) uptake. Whereas CDCA uptake displays linear kinetics 
consistent with absorption via passive diffusion. As Terminal ileum tissue will naturally express ASBT, 
we may observe a different time course and magnitude of response with the conjugated and 
unconjugated BAs.  
 
FGF15 has been shown to have an N terminal sequence suggesting it is a secreted protein. Animal 
studies on FGF15 protein have been impaired by problems developing an assay to measure 
circulating protein. We therefore intended to attempt to measure FGF19 protein in culture 
supernatants at the beginning and the end of the incubations. We aimed to use the commercially 
available FGF19 ELISA (R+D systems) to measure protein release in explant supernatants. This ELISA 
has been used on cell supernatants by other groups [133]. 
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5.2 Aims: 
(1) To establish a short term primary cell culture system using ileal mucosal biopsies explanted into a 
culture media directly after endoscopic ileal biopsies (ileal explants) to investigate FGF19 
transcriptional responses to micromolar concentrations (1-100uM) of CDCA or GCDCA 
(2) To characterise dose response, time course and changes in protein expression for BA stimulated 
FGF19 expression in this human ileal explant system.  
(3) To compare the time course and magnitude of response in paired stimulation experiments with 
both GCDCA and CDCA 
(4) To determine ifFGF19 expression be induced in colonic explants by micromolar 
concentrations of BA 
5.3 Specific methods: 
5.3.1 Patient selection: Healthy controls   
Patients were recruited according to criteria described in chapter 2.3.2. To study normal human 
ileum, healthy controls were selected according to pre-defined inclusion and exclusion criteria as in 
chapter 4, by excluding patients with a previous diagnosis of IBD, coeliac disease and ensuring ileal 
histology was normal on routine biopsies. All patients recruited to this part of the study had clinical 
samples taken from terminal ileum to ensure normal histology in addition to research samples. 
5.3.2 RT-pPCR: Comparative Ct method 
In the explant studies in this chapter we aimed to determine BA stimulated target gene transcript 
expression levels. This involves comparing expression levels in an unstimulated ‘calibrator’ sample to 
levels in a stimulated ‘target’ sample. We refer to these unstimulated ‘calibrator’ samples as control 
samples when describing explant studies.  
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The expression levels in the stimulated ‘treated’ sample can then be converted to fold change in 
expression with respect to the unstimulated ‘calibrator’ sample. Fold changes are calculated using 
the comparative Ct method to calculate the fold change or ‘RQ’   (relative quantity). A fold change or 
RQ of 10 means that the transcript level is 10 times more expressed in the stimulated sample 
compared to the unstimulated control sample. 
ΔCt = CtFGF19 – CtGAPDH 
ΔΔCt values can then be calculated. The ΔΔCt values represent the normalised FGF19 expression of a 
cDNA treated sample relative to a calibrator sample (e.g. CDCA-stimulated sample relative to an 
unstimulated control sample): 
ΔΔCt = ΔCttreated sample – ΔCtcalibrator 
ΔΔCt values can be converted into fold change or RQ values. Fold changes are easier for readers to 
interpret than ΔΔCt values. The following equation is used: 
RQ or fold change = 2 ^(–ΔΔCt) 
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Figure 5.1. Amplification curves from ileal explants from one individual patient. The amplification 
curves furthest to the right are for FGF19 from the control incubation (BA free media), labelled 
‘Control FGF19’. This reveals relatively late amplification and therefore less abundant template in 
these samples. The amplification curves labelled ‘Cdca50 FGF19’ are from explants incubated with 
50uM of Cdca and amplify several cycles earlier than the control FGF19 samples. Due to the 
exponential nature of PCR this several fold earlier amplification represents several hundred fold 
greater quantity of template in these BA stimulated samples. The amplification curve furthest to the 
left are the amplification curves of the GAPDH primers for both control and BA stimulated samples 
which is more abundant but suggesting similar template quantities regardless of  BA stimulation. 
Using the comparative Ct method (also known as the ΔΔCt method). Cts are read off the 
amplification plot from the target and reference gene curves from both of the stimulated and 
unstimulated samples. Using the Ct values, one can calculate the ΔCt value of each sample (the 
expression of a target gene normalised to an endogenous control, which in this case is FGF19 
expression relative to GAPDH expression): Cdca = cheno-deoxycholic acid.    
Gapdh control 
and CDCA50 
Cdca50 
FGF19 
Control 
FGF19 
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5.3.3 Patient demographics 
Healthy controls for ileal explants, N=28  
Age 48 (34-58)* 
  Male 13 
  Female 15 
Indications for colonoscopy  
  Diarrhoea (stool freq ≥3/ 24hrs and BSFS >5) 3 (11%) 
  Non-diarrhoeal indications 25 (89%) 
    Change in stool frequency +/- form 10 
    PR bleed 4 
    Anaemia 5 
    FH of CRC 1 
    Polyp surveillance 7 
    PR mucous 1 
Drug history  
  No medication 20 
  Regular medicaiton 8 
    Proton pump inhibitor 3 
    Statin 2 
    ACE-i 2 
    Antibiotic (co-amoxiclav) 1 
    Oral hypoglycaemics 1 
    Ca- channel blocker 2 
    Thiazide 1 
    Carbimazole 1 
    Paracetamol 2 
    Codeine 1 
    Pro-kinetic 1 
 
Table 5.1 Patient characteristics recruited for explant stimulation experiments. *Median and 
Interquartile Range, % shown where applicable.  
 
5.4 Results 
5.4.1(a) Six-hour ‘control’ incubation of explants does not alter the basal expression of 
FGF19 mRNA 
Due to the use of Fetal Calf serum in our culture media explant incubations it was important to 
establish that the expression of FGF19 was not being altered by constituents within the culture 
media. The relative quantities of FGF19 transcripts in all of the unstimulated ileal explant 
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experiments incubated in control culture media for 6 hours (n=35) was compared to the expression 
of FGF19 in ileal biopsies used for basal expression studies ( biopsies immediately placed in RNAlater 
and frozen at -80 for analysis, n=11). No significant difference in expression levels of FGF19 (relative 
to GAPDH) was found between these incubated control  samples vs non incubated samples (p=0.5, 
Mann-Whitney) Figure 5.2 (A).  In 4 patients, 4 ileal biopsies were taken with 2 biopsies being placed 
in control culture media for 6 hours and the other 2 biopsies from the same patient being placed 
immediately in RNAlater and frozen at -80 for analysis. No significant difference was seen in the 
expression levels of FGF19 between these incubated vs non incubated samples from the same 
patients (n=4, p= 0.2, Mann Whitney) Figure 5.2 (B). 
 
 
Figure 5.2: FGF19 mRNA expression is unchanged during 6h explant culture.  A:  FGF19mRNA in ileal 
biopsies stored for immediate processing (basal expression, n=11) and those incubated in control 
A B 
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culture media for 6h (control incubation, n=35) are shown, together with medians and interquartile 
ranges.  There is no statistically significant difference between them, p = 0.5, Mann-Whitney test.   
 B: The relative quantities of FGF19 mRNA are similar in paired samples taken from the same patient 
Basal expression and that after control incubation are shown (n=4).  The quantity of FGF19 mRNA 
relative to GAPDH has been calculated using the equation 2-(∆Ct). 
5.4.1(b) GAPDH expression is stable despite incubation with BA 
There was no significant difference in mean Ct levels observed for GAPDH in ileal biopsies incubated 
in BA free control culture media compared to those incubated with BAs. This suggests that 
differences in BA stimulated expression of FGF19 relative to GAPDH occur due to increases in FGF19 
rather than decreases in GAPDH expression.  
5.4.2 Potent stimulation of FGF19 transcript expression by CDCA and GCDCA in the human 
ileum 
FGF19 transcript levels were significantly higher in BA stimulated explants compared to unstimulated 
explants after 6hrs. Median levels of FGF19 were 350-fold higher in explants stimulated with 50µM 
CDCA (n = 24, p < 0.0001, two-tailed Wilcoxon test), and 161-fold higher in explants stimulated with 
50µM GCDCA (n = 12, p = 0.0005).  There was no significant difference in FGF19 transcript levels 
comparing CDCA and GCDCA-stimulated explants (p = 0.3, two-tailed Wilcoxon test).  Results are 
expressed graphically in Figure 5.3. 
The responses of other relevant genes to CDCA and GCDCA at 50µM (n = 3 - 4) showed median levels 
of IBABP, OSTα, OSTβ and SHP between 2.4 and 4.0-fold higher, whereas ASBT and FXR showed little 
difference (Figure 4 (iii)).  The unstimulated relative quantity of FGF19 was lower (with a high deltaCt 
value) than the other genes, but two other weakly FXR-responsive genes differed greatly, with SHP 
levels similar to FGF19, but IBABP much higher (with a lower deltaCt value).    
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Figure 5.3  A. Transcript expression after 6h incubation with 50 µM CDCA. Number of subjects( n) 
and p values were: FGF19 (n=24, p<0.0001); ASBT (n=4, p=0.23); FXR (n=4, p=0.30); IBABP (n=4, 
p=0.02); OSTα (n=3, p=0.11); OSTβ (n=4, p=0.02); SHP (n=4, p=0.03).  B: Transcript expression after 
6h incubation with 50 µM GCDCA.  n and p values: FGF19 (n=12, p=0.0005); ASBT (n=4, p=0.40); FXR 
(n=4, p=0.52); IBABP (n=4, p=0.06); OSTα (n=3, p=0.10); OSTβ (n=4, p=0.07); SHP (n=4, p=0.06).  Data 
are expressed as median and interquartile ranges of expression ratio fold-changes, calibrated to 
matched unstimulated control samples, relative to GAPDH.  Control sample mean Ct values for 
GAPDH, FGF19, ASBT, FXR, IBABP, OSTα, OST β and SHP were 22.5, 29.5, 21.9, 24.9, 20.7, 25.7, 23.9 
and 27.8 respectively.  P values were calculated from dCT values by paired t-tests. 
 
5.4.3 Bile acid dose response analysis 
 Incubations with a range of 2 - 5 different CDCA concentrations (5- 100µM) were performed in 
parallel in 10 patients.  The induction of FGF19 mRNA was similar at 100µM and 50µM CDCA (Figure 
5.4).  A non-linear, least squares, sigmoidal curve fitting program was used (GraphPad Prism 5) to 
derive the EC50 for studies which included 4 or 5 different CDCA concentrations (n = 4).  The median 
EC50 was 20µM (range 16-52).  
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Figure 5.4. Dose ranging studies of CDCA induction of FGF19 mRNA:  Graph shows pooled data from 
10 explant studies that were incubated with 2 – 5 different concentrations of CDCA in parallel. 
Concentrations ranged from 1µM to 100µM. Data points are shown from each individual explant 
from each individual patient (see data points A-J).  Fold changes in mRNA were converted to a 
percentage of maximum response which was observed at 50µM in those studies whose data points 
are shown in the oval ring and 100µM for those shown in the rectangular box. 
 
5.4.4 Time course studies: 
Time course experiments showed that FGF19 expression increased over the course of 6h incubation 
with 50µM CDCA (Figure 4).  Stimulation of FGF19 expression increased from under 10-fold at 2h to 
median >40-fold at 3h, to several hundred fold at 6h incubation.  
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Figure 5.5. Time courses (n=4) showing FGF19 expression increased over the course of 6h incubation 
with 50µM CDCA.  Incubations with CDCA were for 0.5h, 1h, 1.5h, 2h, 3h or 6h.  Explants were 
placed into RNAlater immediately after incubation.  FGF19 expression at 0.5h and 1h showed no 
significant change, at 1.5h and 2h was <10-fold, at 3h was >40-fold, and at 6h was dramatically 
higher at several hundred fold.  Data are expressed as median fold-changes, calibrated to matched 
unstimulated control samples, relative to GAPDH. Interquartile ranges are shown where appropriate. 
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5.4.5 Relationship between CDCA stimulated FGF19 fold changes and relative quantities of 
FGF19 expression levels in the unstimulated control explants 
An inverse correlation did exist between FGF19 transcript levels in the unstimulated explant to the 
fold change in the stimulated explants, but this did not achieve statistical significance (figure 5.6). 
Explants with relatively higher levels of basal FGF19 transcripts in the unstimulated explants tended 
to have lower fold changes in BA stimulated explants. 
 
 
Figure 5.6. Relationship between relative quantities of FGF19 transcripts in unstimulated control 
explants vs fold change in FGF19 transcript levels in CDCA stimulated explants. AU – Arbitrary units 
of expression. 
5.4.6 BA stimulated FGF19 expression is not demonstrated in human colon 
Colonic explant studies were performed on 6 patients. Groups of 2-3 biopsies from the same patient 
were incubated seperately in BA free media (unstimulated control),  50uM CDCA (positive control), 
1uM OCA and either 1uM of INT 767 or INT 777.  One of the explant results for INT-777 was 
excluded due to a control gene GAPDH outlier Ct result (see table 3). In 3 of the patients the 
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unstimulated control explant revealed RT-PCR amplification of FGF19 beyond 35 cycles and was 
regarded as undetectable. In one of these patients, the CDCA and INT-767 stimulated explant was 
just within the limits of reliable detection with a Ct of 34.7 and 34.9 respectively.  In 3 patients, 
FGF19 was detectable in the unstimulated control explant but there was no significant difference in 
the relative quantity (dCt) of FGF19 mRNA in the CDCA (n=3) or OCA (n=3) stimulated explants (p= 
1.0, Wilcoxon two tailed). 
 
5.4.7 The induction of FGF19 mRNA in human ileum by different BA correlates with their 
relative potencies as FXR agonists.  
 
Ileal explants were incubated with CDCA in parallel with other natural BA (CA, DCA, and LCA) all at 
50uM or with the semi-synthetic FXR agonist OCA.  Median fold changes in BA stimulated expression 
of FGF19 mRNA were not significantly different with CDCA and CA (n=4).  Median fold change in LCA 
stimulated expression of FGF19 mRNA was significantly lower than CDCA (n=5). The trend in relative 
potencies of BA stimulation of FGF19 mRNA expression suggested that DCA was intermediate 
between CA/CDCA and LCA.  The mean induction of FGF19 mRNA expression with other BAs at 
50uM, normalized to the paired CDCA incubation at 50 µM, was 81% for CA and significantly lower 
with DCA and DCA at 40% and 4% respectively (Figure 5.7).  Mean induction of FGF19 expression 
with 1uM of OCA normalized to paired 50uM CDCA was 70% (n=3). 
After incubations with 1µM OCA for 6h, a median fold-change of 70 (range 40 – 258, n = 3) was 
observed, although no significant changes in FGF19 mRNA expression were observed with 1µM 
CDCA (n = 3).  In paired incubations involving both 20µM CDCA and 20µM OCA, median induction in 
FGF19 mRNA expression was 5 times greater (range 3 - 45, n = 3) with OCA.  The order of potency for 
stimulating FGF19 expression from this data is OCA>CDCA/CA>DCA>LCA.   
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Figure 5.7. Induction of FGF19 mRNA expression with a range of BAs normalised to CDCA stimulated 
expression. Induction of FGF19 mRNA is expressed as a percentage of the induction observed in 
explants stimulated with 50 μM CDCA from the same patient. Mean percentages and range are 
shown. The mean induction of FGF19 mRNA as a percentage of paired CDCA stimulated explants was 
81% with cholic acid (CA) (n = 4), 40% with deoxycholic acid (DCA) (n = 3) and 4% with lithocholic acid 
(LCA) (n= 5). Statistical significance: CA, P = 0.5; DCA, P = 0.03; LCA, P < 0.001; paired t-tests % vs. 
CDCA 50 μM. With obeticholic acid (OCA), induction of FGF19 at OCA 1 μM was comparable with 
that found with CDCA 50 μM (n = 3). 
5.4.8 BA stimulated FGF19 expression by BA analogues: INT 747 vs 767 vs 777 
 
A further cohort of 14 patients was recruited to study the effects of various synthetic BA analogues 
on FGF19 expression. 8 patients underwent ileal biopsies and 6 underwent colonic biopsies for 
explant studies. Groups of 2-3 biopsies from the same patient were incubated seperately in BA free 
media (negative control), 50uM CDCA (positive control), 1uM OCA and either 1uM of INT 767 or INT 
777. In this cohort of ileal explants (n=8), the median fold change in FGF19 RNA expression 
stimulated by CDCA was 110 (IQR 53–500). FGF19 RNA expression was significantly higher in ileal 
explants (n=8) stimulated with INT-767 compared to those stimulated with OCA (p = 0.007, Mann 
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Whitney Figure 5.8). The potency of INT-767 for stimulating FGF19 mRNA expression was 
approximately 10 fold higher than OCA. No significant induction of FGF19 expression was seen in 
colonic explants with either OCA or INT 767 (p=0.25, Mann Whitney). No significant induction of 
FGF19 was seen in either ileal or colonic explants with INT-777. 
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Figure 5.8: Relative potencies of FXR agonists OCA and INT 767 at inducing FGF19 mRNA expression 
in ileal explant (A) and colonic explants (B). Median induction is significantly higher in ileal explants 
incubated with INT 767 vs OCA (245-fold vs. 27-fold, p= 0.02, Mann Whitney). No significant 
induction of FGF19 occurred in colonic explants with either agonist (n=5 , OCA, n=3, INT 767, 
Medians and IQR shown). 
5.4.9 FGF19 protein in culture fluid from ileal explants correlates with fold change in 
FGF19 mRNA 
Culture fluid supernatant concentrations of FGF19 protein were measured in 16 of the explant 
studies by a specific ELISA (Quantikine Ref). The measured concentrations (in pg/ml) were 
normalized according to whether the culture plate well had contained 2 or 3 biopsies and expressed 
as pg/explant (see methods 2.6).  The groups of 2 or 3 biopsies were not weighed before each 
incubation but a separate pilot study on 2 sets of 3 biopsies gave wet weights of 12 and 20ugs.  
 
Levels of FGF19 protein were undetectable or at the limits of the detectable range of the assay in 
many of the fluid samples from unstimulated explants.  Concentrations of FGF19 were reliably 
A B 
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detectable in all fluid samples from stimulated explants. The median concentration of FGF19 protein  
was significantly higher in the supernatants from explants incubated with 50 µM CDCA (56 
pg/explant, range 8 – 169) compared to the control explants (7 pg/explant, range 0 – 46, n = 10, p = 
0.003, two-tailed Mann-Whitney).  The median level of FGF19 was also significantly higher (n = 9, p = 
0.002, two tailed Mann-Whitney) in the culture fluid from explants incubated with 50µM of GCDCA 
(median 24 pg/ml/explant, range 3 – 113) compared to the matched control explants (6 
pg/ml/explant, range 0 – 13, Figure 5.9a).  There was also a significant correlation between the 
culture fluid protein and fold changes in mRNA of FGF19 (CDCA:  n = 10, r = 0.70, p = 0.005, and 
GCDCA: n = 9, r = 0.76, p = 0.003, Spearman’s rank test; Figure 5.9b).  
 
Figure 5.9a Increases in FGF19 protein in culture fluid after BA incubations; CDCA (n=10), GCDCA 
(n=9) FGF19 protein levels were measured by specific ELISA (FGF19 Quantikine ELISA kit,  R&D 
Systems, Minneapolis, MN) at the end of 6h incubations.  FGF19 protein levels (pg/explant) are 
higher in the culture fluid from every BA-stimulated explant compared to their respective paired 
control explant 
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Figure 5.9b Correlation between the culture fluid protein levels and fold changes in mRNA levels of 
FGF19 (CDCA (n=10) and GCDCA (n=9) 
5.5. Potential sources of error in experimental design and suggested solutions: 
5.5.1 Primer efficiency 
At the time of initiating this research, there were no published primer sequences available for 
measuring human intestinal FGF19 mRNA using SYBR green assays.  The primer was designed by 
using BLAT software with the in-silico PCR function. The initial optimization experiments revealed a 
FGF19 primer efficiency of 83%. This is below generally accepted 90% primer efficiencies. This low 
primer efficiency was considered accepted in these experiments for 3 reasons: 
1. The demonstration of similar pcr efficiency in the reference gene primer (from a previously 
published source) with a similar efficiency of 83%. 
2. Pilot experiments revealed our target gene amplification in unstimulated control samples 
(calibrators) as being generally detectable repeatedly less than 35 cycles and usually with Cts 
of 29-33.  
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3. We aimed to compare BA stimulated expression of fold changes in FGF19 mRNA between 
patient groups. Pilot studies had revealed large fold changes rather than small fold changes 
(eg below 2-4 fold).  
However it is possible that this low primer efficiency could have contributed to the wide variability in 
stimulated expression in FGF19 mRNA found.  
5.5.2 FGF19 protein concentrations in culture supernatant: 
Comparisons of FGF19 protein concentrations in culture fluid supernatants between unstimulated 
and stimulated explants was limited by inaccurate normalization for amount of tissue. Measured 
concentrations of FGF19 in the supernatant were only normalised according to the number of 
biopsies contained within each well. This was either 2 or 3 biopsies. However, although the same 
endoscopic biopsy forcep was used for all samples, the amount of tissue obtained will vary according 
to a number of factors (eg. Angle of forcep applied to target tissue, degree of pressure applied and 
consistency of target tissue). A better quantitative expression of protein could have been expressed 
in pg/mg of tissue. It was considered more important to immediately transfer the endoscopically 
obtained biopsies from culture fluid into the complete media and into the incubator rather than 
further manipulating them into separate containers to obtain separate weights for each group of 
biopsies.  
 
The detection of FGF19 protein in unstimulated ‘BA free culture supernatant’ has 3 interpretations: 
1. There is basal secretion of FGF19 in the absence of additional exogenous BA (this has been 
shown with longer cell cultures on intestinal cell lines). 
2. Cell death and lysis may be occurring releasing preformed protein 
3. The ELISA’s specific binding may be affected by constituents of the complete culture media 
113 
 
Investigating the possibility of cell death and lysis could have been further evaluated by measuring 
culture supernatant fluid LDH levels which is a marker of cell lysis. Secondly, a number of explants 
could have been placed in formalin at the end of the incubations and examined histologically. Finally 
the third possibility is limited by diluting and the known FGF19 standards in a buffered protein 
solution, similar to culture fluid (RD5P diluent), for the standard curve. This will aim to limit binding 
differences arising from interference with the assay from constituents within the media. 
5.5.3 Variability of fold change in BA stimulated FGF19 transcript expression 
There are a number of experimental factors that may have influenced this observed trend, including 
luminal BA concentrations and composition at the time of colonoscopy when the primary ileal tissue 
was sampled. Even in the fasted state BAs are present in the lumen of the TI [141] and variability in 
the luminal concentrations may influence the basal expression of FGF19 at the time of sampling. This 
may lead to different baseline levels of expression of FGF19 at the beginning of the 6 hour 
incubations between individuals. Ileal explants exposed to relatively high concentrations of 
endogenous luminal BA in vivo may harbour saturated receptors (eg ASBT or FXR) upstream from 
FGF19 transcription. In this situation then lower induction of FGF19 transcription may be observed 
with the addition of exogenous BA. For example, active uptake of conjugated BA via ASBT is known 
to display saturable kinetics [140]. 
The variability from in vivo endogenous BA concentrations at the time of sampling was controlled for 
by physical washing of explanted ileal biopsies. This involved washing explants with PBS and 
transferring them from a transport media to an incubation culture media. A further optimization 
step could have been leaving the explants for 1-2 hours to reach a steady state in BA free culture 
media prior to the addition of exogenous BA. 
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It is unknown what effect the bowel purgative has on ileal FGF19 expression but it is possible that It 
affects luminal BA concentrations and that patients response to the purgatives in different ways. The 
purgative that we used includes magnesium carbonate and citric acid. This reacts within the 
intestinal lumen to form magnesium citrate which exerts an osmotic effect on cells within the 
intestine. This leads to an osmotic shift of water into the intestinal lumen and stimulates GI motility. 
The net secretion of water into the intestinal lumen and increased small bowel transit may reduce 
the physiological concentrations of BA within the ileum to varying degrees. A non-significant trend 
towards lower serum FGF19 levels after bowel prep has been described in a small group of patients 
(Sanjeev Pattni, PhD, Imperial College 2012).   Further variability in luminal BA concentrations may 
be influenced by compensatory increases in BA synthesis, biliary secretion and gallbladder function.   
To control for variability in luminal BA concentrations at the time of colonoscopy, patients were 
fasted for a similar time period and have undergone colonoscopy at similar time points after having 
taken the purgatives. It would be difficult to optimize this variability further. It is possible that PEG 
based laxatives would lead to less variability as this does not lead to a net secretion of water into the 
intestinal lumen. Mannitol based bowel preparation has not been shown to affect SeHCAT retention 
levels in one small cohort [142].  
Ileal luminal BA composition may vary between individuals. CDCA, CA and DCA have been shown to 
be the majority of luminal BA . Differing levels of conjugated BA will depend upon quantity and types 
of commensal bacteria within the ileum. This will have effects on ASBT. In addition to this, the 
proportion of luminal secondary BA may affect FGF19 stimulation. Luminal LCA and DCA may have 
been absorbed and may have bound to FXR at the time of sampling. These secondary BA are weaker 
FXR agonists than primary BAs for FXR activation [9]. Intracellular DCA and LCA could potentially 
compete with exogenous CDCA in binding to FXR and may influence the kinetics of FGF19 
transcription.  
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Further variability may be related to the sampling of ileal mucosa. FGF19 is thought to be restricted 
to expression within enterocytes only from the intestinal epithelium. Ileal mucosa is known to have 
areas that have interruptions in this enterocyte epithelial lining known as Peyer’s Patches. The 
epithelium in these areas has specialized M-cells at the surface of the mucosa in place of the 
columnar epithelial enterocytes. Biopsies taken from mucosa harbouring a Peyer’s patch is likely to 
have substantially lower levels of FGF19 expression and therefore lower levels of stimulation. A 
biopsy from a Peyer’s patch would lead to both variability between individuals but may also affect 
the relative quantification of FGF19 transcript levels between stimulated and unstimulated explants. 
If the unstimulated explants harbour a sample from a Peyer’s patch then the transcript levels would 
be significantly lower. The stimulated expression is calculated as a quantity (fold change) relative to 
the unstimulated explant. This would lead to erroneously higher fold change in these stimulated 
explants. However, Peyer’s patches are said to be micrometers in diameter on electron miscropes 
whereas biopsies specimens tend to be 2-3mm in diameter. Also 2-3 biopsies are taken and grouped 
for each condition in the incubations to attempt to control for this variability.  
 
5.6 Discussion 
After confirming human ileal expression of FGF19 (chapter 4) we have proceeded to show for the 
first time that ileal FGF19 is greatly stimulated by physiological concentrations of BA.  Prior to this 
study, the effect of BA on FGF19 transcription in human ileum was unknown, because no system 
existed to investigate this.  We have now developed an explant system which is functional and does 
not result in loss of FGF19 mRNA.  The potential applications of this system are numerous, as it 
enables investigation of FGF19 stimulation in human ileum under controlled conditions.  This system 
is more akin to natural human physiological conditions compared to previous systems which used 
mouse ileum, hepatocytes or human cell lines.  The use of explanted human tissue in this system 
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also allows ileal FGF19 stimulation to be directly linked to patients, so that ileal FGF19 stimulation 
may be investigated in different disease states.  
 
We have demonstrated that stimulation of the human ileum with 50 µM CDCA or 50 µM GCDCA 
induces FGF19 transcript expression in all individuals, with a median induction of approximately 300-
fold.  This is much greater than the approximately 80-fold FGF15 induction previously shown in 
mouse ileum after oral administration of the synthetic FXR agonist GW4064 [10].   Species 
differences may have contributed to this much higher FGF19 induction in human ileum compared to 
FGF15 induction in mice. The large induction in ileal FGF19 expression we have shown is also larger 
than that previously observed in primary cultures of human hepatocytes [133].  In those 
experiments, control samples had low expression of FGF19 but a dose dependent increase in FGF19 
mRNA levels was seen, of about 80-120 fold after 6 – 24h incubation with CDCA (50µM) or with 
GW4064 (1µM).   
 
The large 300-fold changes in FGF19 mRNA expression appear to dwarf the <4-fold changes of the 
other BA-regulated genes investigated in this study.  IBABP, OSTα and OSTβ genes have been shown 
to have FXR-mediated transcriptional responses which are predicted to lead to an increase BA-ileal 
fluxes, but their induction in our system was only a fraction of FGF19.  SHP, involved in BA-mediated 
transcription regulation, and previously shown to be highly induced in mouse ileum [143] was also 
stimulated much less than FGF19.  This incongruence may suggest that FGF19 has the dominant role 
in the negative feedback regulation of the BA enterohepatic circulation.   
 
Due to difficulties in assaying the FGF15 protein in previous mouse studies we are the first to show 
FGF19 release and possibly secretion from primary human ileal tissue on exposure to BA. FGF19 was 
detected in a number of the ‘unstimulated explant’ supernatants but it was measured at higher 
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levels in all of the BA stimulated explants.  Previous groups had used a similar technique to show 
FGF19 in cell culture fluid from primary human hepatocytes using the same ELISA[133].  One of the 
main effects of FGF19 is the negative feedback regulation of BA synthesis, and for this to be 
achieved, FGF19 transcripts must be translated into protein and released into the portal circulation.  
Our results reveal significant differences in magnitude between the ≈300-fold change in transcript 
expression and the much lower ≈8-fold-changes in FGF19 protein.  This is likely to be due to the 
extra time needed for translation and export of the protein, but may reflect some additional 
regulation of those processes.   
 
It is also important to note that the measurements we have made in our explant system are steady-
state transcript levels at a particular time, rather than direct measures of FGF19 synthesis or 
degradation.  In order to get a better idea of the dynamics of FGF19 transcript expression, we 
conducted limited time course experiments, which showed that FGF19 transcript expression were 
not increased by 1h of incubation, but after then, continued to increase up to 6h.  This suggests that 
as the length of time of BA exposure increases, more FGF19 transcripts are synthesized than 
degraded, resulting in a net increase in FGF19 transcript levels.  
 
We studied both unconjugated CDCA and conjugated GCDCA in most experiments. GCDCA being a 
polar, hydrophilic BA is likely only to enter enterocytes expressing the BA transporter ASBT. 
Expression of ASBT is a key finding in the ileum with and has been shown to be reduced in ileal 
biopsies from patients with Crohn’s colitis in clinical remission [46]. In human cell lines, ASBT 
transcription may be reduced by c-fos mediated inflammatory pathways. However other studies 
have refuted a link between ASBT expression and ileal inflammation [144]. In our experiments, 
stimulation was found in ileal explants in all cases with GCDCA, but this control cohort of patients 
has not included any subjects with identified ileal disease or histologic microscopic inflammation. 
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CDCA also induced FGF19 expression in all of the explants in our experiments confirming entry into 
cells potentially independent of ASBT.   
 
It is widely acknowledged that the most potent physiological FXR agonist is CDCA but there has been 
some ambiguity regarding the relative potency of CA as an FXR agonist [9, 136, 137, 145].  Minimal 
FXR activation was found in non-intestinal CV-1 cells with CA, when compared to CDCA and 
secondary BA [9], and similar findings were reported using human FXR and a reporter gene in HepG2 
cells [137].  However, other groups have shown CA is able to stimulate FXR responses [136, 145].  
Here we have shown that FGF19 is strongly induced with both CDCA and CA, and, to a lesser extent, 
with DCA.  Our study used human tissue in a physiological system where BA transport occurs, giving 
confidence that this system generated accurate data regarding human ileum.  Nonetheless, putting 
this data into the context of previous findings does raise the question of whether alternative 
mechanisms to FXR activation may be responsible for inducing FGF19.   
 
LCA was poor at inducing FGF19 expression in human ileal explants.  Our data is in keeping with the 
reports that LCA binds and antagonizes FXR [146] but does not concur with other findings [9].  A 
more recent study reported that LCA induced FGF19 expression independently of FXR following 
Pregnane X Receptor (PXR, NR1I2) activation [147].  However LCA has toxic properties [146] which 
could have had a negative bearing on the stability of our ileal explant system.  Further data are 
required to fully elucidate the influence of secondary BA on FGF19.  
 
A number of studies indicate possible candidates for FXR-independent induction of FGF19 with 
different selectivity for various BA.  A novel G-protein coupled membrane receptor, BG37/TGR5, has 
been found, expressed in ileum and other tissues, which binds BA and increases intracellular cyclic 
adenosine monophosphate (cAMP) [148].  No link has been shown between TGR5 activation and 
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downstream FGF15/19 expression or for any other FXR target genes.  Interestingly, one study [149] 
did report a possible ‘crosstalk’ scenario between FGF15 and TGR5 on gallbladder motility.  It 
remains likely that intestinal TGR5 is closely linked to glucose and lipid homeostasis [150] (similarly 
to FXR and also FGF19 [151]) rather than BA regulation.  
 
This study successfully validated previous reports [152, 153] regarding OCA as a potent ligand for 
FXR.  OCA strongly induced FGF19 in all subjects at both of the studied concentrations.  This supports 
the potential therapeutic role of OCA as a novel FXR agonist in gastrointestinal disease with 
defective FXR activation/FGF19 induction patterns.  OCA enters the enterohepatic circulation [154] 
thus can be used to regulate hepatic BA synthesis.  Previous reports have focused on cholestatic 
diseases [145] and, more recently, metabolic disorders [155, 156] but we would also anticipate a 
role in gastro-intestinal disorders. 
The individual variability in ileal FGF19 induction by both CDCA and GCDCA may indicate different 
levels of BA homeostatic equilibrium.  Results from this study indicate that individuals may vary in 
their capacity to produce ileal FGF19 at a transcriptional level. The FXR-FGF19 axis is likely to be 
influenced by factors upstream and down stream from the intracellular BA ligand binding and 
activation of FXR within the enterocyte. Upstream factors may involve the Ileal microbiota. 
Microbiota will influence ileal FGF19 production via their effects on the composition of BAs within 
the intestinal lumen prior to absorption. Dihydroxylation into secondary BAs will lead to the less 
potent FXR activation upon entry into the enterocyte. Downstream effects on the FXR-FGF19 
pathway have been shown to be influence by PPARa activation. PPARa activation can occur with 
certain dietary fats and promotes glucoronidation and disposition of intracellular BAs. This would 
reduce intracellular BA concentrations and reduced FXR-FGF19 activation [157]. A novel protein, 
DIET1 may also influence downstream secretion of FGF19 protein levels [158] and is discussed 
further in chapter 8. 
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The consequences of this variability in FGF19 production may not simply be confined to BA 
homeostasis. Serum FGF19 levels have also been associated with increased BMI, lipid and glucose 
homeostasis [87]. It is interesting to observe the higher median BMIs in patients diagnosed with 
excess faecal BAs or low seHCAT retention levels PBAD [71]. 
Our group has demonstrated that primary BA diarrhea patients have lower median serum FGF19 
levels than controls, and proposed that primary BA diarrhea may be due to inadequate FGF19 
expression, resulting in impaired negative feedback and consequent overflow of BA into the colon 
[159].  One previous study demonstrated a significant depletion in CA levels in primary BA diarrhea 
patients compared to controls [160].  This could have been important if our findings had suggested a 
higher potency for CA in inducing FGF19 compared to CDCA, but was not the case, as CDCA and CA 
were not significantly different.  We did not recruit any patients with diagnosed primary BA diarrhea 
for this part of the study, but explant results are presented in Chapter 6. 
In summary, this study has found that FGF19 expression is highly responsive at a transcriptional level 
with FXR activating BAs in human ileum.  We have demonstrated this through an explant system, 
which in future can be used to investigate the role of FGF19 in disorders of BA homeostasis.
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Chapter 6: Reduced bile acid stimulated expression of FGF19 is associated 
with conditions of bile acid diarrhoea 
 
Abstract 
Introduction: FGF19 is a gut peptide produced from ileal enterocytes in response to absorbed BA. 
FGF19 conserves the bile salt pool by inhibiting hepatic BA synthesis. Ileal disease is common in 
Crohn’s disease. Impaired ileal FGF19 production may lead to excessive BA synthesis and contribute 
to increased fecal BA levels. Increased feacal BA is a causative factor in the pathogenesis of 
diarrhoea in CD patients, referred to as secondary bile acid diarrhoea SBAD. Primary BAD (PBAD) 
occurs in the absence of overt ileal disease or malabsorption. Impaired ileal FGF19 production may 
result in increased faecal BA levels due to excessive hepatic BA synthesis in PBAD. We aimed to 
investigate whether BA-stimulated expression of FGF19 in the ileum is reduced in patients with CD 
and PBAD. 
Methods: Methods: Patients attending for colonoscopy (n=30) were prospectively recruited and 
gave informed consent to give additional ileal biopsies. 14 patients had CD (4 with previous right 
hemi colectomy and 10 without), 16 patients had unexplained diarrhea and had SeHCAT tests. 
Groups of 2-3 biopsies (explants) were incubated separately for 6h with either BA-free culture media 
(unstimulated controls), chenodeoxycholate (CDCA) or glyco-CDCA 
(GCDCA), both at 50uM. After RNA extraction and cDNA synthesis, FGF19 expression was quantified 
relative to GAPDH by RT-PCR. 
Results: Results: In patients with unexplained diarrhoea SeHCAT 7d retention values were <15% in 7 
patients, indicating primary BAD, and >15% in 9 who were normal diarrhea controls. A positive 
correlation was found between SeHCAT retention and the magnitude of the fold change in FGF19 
expression stimulated by either CDCA (r=0.54, n=16, p=0.04) or by GCDCA (r=0.76, n=7, p=0.04). The 
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median CDCA stimulated fold change in FGF19 expression was significantly lower in CD compared to 
healthy controls (87, n=12 vs 351, n=24, p=0.03) and a similar non-significant trend was observed for 
median GCDCA stimulated expression (114, n=11 vs 161, n=12, p=0.65). 
Conclusion: Median CDCA stimulated FGF19 transcript levels were lower in CD patients and PBAD 
patients.  As uptake of CDCA is independent of carrier-mediated apical BA uptake this implies 
abnormalities in ileal FGF19 production rather than active BA uptake processes.  A reduced capacity 
to induce ileal FGF19 expression in response to BA is proposed to lead to excessive hepatic BA 
synthesis and increased faecal BA levels rendering CD patients and PBAD patients more susceptible 
to BAD. 
 
6.1 Background 
The peptide FGF19 is produced from enterocytes in response to BA absorption and binding to the 
farnesoid X receptor FXR. FGF19 maintains homeostasis of the BA pool size by inhibiting hepatic BA 
synthesis. The most potent natural ligand for intestinal intracellular FXR activation is CDCA or its 
conjugated form. For FXR activation to occur, BA must first be absorbed from the luminal aspect of 
the enterocyte into the cell. Any defect in ileal FGF19 production could involve BA uptake, 
intracellular pathways (FXR activation and upregulated FGF19 transcription) or post transcriptional 
pathways (translation and secretion).   
Using our ileal explant system to study BA induced FGF19 expression will identify defects arising 
from either BA uptake, FXR activation or FGF19 transcription. Any defect attributable to active BA 
uptake is more likely to affect conjugated BA explant stimulation which is dependent on the 
expression of ASBT [9]. Unconjugated BA uptake occurs via passive diffusion independent of BA 
transporter expression. 
Other groups have shown that the basal expression of other FXR target gene transcripts SHP + IBABP 
are reduced in biopsies from patients with CD.  The same group has demonstrated inhibitory effects 
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of inflammatory cytokines (TNFa and IL-1B) on FXR activation and target gene transcription via Nf-KB 
pathways [55] in animal studies and human cell lines. GW4046 induced FGF19 transcription was 
shown to be completely abolished by co-incubation with TNFa in human cell lines over 24 incubation 
periods. This suggests potential defects in the BA induced FGF19 stimulation pathway at both the 
intracellular BA-FXR binding and activation stage in addition to BA uptake stage in CD.  
Using our previously described ileal explant system to study BA stimulated FGF19 transcript levels 
we aimed to compare the magnitude of FGF19 fold change (calculated using the comparative Ct 
method, chapter 5) between patient groups.  We hypothesized that reduced production of FGF19 in 
SBAD and PBAD may occur at a transcriptional level (the intracellular BA-FXR binding and activation 
stage). This would lead to significantly lower BA stimulated FGF19 transcript levels in mucosal 
explants from patients with these BAD conditions.   Any impairment in FGF19 production resulting 
from reduced ASBT mediated BA uptake would lead to lower BA induced FGF19 transcript levels with 
conjugated BA (GCDCA) stimulation relative to unconjugated BA. CDCA will enter cells via passive 
diffusion as opposed to active transport process requiring expression of ASBT. If the defect involves 
intracellular BA-FXR activation then we would expect lower BA induced FGF19 transcript levels with 
both GCDCA and CDCA stimulation in BAD patients.  
We have proposed that in PBAD, impaired ileal FGF19 production leads to excessive bile acid 
synthesis and increased faecal bile acids, producing secretory diarrhoea. In SBAD of CD, defective 
FGF19 production results in excessive hepatic bile acid synthesis, which in the presence of sub-
optimal ileal reabsorption of bile acids, will further increase faecal BA levels. 
 
6.2 Aims: 
(1) Establish if BA stimulated FGF19 transcript levels in mucosal explants from BAD patients are 
significantly lower compared to healthy control patients.  
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(2) In CD patients establish if a difference exists in the BA stimulated FGF19 transcript levels when 
comparing conjugated and unconjugated BA stimulation.  
(3) Establish if BA stimulated FGF19 transcript levels in mucosal explants from PBAD patients are 
significantly lower with both conjugated and/or unconjugated BA compared to healthy control 
patients. 
(4) Establish if BA stimulated transcript levels from other FXR responsive genes are attenuated in 
mucosal explants from CD patients. 
(5) Perform exploratory studies on co-incubation and/or pre-incubation of ileal explants with both 
TNFa and BA to establish if TNFa inhibits BA stimulated FGF19 transcript levels ex vivo.  
 
6.3 Specific Methods 
6.3.1 Patients with Crohn’s disease 
14 patients with a histologically confirmed diagnosis of Crohn’s disease were recruited. Pre defined 
clinical phenotypes were recorded according to the Montreal classification. Drug history and 
demographics were also recorded. For patients that had undergone previous ileal resection, the 
length of ileum removed and type of anastamosis was recorded according to previous surgical 
specimen records 
 
6.3.2 Patients assessed by SeHCAT with chronic diarrhoea 
16 patients with normal colonoscopy and a long term history of persistent diarrhoea (an average of 
3 loose, type 6 or 7 stools per day for greater than 3 months) were recruited and then further 
assessed with 7 day SeHCAT scanning. Drug history and demographics were also recorded. 
SeHCAT results of <15%, <10% and <5% were used to diagnose mild, moderate and severe PBAD. 
Patients with other causes of diarrhoea such as GI malignancy, infection, IBD and coeliac disease 
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were excluded. In the 30 patients studied, bile acid stimulated transcript expression was investigated 
using our established ileal explant system previously described in chapter 2.3.5 [109].  A collection of 
6-9 ileal biopsies were obtained and groups of 2-3 biopsies were incubated separately with a bile 
acid-free culture media (unstimulated control), or 50μmol/L of chenodeoxycholate (CDCA) or glyco-
CDCA (GCDCA).  After 6h, biopsies were stored in RNAlater.  RNA extraction and cDNA synthesis 
following standard methods.  BA stimulated expression of FGF19 and other transcripts (FGF19, 
IBABP, ASBT, OSTα, SHP) were quantified relative to GAPDH by qRT-PCR and expressed as fold 
changes (RQ). Stimulated explant FGF19 transcript levels were quantified relative to the transcript 
levels in the unstimulated explants (the ‘calibrator’, or internal control) and fold change (RQ) 
calculated using the comparative Ct method as described in chapter 5.3.2.  
6.4 Results: Crohn’s disease 
6.4.1 Patient demographics 
We set out to study BA induced FGF19 transcript levels in mucosal ileal explants in patients with IR-
CD and NR-CD. Patients with a diagnosis of Crohn’s disease were prospectively recruited whilst 
attending for colonoscopy. Patient clinical phenotypes and characteristics are described in table 6.1. 
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 Healthy controls Crohn’s disease 
n 28 14 
Age (median + IQR) 48 (34-58) 44 (22-74) 
Sex (%)   
  Male 13  (46) 4   (28) 
  Female 15  (54) 10 (72) 
Previous ileal resection 0 4   (28) 
Distribution of CD   
  Ileo-colonic - 7   (50) 
  Ileal - 4   (28) 
  Colonic - 3   (22) 
Medication   
  No medication 20  (71) 5  (43) 
  Long term treatments 8  (29) 8  (57) 
    Bile acid sequestrants - 2  (14) 
    Immunomodulators - 5  (36) 
    Biologics - 1  (7) 
    Budesonide - 1  (7) 
Indications for colonoscopy   
    Disease assessment / new diagnosis - 12/2  (83/17) 
    Change in bowel habit +/- form 10 7 
    PR bleed 4 - 
    Anaemia 5 - 
    FH of CRC 1 - 
    Polyp surveillance 7 - 
    PR mucous 1 - 
 
Table 6.1 Patient demographics of healthy controls and Crohn’s disease patients. 
 
6.4.2 Ileal BA stimulated FGF19 transcript levels in CD 
Mean GAPDH Cts were similar to those observed in healthy control explants. Mean GAPDH Ct levels 
were similar with low SD in both control and CD patients with unstimulated and BA stimulated 
explants suggesting a low variance in the expression of this control gene across experimental 
conditions. Median FGF19 transcript levels were significantly higher in BA stimulated explants from 
CD patients compared to the paired unstimulated control explants from the same patient suggesting 
that BA stimulation of FGF19 expression does occur in ileum from patients with CD (stimulated 
explants vs unstimulated explants p= 0.0001,  for C50 and G50, comparing dCt using Mann Whitney 
test, table 6.2) 
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 CD patients 
 Unstimulated explants 
(n=14) 
C50 Stimulated explants 
(n=12) 
G50 Stimulated explants 
(n=11) 
GAPDH Ct 23.0 (0.3) 24.1(1.0) 23.4 (0.4) 
FGF19 Ct 30.6 (0.6) 24.9 (1.0) 24.8 (1.1) 
FGF19 dCt 7.6 (6-10)* 1.5 (-1 – 4)* 1.2 (-1.6 – 6)* 
 
Table 6.2 Cts from explants in CD, Crohns disease patients. C50 = explants stimulated with 50µM 
chenodeoxycholic acid and G50 = explants stimulated with 50µM glycol-chenodeoxycholic acid. 
Mean Cts and SEM are shown unless marked with an * representing median and IQRs.  
 
6.4.3 Median CDCA stimulated FGF19 transcript levels are lower in CD ileum compared to healthy 
controls  
 
The median CDCA stimulated fold change in FGF19 expression was significantly lower in CD 
compared to healthy control patients (87, IQR 29 -316, n=12 vs 350 IQR 161 - 485, n=24, p=0.02). No 
significant difference in median fold change was seen in GCDCA stimulated expression although a 
trend towards lower levels was observed (114 IQR 20 - 332, n=11 vs 161 IQR 77-350 , n=12, p=0.62 
Figure 6.1). 
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Figure 6.1 Fold change in BAstimulated expression in ileal explants in healthy controls and patients 
with Crohn’s disease. Open circles = ileal resected patients. Median and IQR shown. 
No significant difference in median levels of BA induced FGF19 transcript levels were seen between 
GCDCA and CDCA stimulated explants (p= 0.69, Mann Whitney).  Similarly, there was no significant 
difference in median levels of CDCA induced FGF19 expression when compared to paired GCDCA 
stimulated explants from the same patient (p= 0.5,Wilcoxon paired test, Figure 6.2).  BA stimulated 
expression of FGF19 was not associated with age, or the presence of diarrhoea (Stool freq>3, stool 
form type 5-7 BSFS) or any class of medication. 
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Figure 6.2: Paired fold changes in FGF19 
expression from ileal mucosal explant 
incubations with both CDCA (C50) and 
GCDCA (G50) from 9 individual patients. 
Open circles: represent neo-terminal ileal 
explants (patients with previous right 
hemicolectomy and ileal resection). Lines 
represent paired ileal explants from the 
same patient.  
 
Induction FGF19 expression was also demonstrated with OCA at doses of 1 and 20uM and CDCA at 
lower doses of 20uM in patients with CD. 
6.4.4 Post-hoc analysis of BA stimulated FGF19 transcript levels in IR-CD, neo-terminal ileum 
Observing BA stimulated transcript levels in the 4 patients who had undergone previous ileal 
resection revealed a trend towards a lower fold changes in BA stimulated expression compared to 
healthy controls with the exception of one outlier (red circles, Figure 6.3 table 6.3).  
pt Age s Phenotype IR (cm) Medication Stool Freq Stool form C50 G50 
1 66 f Ileo-
colonic 
45 Colesevalam 
azathioprine 
5 7 4.4 1.4 
2 68 f Ileal 51 Colesevalam 6 5-7 824 1473 
3 45 f Ileal 15  3 5 111  
4 68 f ileal 15  3 6 22.4 22.3 
 
Table 6.3 Patient demographics of IR, ileal resection patients with Crohn’s disease studied with ileal 
explant studies. 
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Figure 6.3. Comparison of fold change in BA stimulated FGF19 expression in neo-terminal ileal 
mucosal explants. Open circles = CDCA stimulated and GCDCA stimulated expression in a patient 
with 2 previous ileal resections (Pt 1). Red circles = FGF19 expression in BA stimulate explants with 
GCDCA and CDCA in a patient of 51cm ileal resection (Pt 2). C50 = Chenodeoxycholic acid at 50uM, 
G50 = Glycho-chenodeoxycholic acid, IR= Ileal resected patients. Median and IQRs are shown where 
appropriate. 
6.4.5 BA stimulated Ileal SHP and IBABP transcript levels in patients with NR-CD 
Fold change in CDCA and GCDCA stimulated SHP or IBABP expression were small but significant in CD 
patients ranging from 2 -20 fold. This is similar to fold changes in SHP and IBABP expression 
observed in healthy controls seen in Chapter 5.3.6.  
There was no significant difference in median CDCA stimulated IBABP transcript levels comparing 8 
CD patients to 6 healthy control patients (Stimulated IBABP median fold change in healthy controls 
3.56 IQR 1.8-4.8 vs CD patients 1.87 IQR 1.3 – 4.0, p=0.32, n= 8). No significant difference in GCDCA 
stimulated transcript levels were seen (stimulated IBABP median fold change in healthy controls 1.9 
IQR 1.7-3.3 vs CD patients 2.1 IQR 0.7-5.5, p=1.0). Likewise, fold change in SHP transcript levels 
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showed no significant differences with CDCA or GCDCA stimulated explants in 8 CD patients 
compared to 6 healthy control patients (p  0.70 and p=  0.72 respectively). 
6.4.6 Post-hoc analysis of Ileitis and BA stimulated expression of FGF19 transcripts in non ileal 
resected patients 
 
Post hoc analysis of the effects of ileal inflammation on BA stimulated expression of FGF19 was 
assessed. Ileal inflammation was either endoscopically evident as inflammation or ulceration within 
the terminal ileum (in 3 patients with NR-CD) or found after histologic examination of biopsies 
(microscopic ileitis) taken from the terminal ileum at the time of research biopsies. Evidence of 
microscopic inflammation was part of the exclusion criteria for the healthy control cohort. Patient 
characteristics are shown in Table 6.4. Patients with previous ileal resections were excluded from 
this part of the analysis to avoid the confounding effect of resection may have on ileal inflammation. 
Within this group of patients GAPDH transcript levels were within expected levels with low 
variability. FGF19 transcript levels were significantly induced in all patients with both macroscopic or 
microscopic ileitis. The median fold change in FGF19 transcript expression from CDCA stimulated 
explants was not significantly different in patients with ileitis compared to healthy controls although 
a possible trend towards lower induction may be present (p=0.12, figure 6.4).   
  
132 
 
Age Sex PMH DHx Ileal  histology Overt ileitis C50 
24 f Obstetric 
cholestasis 
 Villous shortening and 
chronic inflammation 
Nil 316 
62 f Renal 
transplant 
Mycophenolate Mild chronic 
inflammation 
lymphocytic infiltrate 
Nil 220 
25 m UC Asacol Focal granuloma, 
chronic inflammation 
Nil 70 
57 f Hyperthyroid Carbimazole Lymphocytic infiltrate 
and chronic 
iflammation 
Nil 360 
52 f Crohns Azathioprine Chronic inflammation Apthous ulcers 260 
74 m Crohn’s and 
renal dialysis 
Enalapril, 
irbesartan, 
atenolol, aspirin, 
adcal 
Chronic inflammation Inflammation + 
ulceration 
98 
42 f Crohn’s  Chronic inflammation Apthous ulcers 65 
 
Table 6.4. Patients demographics of patients found to have macroscopic ileal inflammation at the 
time of colonoscopy or microscopic inflammation on subsequent ileal histology. 
 
Within this group of patients GAPDH transcript levels were within expected levels with low 
variability. FGF19 transcript levels were significantly induced in all patients with both macroscopic 
and microscopic ileitis. The median fold change in FGF19 transcript expression from CDCA stimulated 
explants was not significantly different in patients with ileitis compared to healthy controls although 
a trend towards lower induction may be present (p=0.12, figure 6.4).   
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Figure 6.4. Comparison of fold change in 
FGF19 expression with 50uM CDCA (C50) in 
healthy controls (n=24) and non ileal 
resected patients with either endoscopically 
visible overt ileitis (red dots) or 
microscopically evidence on subsequent 
histological analysis of ileal biopsies (n=7). 
 
 
 
6.5 Results: PBAD: Positive correlation between BA stimulated FGF19 transcript levels and 
SEHCAT retention levels. 
 
FGF19 expression was studied in 16 patients with diarrhoea in ileal explants cultured for 6h with 
CDCA (50µmol/L), GCDCA or under control conditions using the ileal explant system described 
elsewhere.  Seven patients had PBAD (SeHCAT <15%) and 9 were ID controls (SeHCAT >15%).   
FGF19 transcript expression was stimulated in most subjects, with a median of 184-fold with CDCA, 
similar to values found previously [109].  The lowest fold changes in FGF19 expression were 
observed in biopsies from patients with the lowest SeHCAT retention values (Figure 6.5).  Positive 
correlations were found between SeHCAT retention and the magnitude of the fold change in FGF19 
expression stimulated by CDCA (rs = 0.54, p = 0.04, n = 16) and by GCDCA (rs = 0.61, p = 0.07, n = 7).  
Confirming our previous findings, IBABP, OSTα and SHP transcripts were also significantly stimulated 
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to lesser degrees (all p<0.002) but ASBT was not affected (Table 6.5).   Apart from FGF19, only the 
degree of stimulation of IBABP correlated with SeHCAT (rs =0.47, p=0.04, n=14). 
Transcript Stimulation (RQ) by CDCA Correlation with SeHCAT p 
FGF19 184 0.54 0.02 
IBABP 2.2 0.47 0.04 
OSTα 2.8 -0.10 NS 
SHP 2.6 -0.16 NS 
ASBT 1.0 -0.05 NS 
 
Table 6.5  Stimulation of ileal transcripts by chenodeoxycholic acid (CDCA) and relationship to 
SeHCAT. Median values for stimulation with CDCA 50µmol/L for 6h in ileal explant system shown.  
Spearman rank correlation coefficients and p values are shown for the relationships between 
stimulation and SeHCAT values.  N=12-16 patients.  NS, p>0.05 
 
 
 
Figure 6.5. Stimulation of ileal FGF19 transcript expression related to SeHCAT 7d retention.  The fold-
change in RNA expression is shown with CDCA in (a) and with GCDCA in (b).  The linear regression 
lines are shown. 
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6.6 Pilot data on the effects of TNFaplha on BA stimulated FGF19 transcript levels  
 
Preliminary data was obtained investigating the effects if TNFalpha on BA stimulated transcript 
levels. BA stimulated FGF19 transcript levels were lower in the 2 patients whose explants were 
incubated with CDCA and TNFa compared to explants incubated in parallel with CDCA only from the 
same patient. 
 
 
Figure 6.6 Fold changes in BA stimulated FGF19 expression with and without exogenous TNFa. A. 
(C50 6hrs) Mucosal explants incubated 50uM CDCA or (C50 + TNFa 6hrs) 50uM CDCA + TNFa for 6 
hours. B (C50 3hrs) Mucosal explants pre- incubated in BA free media for 3 hours then moved to 
media containing 50uM CDCA (TNFa + C50 3hrs), Mucosal explants incubated in BA free media + 
TNFa for 3 hours, then moved to media containing 50uM CDCA and TNFa for 3 hours. Each fold 
change is calculated relative to an internal BA free control incubation in the standard way (chapter 
5). 
  
A B 
136 
 
6.7 Discussion 
 
The hypothesis of this chapter was supported by demonstrating that lower ileal BA stimulated FGF19 
transcript levels are found in patients with BAD. Median CDCA stimulated FGF19 transcript levels 
were significantly lower in explants from patients with CD than healthy controls.  Patients with 
chronic diarrhoea and low SeHCAT levels also had low levels of BA stimulated FGF19 expression.  
This points towards a potential defect in the FXR-FGF19 pathway, in response to BAs, occurring at a 
transcriptional level in some of these patients. 
Lower FGF19 transcript levels in GCDCA rather than CDCA stimulated explants were expected in CD 
due to previously described reduced ASBT expression and presumed reduced conjugated BA uptake. 
However we observed the converse (significantly lower levels of BA stimulated FGF19 transcript 
levels in explants stimulated with CDCA rather than GCDCA). It may be that defects in the FXR-FGF19 
pathway occurring post uptake of BA into the ileal enterocyte play a greater role in the pathogenesis 
of BAD than BA malabsorption. 
It is possible that medications taken by some of the patients with CD may have influenced GCDCA 
stimulated FGF19 expression. In Jung et als study on CD patients (where ASBT protein expression 
was found to be 70% that of healthy controls) it is important to note that these patients were not on 
any medication 5 days prior to the study or during the study. Whereas 7 of the 14 CD patients in our 
study were on medications (1x receiving IFX, 5 immunomodulators and 1x budesonide). It is possible 
that medications may restore ASBT expression as observed with budesonide and other 
glucocorticoids. Two glucocorticoid response elements were found in the ASBT promoter conferring 
inducibility by glucocorticoids. Although only one of our CD patients studied was taking budesonide 
ASBT expression may have been influenced by other pathways modulated by other 
immunomodulatory medication or biologic therapy.  
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However, no significant differences were found in FGF19 transcript levels in the patients taking 
medication compared to those on no medication. The contribution of ASBT expression on FGF19 
responses could have been controlled for further by analysing ASBT transcript levels in these 
mucosal explants and expressing FGF19 levels as a proportion to ASBT levels.  
To separate any confounding effects from anatomical differences in expression of carrier mediated 
BA uptake or FGF19 expression that may result from ileal resection it was important to consider 
patients with previous ileal resection separately in post-hoc analysis. (table 6.2). Out of the 4 IR CD 
patients studied, 3 demonstrated relatively low fold changes in BA stimulated FGF19 expression. This 
included one patient (Pt 1) with 2 previous ileal resections and a cumulative TI resection length of 45 
cm. This patient was one of the only patients that did not demonstrate a significant fold change in 
ileal transcript expression levels in GCDCA stimulated explants. This patient only had a fold change of 
1.4 in BA stimulated expression compared to the paired unstimulated mucosal explants.  
One of the other patients (pt 2) who also had undergone an extensive ileal resection in the past 
(51cm) displayed the highest observed fold change in the GCDCA stimulated FGF19 expression. Pt 2 
had been taking a BA sequestrant (cholesevalam) up to 48 hours prior to the colonoscopy, whereas 
pt 1 had stopped her BA sequestrant (Questran) 1 week prior to the colonoscopy. Previous studies 
on serum FGF19 levels have shown dramatic decreases in levels after and during oral administration 
of BA sequestrants [22] . What has not been described so well is what happens to FGF19 levels after 
stopping such treatments. Pattni had performed a pilot study on 2 healthy control subjects and 
demonstrated a significant rebound phenomenon after stopping BA sequestrants with fasting serum 
levels increasing 2 -3 times higher than baseline pre-treatment levels for up to one week after 
treatment cessation (Sanjeev Pattni, Imperial College MD).  
If the outlier with the high FGF19 transcript levels is excluded then this exploratory post-hoc data 
shows very low levels of BA induced FGF19 stimulation in these patients suggesting a reduced 
capacity to induced FGF19 transcription in response to BA in neo-terminal ileum. As the finding is 
138 
 
observed with both G-CDCA and CDCA this reduced capacity may not simply be due to reduced ASBT 
expression in neo-terminal ileum. Again this could have been controlled for by analysing ASBT 
transcript levels in each set of explants and expressing FGF19 as a proportion to ASBT levels.  
We know that the capacity for active BA uptake is highest at the terminal ileum just upstream to the 
ICV . However it is not known how the capacity to produce FGF19 varies along the small intestine. 
We know that the basal expression of FGF19 transcripts are higher at the TI compared to duodenum. 
One would expect a gradient of increasing expression of FGF19 or capacity as one moves from 
proximal to distal small intestine as with ASBT but this has not yet been confirmed. 
The low or absent BA FGF19 response in the pilot studies on neo-terminal ileum from patients with 
resection lengths ranging from 15-51cm could indicate that BA induced FGF19 response may be 
restricted to a limited portion of TI. If the expression of FGF19 is more restricted than the 
distribution of ASBT expression (and carrier mediated BA uptake) then FGF19 signalling rather than 
BA malabsorption could be a predominant factor in the aetiopathogenesis of BAD in some patients 
with CD. Relatively limited ileal resections or inflammation could significantly disturb FGF19 
production with minimal effects on BA absorption. It is not known to what extent BA absorption 
changes as part of the intestinal adaptation that can occur after resection. Further studies on neo-
terminal ileum and the distribution of FGF19 and ASBT expression along the small intestine are 
required. 
Regarding PBAD, the positive correlation with both GCDCA and CDCA stimulated FGF19 expression 
with SeHCAT values is also indicative of a defects in FXR-FGF19 activation that may occur pre- and 
post BA uptake. Unstimulated ASBT transcripts are expressed at lower levels in biopsies from 
patients with low SeHCAT levels (Chapter 4).   This could in itself result in reduced bile acid uptake 
and consequently reduced bile acid/FXR-dependent stimulation of FGF19 transcription in Low 
SeHCAT patients. However, again, this appears not to be the only reason, as incubation with CDCA 
also gives SeHCAT-dependent FGF19 transcript stimulation.  Unconjugated CDCA, unlike glycine-
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conjugated GCDCA, is not dependent on transport by ASBT and will produce FXR-mediated 
transcription in cells not expressing ASBT [9, 137].  
If the defect in FGF19 production in PBAD does lie with BA stimulated FXR activation then one might 
expect to see a relationship with SeHCAT values and other FXR target genes. A similar positive 
correlation was observed with BA stimulated IBABP transcript levels and SeHCAT values. However 
the BA stimulated responses in other target genes (OSTa, ASBT, SHP) studied here is very small, as in 
chapter 5 (median twofold difference in expression), compared to FGF19 and it may be difficult to 
see a relationship with such small BA stimulated expression levels.  
The mechanism of a potential defect in BA stimulated FXR activation of FGF19 transcription is not 
clear in PBAD. Cell cultures incubated with FXR agonists and inflammatory cytokines (TNFa, IL-1B, IL-
6) have implicated Nf-KB surpression of FXR activation and FGF19/15 transcription. However PBAD 
has not been associated with ileal inflammation and all of the PBAD patients studied here had 
histologically normal TI biopsies.  It is possible that PBAD is associated with sub-clinical upregulation 
of inflammatory cytokines. Increased cytokine secretion (TNFa, IL-1B, IL-6) has been demonstrated 
upon LPS activation of PBMC in patients with IBS-D compared to healthy controls [161]. Enhanced 
immune activation is thought to play a role in symptoms of IBS, particularly those suffering from 
chronic diarrhoea [162, 163]. 
Other transcription factors may affect FXR activation and FGF15/19 transcription.  Cross talk 
between transcription factors is well described (ref). Transcription factors with an inhibitory 
influence on FXR have recently been described such as SIRT1[131, 164] or Yin Yang-1 [165]. FXR 
activity is also affected indirectly by other pathways; for instance, intestinal peroxisome proliferator-
activated receptor α -UDP-glucuronosyltransferases signalling has recently been suggested. Mouse 
models Dextran sulphate sodium (DSS)-induced colitis demonstrate activated 
intestinal peroxisome PPARα-UGTs pathway in inflamed colonic mucosa. UGTs normally accelerate 
the metabolic elimination of BAs, and thereby decrease their intracellular levels in the small 
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intestine. Activation of UGTs mediated by inflammation therefore lead to reduced intracellular BAs 
resulting in repressed FXR-FGF15 signalling [132].   
 
In conclusion, results from this chapter have demonstrated that patients with primary or secondary 
bile acid diarrhoea may have a reduced capacity to produce FGF19. Increased faecal BA may occur as 
a result of BA malabsorption in CD but malabsorption has never been demonstrated in PBAD 
patients. The relationship between both conjugated and unconjugated BA stimulated FGF19 and 
SeHCAT retention levels also supports our hypothesis. 
Low seHCAT retention levels represent increased faecal BA loss from the enterohepatic circulation. 
Increased BA loss can occur through other mechanisms other than ileal malabsorption. Low FGF19 
levels would lead to increased synthesis of new BA. The bile acid pool size would be larger and with 
ileal reabsorption at saturation point a new steady state would ensue with greater levels of BA 
entering the colon and being lost in the feaces. 
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Chapter 7: The response of patients with secondary bile acid diarrhoea to the 
farnesoid X receptor agonist obeticholic acid 
 
Abstract: 
Background & Aim:  Bile acid diarrhea (BAD) is a common yet unrecognized cause of chronic 
diarrhea secondary to ileal disease or resection in Crohn’s disease.  Many patients have reduced 
levels of the ileal hormone fibroblast growth factor 19 (FGF19), a negative regulator of hepatic bile 
acid synthesis, secreted in response to farnesoid X receptor (FXR) agonists.  We hypothesized that 
obeticholic acid (OCA), a potent FXR agonist, could increase FGF19 in BAD patients and produce 
clinical benefits. 
Methods:  After a 2-week run-in when bile acid sequestrants were discontinued, patients with 
previously diagnosed Crohn’s disease and secondary BAD (n=10) or idiopathic chronic diarrhea (n=8), 
received oral OCA 25mg daily for 2 weeks.  Serum FGF19, total bile acids and 7α-OH-4-cholesten-3-
one (C4) were measured fasting and for 6h before and after 2w OCA treatment.  Symptom diaries 
were recorded. 
Results:  In the group of patients overall OCA increased median fasting FGF19 from 43 to 104 pg/mL 
(P=0.03) and significantly reduced fasting C4 and bile acid responses.  In the secondary BAD group, 
improvements occurred in stool form (P=0.04) and in a diarrhea index (P=0.03) and this was 
associated with increases in FGF19 and reductions in C4 and BA levels in patients with shorter ileal 
resections (resections < 45cm, n=7/10). Symptoms of abdominal pain and urgency also improved.  
FGF19, C4 and bile acids changed in the idiopathic diarrhea control group, but no significant clinical 
improvements occurred.  Total and LDL cholesterol increased.  OCA treatment was well tolerated.   
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Conclusions:  This proof-of-concept study has shown that OCA stimulates FGF19, reduces bile acid 
synthesis and produces clinical benefits in most patients with secondary BAD.  FXR agonists have 
therapeutic potential in diarrhoea in symptoms of CD. 
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7.1 Background 
FGF19 production in the ileum is stimulated by BA binding to the farnesoid X receptor (FXR) and 
activating transcription [7].  Using explants of human ileum, we showed that FGF19 transcripts and 
protein levels were potently stimulated by chenodeoxycholic acid (CDCA), the most active natural 
FXR agonist [109].  More potent FXR agonists have been synthesized with the aim of treating liver 
and other disorders [152].  Obeticholic acid (OCA, also known as 6α-ethyl-CDCA and INT-747) is 
about 100-fold more potent as an FXR agonist than CDCA [166].  Clinical trials of OCA in primary 
biliary cirrhosis and non-alcoholic steatohepatitis (NASH) have been published or are in progress [87, 
167, 168].   
We hypothesized that, if potent FXR agonists such as OCA were to stimulate FGF19 in patients with 
BAD, this would reverse the impaired regulation of BA synthesis and, by reducing BA production, 
lead to clinical improvement.  We anticipated that the effect would be most marked in primary BAD 
but that impaired BA absorption could limit the effect in secondary BAD.  To test this hypothesis, we 
have performed a proof-of-concept study in two groups of patients, with secondary BAD, and 
idiopathic controls with chronic diarrhea. 
Methods are outlined in Chapter 2.8  
 
7.2. Results 
7.2.1 Study patients 
A total of 25 patients entered the study but seven patients (three in the secondary BAD group and 
four in the chronic idiopathic diarrhea control group) withdrew for personal reasons before the first 
dose of OCA.  None of these patients received OCA.  Consequently, 18 patients (10 secondary BAD 
and 8 idiopathic diarrhea controls) received OCA and had blood sampling.  Further details of these 
groups are shown in Table 1. 
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 Secondary 
BAD 
Idiopathic 
controls 
Number 10 8 
Sex  (%) 
   Male 
   Female 
 
3 (30) 
7 (70) 
 
5 (63) 
3 (37) 
Age (y) 
  Median 
  Range 
 
45 
27 – 71 
 
39 
25 – 68  
SeHCAT (7d retention %)  
  Number 
  Median 
  Range 
 
6 
0.6 
0 – 10.4 
 
8 
25.7 
16.0 – 40.0  
Previous ileal resection (n) 
  Median length (cm) 
  Range (cm) 
  0 – 45 cm (n) 
  >45cm (n) 
8 
34 
0 – 71 
7 
3 
0 
- 
- 
- 
- 
Previous BA sequestrant use (n) 
  Yes 
  No 
 
4 
6 
 
0 
8 
 
Table 1.  Demographics of the two patient groups in this study 
 
7.2.2 FGF19 
The baseline (D0) median fasting FGF19 in the secondary BAD group (32 vs 57ng/L) was significantly 
lower than the idiopathic control group (0.004, Mann-Whitney test). The changes in fasting FGF19 
after 2 weeks of OCA treatment (D14) were variable in the secondary BAD group (median % increase 
over baseline = 25%, IQR -6 – 140; P=0.11) with some patients having large increases and others 
having only small changes. Serial FGF19 samples post OCA and after meals revealed a generally ‘flat’ 
response, figure 1. In the idiopathic control group, FGF19 increases were also variable and did not 
reach significance (median % change = 130%, IQR -14 – 304; P=0.12). 
As expected, FGF19 increased in the serial blood samples taken for 6h after the OCA doses.  The 
groups differed in D0 AUC (Mann Whitney, P=0.002) and peak FGF19 values (P=0.0005) with the 
responses being higher in the idiopathic controls than the secondary BAD groups.  There were no 
significant differences between the responses on D0 compared to D14 in FGF19 AUC or 6h peak in 
either group. 
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Figure 7.1. Serial FGF19 levels in SBAD patients following an overnight fast on the first day of the 
study D0, serial FGF19 measurements taken before and after OCA + breakfast administration (black 
arrow) and lunch (blue arrow).  The 3 coloured lines represent the values from the 3 patients with 
ileal resection >45cm. 
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Table 2.  FGF19, C4 and Bile Acids: fasting , 6h AUC and peak values on Day 0 and Day 14. Values are medians and IQR.  AUC = area under the curve.  D0 and 
D14 values were compared by Wilcoxon paired rank tests. Significant values (P< 0.05) are in bold 
 Secondary BAD 
(n=10) 
Idiopathic controls 
(n=8) 
Overall 
(n=18) 
 D0 D14 P D0 D14 P D0 D14 P 
FGF19 (ng/L) 
   Fasting 
32 
24–42 
46 
24–72 0.11 
116 
57–186 
194 
126–344 0.12 
43 
29–114 
104 
41-205 0.03 
   6h response AUC 401 
267–1086 
457 
316–1016 0.51 
1644 
1247–2776 
2099 
1972–2341 0.13 
1105 
324-1675 
1120 
389-2097 0.07 
   6h peak  102 
47–296 
126 
58–229 0.96 
530 
392–805 
588 
480–800 0.40 
319 
78-528 
313 
108-580 0.6 
C4 (µg/L) 
   Fasting 
104 
48–134 
56 
14–122 
0.11 
9 
3–14 
1 
1–3 
0.02 
26 
8-112 
9 
1-74 
0.01 
Bile Acids (µmol/L) 
   Fasting 
2.5 
2.0–6.0 
2.5 
1.0–4.0 
0.12 
1.5 
1.0–2.8 
1.0 
0.9–1.8 
0.12 
2.0 
1.0–3.5 
1.5 
1.0–3.3 
0.1 
   6h response AUC 32.0 
20.5–39.0 
22.0 
15.8–30.0 
0.04 
29.0 
23.2–44.7 
17.0 
10.6–20.0 
0.02 
31 
22.0–39.0 
20.0 
14–30.0 
0.002 
   6h peak 6.5 
3.8–9.3 
4.5 
3.0–6.3 
0.21 
8.0 
7.0–11.5 
4.0 
3.0–4.0 
0.02 
7.0 
6.0–10 
4.0 
3.0–6.0 
0.004 
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7.2.3 7α-hydroxy-4-cholesten-3-one (C4) 
Fasting C4 values were significantly different between the groups (Table 2), with those with 
secondary BAD being much higher than the controls.  OCA treatment reduced C4 in both groups, but 
this did not reach significance in the entire secondary BAD group.   
7.2.4 Total bile acid values 
Fasting BA values were not different between the groups (Table 2).  After 2w OCA treatment, 
median fasting values were lower overall but this did not reach significance. The BA increases after 
OCA and meals during the 6h serial sampling showed significant changes after 2w OCA treatment. 
 
7.2.5 Changes in clinical symptoms 
There were changes in clinical parameters during the 6 weeks of the study; In the secondary BAD 
group there were significant changes with OCA therapy in stool form (P=0.04) and in the stool index 
(P=0.03, table 3).  The median % index change was -29%.  These secondary BAD patients’ symptoms 
were variable, with some being more severely affected than the primary patients.  One patient had a 
weekly stool number of over 100 type 6-7 stools.  Of the 4 patients who needed loperamide rescue 
therapy, none was able to stop it. 
The patients with long resection responded less well than those with short or no resection. Limiting 
the analysis to the seven patients with an ileal resection length < 45cm produced significant changes 
in stool number (P=0.03), stool form (P=0.02) and index (P=0.02).  This group also had significant 
changes in FGF19 (38 to 50, P=0.03) and C4 (90 to 32, P=0.02). 
Patients in the idiopathic diarrhea control group showed no significant changes in median stool 
number, form or index.  Changes were generally small; the median % index change was +6%. 
Associated symptoms showed improvement in many patients.  There were significant median 
reductions in urgency score in secondary BAD with resection < 45cm (% change -56%, P=0.03).  Pain 
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scores in hours (% change -64%, P=0.03) and severity (% change -71%,P=0.04) both improved in the 
secondary BAD group.  None of these symptoms changed significantly in the idiopathic control 
group.  Bloating scores were unaffected. 
 
Weekly number of stools Mean stool form (BSFS) Stool index 
a
 
W2 W4 p W2 W4 p W2 W4 p 
Secondary BAD 
  n=10 
23 
14–44 
17 
17–42 
0.17 
6.0 
5.3–6.9 
5.6 
4.6–6.7 
0.04 
132 
72–473 
127 
47–321 
0.03 
  Resection <45cm 
  n=7 
17 
15–29 
12 
10–27 
0.03 
5.7 
4.4–6.2 
5.2 
4.2–6.0 
0.02 
95 
71–202 
62 
42–166 
0.02 
Idiopathic  
  n=7 
b
 
15 
11–17 
18 
13–19 
0.31 
4.9 
4.3–5.9 
4.9 
4.1–5.0 
0.74 
96 
69–100 
83 
65–101 
0.61 
Overall  
  n=17
 
16 
12–29 
17 
12–27 
0.82 
5.7 
4.5–6.4 
5.0 
4.3–6.0 
0.27 
96 
72–186 
88 
60–171 
0.44 
                    
Table 3. Values are medians and IQR.  Week 2 (W2) and 4 (W4) values were compared by Wilcoxon 
paired rank tests. BSFS = Bristol Stool Form Scale.  Significant values (P< 0.05) are in  bold.  
a The stool index = ([weekly stool frequency x mean BSFS] + loperamide use [weekly mg x 3]).   
b One patient did not return diaries that could be analyzed 
In the secondary BAD group, the change in stool number was associated with the % change in fasting 
FGF19 (r=-0.56, P=0.05). The resection length was associated overall with % changes in stool 
form(r=0.54, P=0.05), stool number (r=0.46, P=0.09) and in urgency (r=0.77, P=0.01). BA D0 AUC and 
percentage change in stool number correlated (r=0.56, P=0.05), but changes in BA were not 
significantly related to clinical symptoms overall in this group. 
7.2.6 Ileal resection length 
SeHCAT retention was inversely related to ileal resection length (r=-0.97, P=0.001), positively to 
FGF19 D0 six hour responses (AUC r=0.99, P<0.001; peak r=0.93, P=0.004) and C4 (r=0.76, P=0.04), 
and inversely with BA changes (AUC r=-0.99, P<0.001; peak rs=-0.91, P=0.01).  The percentage 
change in fasting C4 was associated with the percentage change in stool number (r=0.80, P=0.003). 
Resection length was also inversely associated with FGF19 fasting, AUC and peak values 
(r=-0.54, -0.91, -0.81, P=0.06, <0.001, 0.002 respectively); BA peak on D0 and the percentage change 
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in BA AUC (r=-0.54, 0.63, P=0.05, 0.03 respectively); and C4 for D0 and D14 fasting values and 
percentage change (r=0.73, 0.84, 0.71, P=0.008, 0.001, 0.01, respectively). 
 
7.2.7 Idiopathic diarrhoea controls 
In the idiopathic chronic diarrhoea controls, although there were no significant clinical median 
differences, age was associated with the percentage changes in index and urgency (r=-0.68, -0.77, 
P=0.05, 0.04, respectively), so the older patients had bigger improvements.  Fasting FGF19 on D0 and 
D14 and the index were positively associated (D14, r=0.75, P=0.03), meaning in this group that the 
lower FGF19 values had the larger decreases in the index.  Clinical changes (stool frequency and 
form) were negatively associated with the percentage change in BA AUC (r=-0.75, -0.77, P=0.04, 0.04 
respectively), so that bigger reductions in the BA response were associated with smaller changes in 
the symptoms.  
 
7.2.8 Tolerability, liver enzymes and lipid analyses 
OCA was well tolerated and only a few minor adverse effects were reported of limited clinical 
significance.  Three patients (2 in the secondary BAD group and 1 in the idiopathic group) reported 
mild headaches during OCA treatment in week 3 or 4.  One patient recorded that she was suffering 
from “a viral infection” at the time of the headache.  In the absence of a placebo-treated group, it is 
uncertain how these relate to OCA treatment.  Another patient with Crohn’s disease experienced 
worsening of abdominal pain after starting OCA and did not have a bowel movement for 24h.  Her 
symptoms settled on omitting OCA for 1d and then continuing with OCA 25mg on alternate days. 
Lipid measurements showed higher values for total and LDL-cholesterol (median % increases of 10.4 
and 19.7 respectively, both P<0.001 overall) and a reduction in triglycerides (median % decrease of 
11.8, P=0.06) after 2w OCA.  Similar magnitudes of changes were found in each group and are 
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comparable to those published previously [87].  There were no significant changes in median values 
of LFTs including alkaline phosphatase, alanine transaminase, bilirubin and albumin. 
 
7.3 Discussion 
Results from this work contributed to the first study of an FXR agonist, OCA, being used as a 
treatment for diarrhoea [96]. It is the first study to demonstrate that FGF19 levels increase after 2 
weeks of OCA in patients with chronic diarrhoea. Previous work (chapter 3) had shown very low 
levels of FGF19 in patients with CD and that reduced levels were associated with the severity of 
symptoms of diarrhoea and the length of ileum resected [169]. In this study FGF19 was shown to 
significantly increase after 2 weeks of OCA in CD patients with limited ileal resections (excluding 3 
patients with resections > 45m), resulting in significant reductions in BA synthesis and improvements 
in symptoms of diarrhoea. Clinical improvements were not seen in the idiopathic control patients 
despite similar changes in FGF19 levels and BA synthesis. 
The group of patients (not part of this thesis) that benefited the most symptomatically in this study 
were the primary BAD patients [96]. These patients had the largest increase in fasting FGF19 and 
reductions in C4 and BA levels. It is likely that these patients achieve the greatest reductions in faecal 
BA levels that drive the secretory diarrhoea in this condition. Patients with SBAD are usually 
observed to have the highest concentrations of faecal BA concentrations and may have the potential 
to gain most from treatments aimed at reducing faecal BA. However it appears that OCA 
administration is more effective at stimulating FGF19 in PBAD than SBAD probably due to the intact 
ileum in the former condition. 
Idiopathic diarrhoea patients did not demonstrate any significant clinical improvements with 2 
weeks of OCA treatment despite significant reductions in C4 and BA levels. It may be that faecal BA 
levels are reduced in this group of patients but this may not have any beneficial effects if the faecal 
BA concentrations are not already present at pathological concentrations. 
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In the SBAD group, a number of correlations were observed between ileal resection length and the 
biochemical and symptomatic changes induced by 2 weeks of OCA. This underlines the importance 
of the terminal ileum in the expression of circulating FGF19 levels. We had considered excluding 
patients with more extensive ileal resections prior to recruitment based upon the observed ‘flat’ 
post prandial FGF19 response observed in 3 CD patients (Chapter 3).  However extensive ileal 
resected patients can be the most severely affected patients with SBAD so we felt it was important 
to include them.  
The increase in median fasting levels of FGF19 in conjunction with the decrease in median C4 levels 
after 2 weeks of OCA administration suggests that OCA has been retained within enterohepatic 
circulation of BA despite limited ileal resections in most patients. However, in patients with more 
extensive ileal resection, increases in fasting FGF19 were not seen after 2 weeks of OCA.  The 3 
patients with resections >45cm were 3 of only 4 patients in which the post-OCA,  post prandial 
FGF19 levels revealed a completely flat response similar to the  post prandial responses observed in 
chapter 3. This implies that the greater potency for FXR binding and activation has not overcome the 
flat post prandial FGF19 response in similar patients in this study.  
There are two possible explanations for the lack of post OCA and meal induced rise in FGF19 with 
OCA administration in resectedpatients: Either OCA is not being absorbed or FGF19 is only secreted 
in response to BA absorption from a limited portion of terminal ileum. Previous bile acid kinetic 
studies suggest that the latter is more likely. OCA tends to follow the kinetics of any other orally 
administered BA. Peak plasma concentrations occur within 90-120 minutes. OCA is a derivative of 
CDCA, 6 ethyl-CDCA. Post prandial rises in CDCA generally tend to be greater than cholic acid. This 
may relate to the faster jejunal rates of absorption of unconjugated CDCA compared to other 
unconjugated bile acids [140]. Previous studies on patients with ileal resection have shown that the 
post prandial rise in serum CDCA are generally preserved despite involving patients with resection 
lengths greater than our patients ranging from 50 - 280cm [170]. It was also noted that having an 
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ileo-transverse, rather than an ileo-ascending colon anastomosis may attenuate the post prandial 
rise also.   
It is important to point out that a lack of FGF19 stimulation does not necessarily imply a lack of FXR 
activation. OCA induced FXR binding and activation has been proposed to promote anti-
inflammatory and protective intestinal pathways [86, 171]. FXR expression appears to be more 
widespread than FGF15/19 across the intestine [118]. FXR agonists may also have direct roles on the 
colonic epithelium, regulating chloride and water secretion [172]. Results from this study would 
suggest that the results of FXR activation on ileal FGF19 secretion predominate on colonic function in 
the context of chronic diarrhoea. OCA may be best placed for use in patients with ileal Crohn’s 
disease or limited ileal resection as both an oral anti-inflammatory drug and a symptomatic 
treatment. 
OCA stimulated blood levels of FGF19 as has been shown before [87].  We expected to find increases 
in FGF19 with OCA in the control subjects in this study, but were uncertain whether patients with 
secondary BAD would be able to respond.  The responses (not part of this thesis), both in the short 
term after the first OCA dose, and after 2 weeks treatment, show that in primary BAD, a potent FXR 
agonist like OCA is able to enter the ileal enterocyte and stimulate FGF19 transcription and blood 
levels to median values similar to those found in healthy controls. In SBAD patients median levels of 
FGF19 were stimulated in patients excluding the 3 >45cm ileal resection patients but levels still did 
not reach the same levels achieved in the idiopathic control or PBAD patients.   
OCA was well tolerated, confirming findings in other trials.  A recently completed phase IIB trial into 
the use of OCA in non-alcoholic steatohepatitis involving 25mg OCA therapy for 72 weeks has 
recently been published providing some data on long term safety [168].   The increases in total and 
LDL-cholesterol found here are similar to those found before in patients with nonalcoholic fatty liver 
disease and type 2 diabetes treated with OCA[87], and also in gallstone patients treated with CDCA, 
the natural FXR agonist [173].  This may be an expected consequence of lowering bile acid synthesis.  
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In our overall study population, new bile acid synthesis (as measured by fasting C4 levels) is reduced 
by 80% from the pretreatment values, and as bile acid excretion is the main means of cholesterol 
loss from the body, the 10-20% increase in serum cholesterol levels is not surprising.  The time 
course of these changes and any long term effects are unknown. 
A clear limitation of this study is that recording symptoms in diaries is subjective and could easily 
have been influenced by placebo effects.  However, symptomatic responses were considered 
together with the operator-blinded biochemical measures (FGF19, C4 and BA) and the primary 
outcome of this proof-of-concept study (fasting FGF19) was a quantitative endpoint.  Future trials of 
the clinical effects of OCA will utilize a double-blind, randomized, placebo-controlled study design.  
The present study also compared symptoms on OCA therapy to symptoms without specific therapy 
and future trials should include comparisons of OCA to treatment with bile acid sequestrants. 
In conclusion, this proof-of-concept study provides the first evidence that FXR agonists produce 
reductions in bile acid synthesis and clinical symptom responses in patients with BAD.  Targeting FXR 
to stimulate FGF19 is a novel therapeutic approach for many patients with secondary BAD, and for 
the large group of patients with primary BAD, currently receiving other treatments for functional 
diarrhea or D-IBS.
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Chapter 8: Variation in DIET1 may modify the PBAD phenotype by influencing 
serum FGF19 levels 
 
Abstract 
Backround: Serum fasting FGF19 is positively correlated with SeHCAT retention in patients with 
chronic diarrhoea. The phenotype of PBAD is associated with low median levels of FGF19, excessive 
BA synthesis and low SeHCAT retention due to excessive faecal BA loss. A novel protein DIET1 
promotes FGF15/19 secretion from cell lines. A common non-synonymous SNP in the DIET1 gene has 
recently been shown to enhance FGF19 secretion. It has been hypothesized that this DIET1 variant 
may be a modifier of BAD severity. 
Methods: We performed a case-control, candidate gene study for this SNP on 78 patients with 
chronic diarrhoea who had been assessed with fasting FGF19 levels and SeHCAT testing. We 
genotyped each patient for this SNP using an allelic discrimination assay. We hypothesized that the 
SNP would have a reduced frequency in the PBAD patients defined by seHCAT retention levels. 
Results: The SNP occurred with a minor allele frequency of 0.25 in our cohort of patients which is 
similar to findings from the human genomes project. The SNP was not found to be associated with 
either control patients or PBAD patients defined by SeHCAT. However in the PBAD patients defined 
by a SeHCAT retention of <10%, the variant was associated with a significantly higher mean fasting 
FGF19 (253 ± 53 vs 119 ± 19, p=0.02). Significant positive correlation between SeHCAT retention and 
FGF19 levels were present in patients expressing the major allele but this relationship was not 
present in patients expressing the minor allele. 
Conclusion: The association between fasting FGF19 levels and Faecal BA losses may be modified by 
this DIET1 variant in patients with chronic diarrhoea. This variant may also contribute to the large 
variability of fasting FGF19 levels in human studies in general. 
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8.1 Background 
 
Given the similarity between the phenotype of Diet1-deficient mice and the clinical features of BAD 
(described in the introduction, [158]), Karen Reue et al had sequenced the coding region of DIET1 in 
a case-control study sample (provided by our research group) of primary BAD (unpublished work, 
personal communication). This preliminary study had genotyped 44 patients including 22 patients 
with PBAD and 22 control patients. Although no causative variants were found, a common non-
synonymous SNV rs12256835 was found exclusively in the controls. The SNV leads to an amino acid 
substitution of glutamine at position 1721 in place of a histidine residue, H1721Q. Functional studies 
revealed that the Diet1–1721Q isoform promotes FGF19 secretion in a human intestinal cell lineHT-
29 using the FGF19 R+D Quantikine assay also used in this thesis [174]. It is hypothesized that this 
variant may modify the phenotype of PBAD by enhancing FGF19 secretion. 
Using a candidate gene approach we went on to perform a genotype study of this SNV on a further 
larger replication case-control cohort of patients. PBAD can be regarded as mild moderate or severe 
according to SeHCAT retention values. We aimed to look for associations of this SNV according 
commonly used SeHCAT ‘cut-off’ levels at 5, 10 and 15% to define mild, moderate or severe 
phenotypes. 
8.2 Specific methods genotyping 
Previously extracted genomic DNA was studied for the  rs12256835 SNP in a cohort of patients who 
have been previously described[71]. This cohort consisted of 78 prospectively recruited patients 
with chronic diarrhoea who underwent SeHCAT testing and fasting FGF19 serum sampling. Other 
intestinal diseases such as IBD or coeliac disease had been excluded from this cohort and the ethnic 
origin was predominantly caucasian. The 1000 genome project had revealed an rs12256835 minor 
allele frequency (MAF) of 0.28 [100]. We assumed a similar MAF of 0.28 in the diarrhoea control 
patients from this study. On the basis of recent findings  of lower prevalence of the minor allele in 
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PBAD patients, power calculations were therefore designed to detect a low frequency of 0.05. For 
90% probability at detecting a significant difference between a prevalence of 0.28 and 0.05 we 
would need 64 alleles (32 patients) in each group (diarrhoea controls vs PBAD).  Diarrhoea controls 
were defined as patients with symptoms of chronic diarrhea who did not demonstrate excessive 
faecal BA loss with SeHCAT retention levels of >10%. Other causes of  chronic diarrhea such as 
coeliac disease or inflammatory bowel disease had been excluded. The Allelic discrminination assay 
used to genotype the patients is described in Chapter 2.7 
8.3 Results: The minor allele may attenuate the reduced FGF19 levels associated with 
PBAD  
 
Dominant genetic models were used to compare patient phenotypes according to the presence or 
absence of the minor ‘G’ allele (the rs1225683 SNV).  The allelic discrimination assay assigned a 
genotype for all 78 patients (figure 1). 34 patients had a genotype containing the minor allele (5 
homozygous, 29 heterozygous) and 44 without.  Thirty nine minor alleles (the rs1225683 SNV) were 
observed out of the total 156 alleles giving an overall minor allele frequency in this cohort of 0.25.  
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Figure 2. Allelic discrimination plot from Taqman rs12256835 genotype assay, StepOne software 
V2.3. The blue dots signify samples where only the VIC dye was detected (T/T genotype). The red 
dots signify the small number of patients where only the FAM dye was detected ie the patients 
homozygous for the minor allele (G/G genotype). The green dots represent samples where a mixture 
of the two dyes were detected ie heterozygous, genotype G/T . 
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The median SeHCAT retention value from all 78 patients studied was 16.5 %  (IQR 8 – 29). Basic 
patient characteristics according to SeHCAT retention levels < or >10% are shown in table 1. In this 
larger replication cohort of patients there was no significant association between the SNV and 
groups of patients according to the seHCAT definition of mild, moderate or severe PBAD. Unlike the 
preliminary case-control study the SNV was not found to have significantly increased expression in 
control patients. Further analysis of the cohort of 78 patients revealed that the rs1225683 SNV was 
associated with significantly higher mean fasting FGF19 values in patients with moderate PBAD 
(seHCAT < 10%) table 2.   A similar trend revealed a higher mean fasting FGF19 level in patients 
expressing the rs1225683 SNVwhen comparing patients from the upper quartile to the lower 
quartile of SeHCAT values (≤8% SeHCAT retention vs ≥29%) table 2. 
  T/G & G/G T/T 
SeHCAT ≤10% n 12 14 
 Age 
M:F 
Ethnicity 
W 
AI 
AC 
ME 
Other 
48 ± 5 
7:5 
 
8 (67%) 
1 (8%) 
1 (8%) 
1 (8%) 
0 
43 ± 4 
5:9 
 
10 (71%) 
2 (14%) 
0 
1 (7%) 
1 
SeHCAT >10% n 
Age 
22 
43 ± 4 
30 
50 ± 3 
 
 M:F 
Ethnicity 
W 
AI 
AC 
ME 
Other 
8:14 
 
15 (68%) 
3 (14%) 
3 (14%) 
1 (14%) 
0 
14:16 
 
26 (90%) 
2 (7%) 
0 
0 
1 (3%) 
 
Table 1. Demographics table: Showing age, male:female ratios and ethnicity according to genotype 
and SeHCAT retention < or > 10%. 
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  FGF19 (pg/ml) 
  T/G & G/G T/T 
SeHCAT ≤10% n 12 14 
 Mean ± SEM 253 ± 56 119 ± 19 * 
SeHCAT >10% n 22 30 
 Mean ± SEM 215 ± 28 246 ± 24 
 
Table 2.  2x2 table comparing mean FGF19 values +/- SEM in patients with T/G or G/G genotype to 
those with genotype T/T in patients with SeHCAT >or <10%. * p=0.022, T/T vs. T/G & G/G, SeHCAT 
≤10%, independent t-test. 
  FGF19 (pg/ml) 
  T/G & G/G T/T 
Lower Quartile  n 7 12 
SeHCAT ≤8% Mean ± SEM 202 ± 62 116 ± 20.73 
Upper Quartile n 5 14 
SeHCAT ≥29% Mean SEM 255.5 ± 42 245.0 ± 42 
 
Table 3.  2x2 table comparing mean FGF19 values +/- SEM in patients with T/G or G/G genotype to 
those with genotype T/T in patients with SeHCAT values in the upper and lower quartiles (≤8% 
SeHCAT retention and ≥29% SeHCAT retention). 
 
Linear regression analysis demonstrated FGF19 levels were related to SeHCAT retention levels in T/T 
genotype patients without the minor G allele (n = 44, P = 0.034) but this relationship was not present 
in the patients with the genotypes containing the G allele (n = 34, P = 0.732, Figure 3). Multiple 
regression analysis of age, BMI, FGF19 and rs1225683 genotype revealed that SeHCAT values were 
significantly dependent upon the presence and number of minor alleles (P = 0.036).     
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Figure 3. Linear regression analysis of % SeHCAT retention at 7 days vs fasting FGF19 levels taken at 
the time of SeHCAT testing according to rs1225683 genotype. Lower SeHCAT retention signifies 
greater fecal loss of bile acids from the enterohepatic circulation. A positive relationship between 
SeHCAT retention and FGF19 levels was present in the patients with a T/T genotype but not in those 
containing the G allele. By potentially enhancing FGF19 secretion, this SNV may protect against the 
reduced FGF19 production associated with PBAD. It may be that some patients with PBAD still have 
excessive BA production and losses due to FGF19 receptor defects within the liver (FGFR4 / ßKlotho) 
[175]. (Pearson’s correlation coefficients shown). 
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8.4 Discussion 
This SNP has a frequency of 0.2816 in the 1000 Genomes project, suggesting that it is a common 
source of polymorphism in the Diet1 protein.  Interestingly, in 1000 Genomes project[100] , the 
allele frequency for rs12256835 is similar in European and Asian individuals (MAF 0.17, 0.24 
respectively). However there is an increased frequency in the Luhya of Webuye, Kenya (MAF 0.57), 
the Yorubans of Ibadan, Nigera (MAF 0.63), and in individuals of African ancestry in the 
southwestern United States (MAF 0.43).  Individuals of African descent were not present in our study 
sample. Our cohort consisted of patients of mainly white European ethnicity and we found a MAF of 
0.25 in our cohort as a whole which is consistent with the 1000 Genomes project. 
The preliminary results from the small case-control candidate gene study on the SNV had revealed a 
complete absence on the minor allele in patients with PBAD. All of the PBAD in this cohort had 
SeHCAT’s less than 10%. This finding was not borne out in our larger replication cohort. There were 
no significant associations in cases vs control despite analysing according to mild, moderate or 
severe phenotypes based on SeHCAT testing. Although this SNP may not completely protect against 
the PBAD phenotype, our findings suggest that it may have an ameliorating influence. The SNV was 
associated with a relatively higher mean fasting FGF19 than those without the SNV in the group of 
patients with PBAD. This DIET1 variant may therefore modify FGF19 levels in PBAD.  The positive 
correlation that is usually observed between SeHCAT levels and FGF19 levels is not found in the 
cohort of patients carrying the SNP. It would be interesting to characterize these patients further to 
see if they have less severe symptoms or differences in post-prandial FGF19 rather than fasting 
FGF19. In the earlier mouse models, diet1 deficient mice had reduced fgf15 expresion, increased BA 
synthesis,  were protected against atherosclerosis and had reduced circulating cholesterol levels. It 
would be interesting to see if this SNV is associated with increased FGF19 levels in other patient 
groups and whether this may be associated with dyslipidaemia.  
 
162 
 
8.5 Conclusion 
Defective ileal FGF19 secretion is a putative mechanism in PBAD. The H1721Q variant resulting from 
this SNP may enhance FGF19 secretion. This study   demonstrates that this SNV may have clinical 
relevance. In a condition associated with low median levels of FGF19, patients expressing this variant 
had significantly higher median levels of FGF19 than those that did not. The variant may modify The 
phenotype of BAD by influencing FGF19 production.  However it is recognised that this is only a 
candidate gene study in a small cohort of patients. A full genome wide association study would be 
required to produce more statistically meaningfull results.  
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Chapter 9: Conclusion and future work 
The results from this thesis include the first study to demonstrate an association between reduced 
median levels of serum FGF19 levels and symptoms of diarrhoea in CD, a condition strongly 
associated with bile acid malabsorption and SBAD. It is also the first to demonstrate reduced basal 
and BA stimulated FGF19 transcripts in ileum from patients with PBAD and low SeHCAT levels. 
Reduced median BA stimulated FGF19 expression was also found in ileum from CD using 
unconjugated CDCA.  Reduced expression of FGF19 transcripts has therefore been observed in both 
BAD conditions, PBAD and SBAD and supports the role of an impaired FXR-FGF19 pathway in the 
pathogenesis of BAD.  The two conditions of BAD are contrasted throughout the thesis by the 
fundamental difference that SBAD is associated with BAM yet in PBAD BA absorption is thought to 
remain preserved.  
In chapter 3 in patients with CD we have demonstrated an inverse relationship between fasting 
serum FGF19 levels and the extent of ileal resection or the severity of diarrhoea symptoms 
suggesting a semi-quantitative relationship between FGF19 levels and the amount of remaining 
functioning ileum. However there is also a suggestion from the results in chapter 3 that FGF19 levels 
may be more dependent on the degree of ileal inflammation than remaining functional ileum as the 
lowest levels of FGF19 were actually observed in non-resected patients with relatively short 
segments of ileal inflammation. In ileal resected patients with quiescent disease the relationship 
between FGF19 and resection length may not be linear. There seems to be a minimum basal level of 
circulating FGF19 which is low but does not become undetectable despite more extensive ileal 
resections. Other work has demonstrated low FGF19 levels in short bowel patients but the levels 
observed were within a similar range to the cohort of patients studied in this thesis with much 
shorter resections. 
Although detectable basal fasting levels of FGF19 may be preserved despite extensive small bowel 
resections, results from this thesis has suggested that the post prandial rise in FGF19 levels is 
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dependent on a relatively short section of terminal ileum. Exploratory studies on serial post-prandial 
FGF19 levels revealed a complete lack of meal induced rise in 3 patients from chapter 3 with 
relatively limited ileal disease or resection. In chapter 7, serial post-prandial levels also lacked a post-
prandial rise in levels in 3 patients with slightly more extensive ileal resections (45 – 78 cm)  despite 
the administration of the potent FXR agonist (obeticholic acid) with meals. Chapter 6 refers to a 
small pilot study on BA stimulated FGF19 transcript expression in ileal explants from neo-terminal 
ileum in previous ileal resected CD patients which revealed a trend towards very low levels of 
expression. 
The CD study of chapter 3 suggests that low levels of this hormone may have a high sensitivity for 
predicting BAD. As virtually all non-resected patients with diarrhoea and known ileal disease, 
undoubtedly associated with increased faecal BA losses, had low levels of FGF19. We were unable to 
properly assess sensitivity and specificity in this study without a parallel gold standard assessment of 
faecal BA losses (Faecal BA levels, SeHCAT levels, or C4, or response to BA sequestrants).  
Reduced FGF19 levels may be less specific for SBAD as a number of CD patients with low levels did 
not experience diarrhoea symptoms. Despite this potential lack of specificity, a low FGF19 may have 
clinical utility as a marker of BAD and may predict a response to BA sequestrants in CD patients 
suffering from diarrhoea with unknown disease distribution. To confirm this a larger study of FGF19 
which includes other markers of BAD and / or a subsequent trial of BAD specific therapy. If the study 
included prospective data on the presence of ileal inflammation (colonoscopy, or small bowel MRI) 
then one could assess if low levels were more sensitive as a biomarker ileal inflammation rather than 
BAD. BAD does not always appear to be associated with ileal inflammation or resection. The reasons 
for this have not been elucidated and also requires further study. Factors involve are likely to 
encompass a number of factors such as: the degree of associated colonic inflammation, microbial 
de-toxification of BA, colonic adaptation to increased faecal BAs. 
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The individual variability in ileal FGF19 induction by both CDCA and GCDCA may indicate different 
levels of BA homeostatic equilibrium.  Results from Chapter 5 indicate that individuals vary 
significantly in their capacity to produce ileal FGF19 at a transcriptional level. 
In BA physiology, the main variable that must be maintained for efficient fat digestion is a high 
concentration of BAs within biliary secretions and small intestine. The enterohepatic circulation of a 
pool of recycled BA provides  a high efficiency, low energy process, where the liver does not have to 
synthesize large quantities of new BA.   There seems to be a great deal of redundancy in thisprocess 
as patients can usually maintain nutritional status without the need for parenteral nutritional 
support with as little as 50cm of remaining small bowel in continuity with colon, or as little as 100cm 
of small bowel as a jejunostomy. The same can be said for patients that have undergone 
cholecystectomy. This is due to the livers capacity to increase BA synthesis up to 15 fold the normal 
baseline levels if required [176].  
With this level of redundancy in the levels of BA synthesis, there may be a great deal of variability in 
the BA pool size between individuals under normal conditions. This would be largely dictated by 
levels of hepatic BA synthesis. Some individuals will therefore have larger pool sizes and higher levels 
of BA entering the colon, being lost in faeces and vice versa. Levels of FGF19 expression is a likely to 
be key factor in the set point at which the bile acid pool size is maintained between individuals. The 
wide variability in ileal BA stimulated FGF19 expression observed in chapter 5 may underlie this 
variability in levels of BA synthesis and BA pool size.  
Some patients may have low ileal BA-FGF19 responsiveness. This would lead to a steady state with 
low basal and/or post prandial FGF19 levels, higher Hepatic BA synthesis rates, large BA pool size, 
increased faecal BAs and convey a degree of susceptibility to BA diarrhoea and possibly gallstones or 
even obesity. Conversely, others may have high levels of ileal BA-FGF19 responsiveness maintaining 
a smaller BA pool size, lower faecal BAs and be more susceptible to constipation. Consistent with the 
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central role of FXR-FGF19 and BAs in the balance between diarrhoea and constipation are studies 
that have observed Low feacal BA levels in patients with constipation and irritable bowel 
syndrome[177].  Elobixibat is an ASBT antagonist which has been shown to block the uptake of BA at 
the terminal ileum and resolve constipation by increasing faecal BAs [178, 179]. This would also be 
expected to reduce ileal BA induced FGF19 expression and further increase BA synthesis and faecal 
BA levels. This represents a converse approach to stimulating FGF19 in the treatment paradigm 
described in chapter 7. A new emerging treatment paradigm is to treat IBS related constipation or 
diarrhoea by manipulating faecal BA excretion [127, 180-182]. Most clinical trials are at phase II 
status in this respect as in Chapter 7 of this thesis. Further phase III trials are eagerly awaited. 
This thesis has demonstrated that in PBAD FGF19 transcripts are significantly lower in basal, 
unstimulated, fasting samples from patients with low SeHCAT values.  However ASBT transcripts are 
also lower in basal expression samples (chapter 4); if ASBT protein levels are also reduced, it could 
be that this results in reduced bile acid uptake and consequently reduced bile acid/FXR-dependent 
stimulation of FGF19 transcription.  This appears not to be the only reason, as incubation with CDCA 
also gives SeHCAT-dependent FGF19 transcript stimulation.  Unconjugated CDCA, unlike glycine-
conjugated GCDCA, is not dependent on transport by ASBT and will produce FXR-mediated 
transcription in cells not expressing ASBT. Significantly lower CDCA stimulated FGF19 transcript 
expression was also found in CD patients compared to healthy controls. This suggests that both 
SBAD and PBAD may be associated with defects in BA stimulated FGF19 production at a 
transcriptional level that is not simply a result of impaired active BA transporter defects. BA 
stimulated FXR transcription of target genes has been shown to be inhibited by a number of other 
intracellular pathways. 
This thesis supports the role of an impaired FXR-FGF19 pathway in the pathogenesis of BAD in some 
patients in even in the absence of BAM. In CD, an impaired FXR-FGF19 may contribute to the BAD 
experienced by these patients in addition to BAM[169]. We know that the last 100cm of terminal 
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ileum is important in maintaining the BA pool size as resections beyond this will lead to a depleted 
BA pool and steatorrhoea [183]. This distance relates to a gradient of ASBT expression and is likely to 
represent the length of terminal ileum that is critical to the reabsorption of luminal BAs. There is a 
suggestion from exploratory data in this thesis that post-prandial FGF19 expression may be 
expressed over a shorter length of 50cm of terminal ileum . Older BA kinetic studies in CD have 
confirmed that despite the presence of sub-optimal ileal reabsorption of BA with limited ileal 
resection or ileal inflammation, the BA pool size is maintained. More recent studies have confirmed 
a rise in FGF19 levels post oral CDCA administration CD patients in the absence of known ileal 
involvement or ileal resection [117]. However if post prandial FGF19 response is lost then this could 
lead to disproportionately high levels of hepatic BA synthesis which is in excess of what is required 
to maintain the BA pool size. The new steady state would be associated with higher faecal BA levels. 
Larger prospective studies of post-prandial FGF19 measurements in ileal CD would be required to 
confirm this. 
Exploratory studies of certain functional genetic variants have been undertaken in PBAD patients but 
none have been shown to specifically associate significantly with this seHCAT defined phenotype. 
The association of the variant in the DIET1 gene with FGF19 levels in moderate PBAD (SeHCAT<10%) 
presented in this thesis is the first study to show a potential association between genetic variation 
and clinical features of the condition (FGF19 levels in SeHCAT < 10%). The H1721Q variant of the 
DIET1 protein is thought to enhance the secretion of FGF19 protein. This would not be related to the 
findings of reduced FGF19 transcription that we have found in ileal explant studies. However, the 
variant may modify the expression of serum levels of FGF19 protein. Our explant protocol could be 
used to investigate this aspect further by studying FGF19 culture fluid levels from patients that have 
been genotyped for the H1721Q variant. An association between BA stimulated culture fluid FGF19 
levels and genotype could be examined in relation to the BA stimulated FGF19 transcript levels. This 
would require analysis of the explant culture fluid from the cohort of patients studied in chapter 6. 
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Patients could be genotyped with future recall for blood sampling and genotyping for the DIET 
variant. An alternative approach would be to PCR the cDNA from the explant samples with the 
primers used for allelic discrimination assay in chapter 8. This would be possible as the variant is 
within the coding sequence of the gene and hence would be part of the mRNA and represented 
within the cDNA. The presence or absence of amplification with the primers would allow a crude 
assessment of the expression of the variant. It would not accurately determine if a heterozygous or 
homozygous expression of the genotype is present however. Also, some genes show allelic 
imbalance in their expression which would need to be taken into consideration[184]. The primers 
would also have to be carefully optimized for use with different SYBRgreen chemistries. 
Summary 
In summary, this thesis presents results that supports the original hypothesis. The results 
demonstrate impairment in the ileal FXR-FGF19 pathway at multiple levels in patients with a 
diagnosis of PBAD (diagnosed by SeHCAT) or SBAD.  We have demonstrated that serum FGF19 levels 
may have clinical utility as a marker of BAD or ileal inflammation in patients with Crohn’s disease. 
The thesis also supports the possibility that disturbances in the FXR-FGF19 pathway may not simply 
occur at the BA absorption or FGF19 transcription level but may also relate to FGF19 secretion 
influenced by genetic variation in the DIET1 gene. This may further impact upon hepatic FGF19 
responses to secreted FGF19. The relationship between ileal FGF19 expression and SeHCAT levels in 
chapter 6 strengthens the role of SeHCAT as a diagnostic tool for defining the PBAD group of 
patients. The observation of low FGF19 expression in patients with low seHCAT retention confirms 
and further characterizes the specific phenotype of this subgroup of patients who might otherwise 
be diagnosed as diarrhoea-predominant irritable bowel syndrome.  As BA have emerged of as 
modulators of (postprandial) lipid, glucose and energy metabolism (via FXR and TGR5 receptors) 
further associations of the PBAD phenotype with other metabolic diseases [185-187]is being 
elaborated further. Finally the proof-of-concept OBADIAH1 study provides the first evidence that 
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FXR agonists produce reductions in bile acid synthesis and clinical symptom responses in patients 
with BAD.  This study supports a new treatment paradigm aimed at manipulating faecal BA levels to 
improve functional GI symptoms. 
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